documents incorporated reference document part proxy statement annual meeting shareholders held may filed part iii securities exchange commission within days close fiscal year covered reporttable contents table contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings item mine safety disclosures executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data afinancial statements notes consolidated financial statements report independent registered public accounting firm bsupplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information item c disclosure regarding foreign jurisdictions prevent inspections part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures table contents part item business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include two operating segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines company sells human health vaccines primarily physicians wholesalers physician distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers company previously healthcare services segment provided services solutions focused engagement health analytics clinical services improve value care delivered patients company divested remaining businesses segment first quarter product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted trademarks services marks respective owners spinoff organon co june merck completed spinoff spinoff products womens health biosimilars established brands businesses new independent publicly traded company named organon co organon distribution organons publicly traded stock company shareholders established brands included transaction consisted dermatology nonopioid pain management respiratory select cardiovascular products well rest mercks diversified brands franchise mercks existing research pipeline programs continue owned developed within merck planned table contents product sales total company sales including sales companys top pharmaceutical products well sales animal health products follows millions total sales pharmaceutical keytruda gardasilgardasil januviajanumet proquadmmr iivarivax bridion alliance revenue lynparza molnupiravir pneumovax simponi rotateq isentressisentress hd alliance revenue lenvima animal health livestock companion animals revenues alliance revenue represents mercks share profits product sales net cost sales commercialization costs revenues primarily comprised thirdparty manufacturing sales miscellaneous corporate revenues including revenue hedging activities pharmaceutical pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders human health vaccine products consist preventive pediatric adolescent adult vaccines certain products within companys franchises follows oncology keytruda pembrolizumab companys antipd programmed death receptor therapy monotherapy treatment certain patients cervical cancer classical hodgkin lymphoma chl cutaneous squamous cell carcinoma cscc esophageal gastroesophageal junction gej carcinoma head neck squamous cell carcinoma hnscc hepatocellular carcinoma hcc nonsmallcell lung cancer nsclc melanoma merkel cell carcinoma microsatellite instabilityhigh msih mismatch repair deficient dmmr cancer solid tumors including msihdmmr colorectal cancer crc primary mediastinal large bcell lymphoma pmbcl tumor mutational burdenhigh tmbh cancer solid tumors urothelial carcinoma including nonmuscle invasive bladder cancer keytruda also approved treatment certain patients combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy hnscc combination trastuzumab fluoropyrimidine platinumcontaining chemotherapy human epidermal growth factor herpositive gastric gej adenocarcinoma combination platinumand fluoropyrimidinebased chemotherapy esophageal gej carcinoma combination chemotherapy without bevacizumab cervical cancer combination chemotherapy triplenegative breast cancer tnbc combination axitinib advanced renal cell carcinoma rcc combination lenvatinib endometrial carcinoma rcc keytruda also approved certain patients highrisk earlystage tnbc combination chemotherapy neoadjuvant treatment continued single agent adjuvant treatment surgery keytruda also approved monotherapy adjuvant treatment certain patients rcc addition company recognizes alliance revenue related sales lynparza olaparib oral poly adpribose polymerase parp inhibitor certain types advanced ovarian breast pancreatic prostate cancers lenvima lenvatinib certain types table contents thyroid cancer hepatocellular carcinoma combination everolimus certain patients rcc combination keytruda certain patients endometrial carcinoma rcc vaccines gardasil human papillomavirus quadrivalent types vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccines help prevent certain diseases caused certain types human papillomavirus hpv proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine help protect measles mumps rubella varicella mmr ii measles mumps rubella virus vaccine live vaccine help prevent measles mumps rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children vaqta hepatitis vaccine inactivated indicated prevention disease caused hepatitis virus persons months age older hospital acute care bridion sugammadex injection medication reversal two types neuromuscular blocking agents used surgery prevymis letermovir prophylaxis cytomegalovirus cmv reactivation disease adult cmvseropositive recipients r allogeneic hematopoietic stem cell transplant primaxin imipenem cilastatin injection antibiotic treatment certain bacterial infections noxafil posaconazole antifungal agent prevention certain invasive fungal infections cancidas caspofungin acetate injection antifungal agent treatment certain fungal infections invanz ertapenem injection antibiotic treatment certain bacterial infections zerbaxa ceftolozane tazobactam injection combination antibacterial betalactamase inhibitor treatment certain bacterial infections immunology simponi golimumab oncemonthly subcutaneous treatment certain inflammatory diseases remicade infliximab treatment inflammatory diseases company markets europe russia turkey neuroscience belsomra suvorexant orexin receptor antagonist indicated treatment insomnia characterized difficulties sleep onset andor sleep maintenance virology molnupiravir investigational oral antiviral covid medicine isentressisentress hd raltegravir hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection cardiovascular adempas riociguat cardiovascular drug treatment pulmonary arterial hypertension verquvo vericiguat medicine reduce risk cardiovascular death heart failure hospitalization following hospitalization heart failure need outpatient intravenous diuretics certain adults symptomatic chronic heart failure reduced ejection fraction diabetes januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabetes animal health animal health segment discovers develops manufactures markets wide range veterinary pharmaceuticals vaccines health management solutions services well extensive suite digitally connected identification traceability monitoring products principal products segment include livestock products nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorders cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory table contents drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease zilmax zilpaterol hydrochloride revalor trenbolone acetate estradiol improve production efficiencies beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type killed baculovirus vector vaccine lines infectious diseases swine nobilisinnovax live mareks disease vector vaccine lines poultry paracox coccivac coccidiosis vaccines exzolt systemic treatment poultry red mite infestations slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor florfenicol antibiotic farmraised fish allflex livestock intelligence solutions animal identification monitoring traceability companion animal products bravecto line oral topical parasitic control products including original bravecto fluralaner products dogs cats last weeks bravecto fluralaner onemonth monthly product dogs bravecto plus fluralanermoxidectin twomonth product cats sentinel line oral parasitic products dogs including sentinel spectrum milbemycin oxime lufenuron praziquantel sentinel flavor tabs milbemycin oxime lufenuron optimmune cyclosporine ophthalmic ointment nobivac vaccine lines flexible dog cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabetes mellitus treatment dogs cats panacur fenbendazolesafeguard fenbendazole broad spectrum anthelmintic dewormer use many animals regumate altrenogest fertility management horses prestige vaccine line horses scalibor deltamethrinexspot protecting bites fleas ticks mosquitoes sandflies sure petcare products companion animal identification wellbeing including microchip pet recovery system home discussion sales companys products see item managements discussion analysis financial condition results operations product approvals authorizations set forth summary significant product approvals authorizations received company product date approval european commission ec approved keytruda monotherapy firstline treatment adult january patients msih dmmr crc ec approved keytruda monotherapy treatment adult pediatric patients aged years older relapsed refractory chl failed autologous stem cell transplant asct following march least two prior therapies asct treatment option us food drug administration fda approved keytruda combination platinum fluoropyrimidinebased chemotherapy treatment patients locally advanced metastatic march esophageal gej tumors epicenter centimeters gej carcinoma keytruda amenable surgical resection definitive chemoradiation fda approved keytruda combination trastuzumab fluoropyrimidine platinumcontaining chemotherapy firstline treatment patients locally advanced unresectable metastatic may herpositive gastric gej adenocarcinoma chinas national medical products administration nmpa approved keytruda monotherapy firstline treatment patients unresectable metastatic msih dmmr crc kras nras june braf wildtype table contents ec approved keytruda combination platinum fluoropyrimidinebased chemotherapy firstline treatment patients locally advanced unresectable metastatic carcinoma june esophagus hernegative gej adenocarcinoma adults whose tumors express pdl combined positive score cps fda approved keytruda monotherapy treatment patients locally advanced cscc july curable surgery radiation fda approved keytruda plus lenvima treatment patients advanced endometrial carcinoma msih dmmr disease progression following prior systemic therapy july setting candidates curative surgery radiation fda approved keytruda treatment patients highrisk earlystage tnbc combination july chemotherapy neoadjuvant treatment continued single agent adjuvant treatment surgery fda approved keytruda treatment patients locally advanced metastatic urothelial august carcinoma eligible platinumcontaining chemotherapy japan pharmaceuticals medical devices agency pmda approved keytruda treatment patients pdlpositive hormone receptornegative hernegative inoperable recurrent august breast cancer keytruda pmda approved keytruda treatment patients unresectable advanced recurrent msih august crc fda approved keytruda plus lenvima firstline treatment adult patients advanced rcc august nmpa approved keytruda combination platinum fluoropyrimidinebased chemotherapy firstline treatment patients locally advanced unresectable metastatic carcinoma september esophageal gej fda approved keytruda combination chemotherapy without bevacizumab treatment patients persistent recurrent metastatic cervical cancer whose tumors express pdl october cps determined fdaapproved test ec approved keytruda combination chemotherapy firstline treatment locally recurrent unresectable metastatic tnbc adults whose tumors express pdl cps october received prior chemotherapy metastatic disease fda approved keytruda adjuvant treatment patients rcc intermediatehigh high november risk recurrence following nephrectomy following nephrectomy resection metastatic lesions ec approved keytruda plus lenvima firstline treatment adult patients advanced rcc november table contents ec approved keytruda plus lenvima treatment advanced recurrent endometrial carcinoma adults disease progression following prior treatment platinumcontaining november therapy setting candidates curative surgery radiation pmda approved keytruda combination chemotherapy fluorouracil plus cisplatin november firstline treatment patients radically unresectable advanced recurrent esophageal carcinoma fda approved keytruda monotherapy adjuvant treatment adult pediatric years keytruda older patients stage iib iic melanoma following complete resection fda also expanded indication keytruda adjuvant treatment stage iii melanoma following complete december resection include pediatric patients years older japans ministry health labor welfare mhlw approved keytruda combination lenvima treatment patients unresectable advanced recurrent endometrial carcinoma december progressed cancer chemotherapy nmpa approved lynparza monotherapy treatment adult patients germline somatic lynparza june brcamutated metastatic castrationresistant prostate cancer progressed following prior treatment included new hormonal agent abiraterone enzalutamide fda granted emergency use authorization eua molnupiravir treat mild moderate covid adults positive results direct sarscov viral testing high risk progression severe covid including hospitalization death alternative covid december treatment options authorized fda accessible clinically appropriate molnupiravir mhlw granted molnupiravir special approval emergency treatment infectious disease december caused sarscov fda approved vaxneuvance active immunization prevention invasive disease caused streptococcus pneumoniae serotypes b f v c f f f f july adults years age older vaxneuvance ec approved vaxneuvance active immunization prevention invasive disease pneumonia caused streptococcus pneumoniae individuals years age older december fda approved verquvo reduce risk cardiovascular death heart failure hf hospitalization following hospitalization heart failure need outpatient intravenous iv january diuretics adults symptomatic chronic hf ejection fraction less verquvo ec approved verquvo treatment symptomatic chronic heart failure adult patients july reduced ejection fraction stabilized recent decompensation event requiring iv therapy fda approved welireg adult patients von hippellindau vhl disease require therapy welireg august associated rcc central nervous system hemangioblastomas pancreatic neuroendocrine tumors requiring immediate surgery jointly developed commercialized worldwide collaboration astrazeneca jointly developed commercialized worldwide collaboration ridgeback biopharmaceuticals lp molnupiravir approved fda authorized emergency use jointly developed commercialized worldwide collaboration bayer ag table contents competition health care environment competition markets company conducts business pharmaceutical industry general highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug manufacturers animal health care companies companys operations may adversely affected generic biosimilar competition companys products mature well technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance addition patent rights increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result payment royalties recognition impairment charge respect intangible assets associated certain products pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively long standing emphasis research development company wellpositioned compete search technological innovations company active acquiring marketing products external alliances licensing arrangements collaborations refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth reduced sales companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products well competitors products effective promotional efforts frequent introduction generic products competitors health care environment government regulation global efforts toward health care cost containment continue exert pressure product pricing market access changes us health care system part health care reform enacted prior years well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries contributed pricing pressure several international markets governmentmandated pricing actions reduced prices generic patented drugs addition companys revenue performance negatively affected costreduction measures taken governments third parties lower health care costs us biden administration congress continue discuss legislation designed control health care costs including cost drugs company anticipates actions additional actions future continue negatively affect revenue performance united states company faces increasing pricing pressure managed care organizations government agencies programs could negatively affect companys sales profit margins including practices managed care organizations federal state exchanges institutional governmental purchasers ii federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act aca us federal state governments many years pursued methods reduce cost drugs vaccines pay example federal state laws require company pay specified rebates medicines reimbursed medicaid provide discounts medicines purchased certain state federal entities department defense veterans affairs public health service entities hospitals serving disproportionate share low income uninsured patients table contents additionally us consolidation integration among health care providers major factor competitive marketplace pharmaceutical products health plans pharmacy benefit managers pbms consolidating fewer larger entities thus enhancing purchasing strength importance private thirdparty insurers well governments employ formularies control costs negotiating discounted prices exchange formulary inclusion failure obtain timely adequate pricing formulary placement mercks products obtaining placement unfavorable pricing could adversely affect revenue addition formulary tier copay differentials private health insurance companies selfinsured employers increasing costsharing required beneficiaries particularly branded pharmaceuticals biotechnology products private health insurance companies also increasingly imposing utilization management tools clinical protocols requiring prior authorization branded product requiring patient first fail one generic products permitting access branded medicine management tools also used treatment areas payor taken position multiple branded products therapeutically comparable us payor market concentrates pharmaceutical companies may face greater pricing pressure private thirdparty payors order provide information companys pricing practices company annually posts website pricing transparency report us report provides companys average annual list price net price increases average discounts across companys us portfolio dating back companys gross us sales reduced result rebates discounts returns legislative changes congress actively considered multiple versions drug pricing legislation could significantly impact branded pharmaceutical manufacturers legislation would implement government negotiation plan certain products covered medicare parts b institute financial penalties price increases inflation redesign medicare part program include cap patients pocket costs realign liability costs benefit among manufacturers health plans government unclear legislation passed congress remains uncertain proposals may included part future federal legislative proposals would directly indirectly affect company also congress passed american rescue plan act included provision eliminates statutory cap rebates drug manufacturers pay medicaid beginning january rebates act discount list price eliminating cap means manufacturer discounts paid medicaid increase prior change manufacturers required pay average manufacturer price amp rebates state medicaid programs medicaidcovered drugs result provision beginning possible manufacturers may pay state medicaid programs rebates received sales particular products change could present risk merck future drugs high medicaid utilization rebate exposure amp company also faces increasing pricing pressure states looking exert greater influence price prescription drugs number states passed pharmaceutical price cost transparency laws laws typically require manufacturers report certain product price information financial data state laws also require manufacturers provide advance notification price increases company expects states continue focus pharmaceutical pricing increasingly shift aggressive price control tools prescription drug affordability boards authority conduct affordability reviews establish upper payment limits regulatory changes february centers medicare medicaid services cms issued medicaid rebate final rule implemented provisions aca effective april rule provides comprehensive guidance calculation amp best price two metrics used determine rebates drug manufacturers required pay state medicaid programs december cms issued final rule making significant changes requirements effective january final rule changes way manufacturers must calculate best price relation certain patient support programs including coupons phrma pharmaceutical industry trade group company member filed complaint challenging rule invalid asserting conflicts table contents plain language medicaid drug rebate statute legal challenge fail impact provisions final rule could adversely impact companys business cash flow results operations financial condition prospects november department health human services office inspector general issued final rule would effective january eliminate antikickback statute safe harbor rebates paid medicare part plans pbms behalf plans company anticipate effects change way currently contracts new framework could significantly alter way business part plan sponsors pbms behalf plans rulemaking also established effective january new safe harbor point sale discounts pharmacy counter new safe harbor certain service arrangements pharmaceutical manufacturers pbms congress delayed implementation final rule january pending federal legislation would repeal entirely pharmaceutical industry also could considered potential source savings via legislative administrative proposals debated enacted types revenue generating cost saving proposals include additional direct price controls european union efforts toward health care cost containment remain intense european union eu company faces competitive pricing pressure resulting generic biosimilar drugs addition majority countries eu attempt contain drug costs engaging reference pricing authorities examine predetermined markets published prices drugs reference pricing may either compare products prices markets external reference pricing compare products price products national class internal reference pricing authorities use price data set new local prices brandname drugs including companys drugs guidelines examining reference pricing usually set local markets changed pursuant local regulations eu member states established freepricing systems regulate pricing drugs profit control plans others seek negotiate set prices based costeffectiveness product assessment whether offers therapeutic benefit products relevant class downward pressure health care costs general particularly prescription drugs become intense result increasingly high barriers erected entry new products eu member states crossborder imports lowpriced markets also exert competitive pressure may reduce pricing within eu member state additionally eu member states power restrict range pharmaceutical products national health insurance systems provide reimbursement eu pricing reimbursement plans vary widely member state member state eu member states provide drug products may marketed reimbursement price agreed eu member states may require completion additional studies compare cost effectiveness particular product candidate already available therapies socalled health technology assessments hta order obtain reimbursement pricing approval hta pharmaceutical products becoming increasingly common part pricing reimbursement procedures eu member states hta process governed national laws countries involves assessment costeffectiveness public health impact therapeutic impact andor economic social impact use given pharmaceutical product national health care system individual country conducted ultimately hta measures added value new health technology compared existing ones outcome htas regarding specific pharmaceutical products often influence pricing reimbursement status granted pharmaceutical products regulatory authorities individual eu member states negative hta one companys products may mean product reimbursable may force company reduce reimbursement price offer discounts rebates negative hta leading recognized hta body could also undermine companys ability obtain reimbursement relevant product outside jurisdiction example eu member states yet developed hta mechanisms may rely extent hta performed countries developed hta framework inform pricing reimbursement decisions hta procedures require additional data reviews administrative processes increase complexity timing costs obtaining product reimbursement exert downward pressure available reimbursement table contents obtain reimbursement pricing approval eu member states company may required conduct studies compare cost effectiveness companys product candidates therapies considered local standard care assurance eu member state allow favorable pricing reimbursement market access conditions companys products feasible conduct additional costeffectiveness studies required brexit united kingdom uk held referendum voters approved exit eu commonly referred brexit result referendum subsequent negotiations uk left eu january transitional period applied january december period eu uk operated uk eu member state uk continued participate eu customs union allowing freedom movement people goods announced december eu uk agreed trade cooperation agreement tca tca sets new arrangements trade goods including medicines vaccines allows goods continue flow eu uk tca signed december applied provisionally january entered force may result tca company believes operations materially adversely affected brexit japan japan pharmaceutical industry subject governmentmandated annual price reductions pharmaceutical products certain vaccines furthermore government order repricings specific products determines use product exceed certain thresholds defined applicable repricing rules next governmentmandated price reduction occur april china companys business china grown rapidly past years importance china companys overall pharmaceutical vaccines business increased accordingly continued growth companys business china dependent upon ongoing development favorable environment innovative pharmaceutical products vaccines sustained access companys current inline products absence trade impediments adverse pricing controls recent years chinese government introduced implemented number structural reforms accelerate shift innovative products reduce costs since multiple new policies introduced government improve access new innovation reduce complexity regulatory filings accelerate review approval process led significant increase number new products approved year mechanism drugs added governments national reimbursement drug list nrdl evolves inclusion may require price negotiation could impact outlook market selected brands drugs added nrdl average price reductions pricing pressure always existed china health care reform increased pressure part due acceleration generic substitution volume based procurement vbp government implemented vbp program tendering process mature products generic substitutes generic quality consistency evaluation approval mature products entered last five rounds vbp average price reduction company expects vbp semiannual process significant impact mature products moving forward emerging markets companys focus emerging markets addition china continued governments many emerging markets also focused constraining health care costs enacted price controls measures impacting intellectual property including exceptional cases threats compulsory licenses especially covid vaccines drugs aim put pressure price innovative pharmaceuticals result constrained market access innovative medicine company anticipates pricing pressures market access challenges continue future varying degrees emerging markets beyond pricing market access challenges conditions emerging market countries affect companys efforts continue grow markets including potential political instability changes trade sanctions embargoes significant currency fluctuation controls financial crises limited changing table contents availability funding health care credit worthiness health care partners hospitals due covid developments may adversely impact business environment company company may engage thirdparty agents assist operating emerging market countries may affect ability realize continued growth may also increase companys risk exposure addressing global cost containment pressures company engages public policy advocacy policymakers continues work demonstrate medicines provide value patients pay health care company advocates government policymakers encourage longterm approach sustainable health care financing ensures access innovative medicines disproportionately target pharmaceuticals source budget savings markets historically low rates health care spending company encourages governments increase investments adopt market reforms order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes wellpositioned respond evolving health care environment market forces regulation pharmaceutical industry also subject regulation regional country state local agencies around world focused standards processes determining drug safety effectiveness well conditions sale reimbursement particular importance fda us administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals cases fda requirements practices increased amount time resources necessary develop new products bring market us time fda committed expediting development review products bearing breakthrough therapy designation accelerated regulatory review process medicines designation fda also undertaken efforts bring generic competition market efficiently timely manner eu adopted directives legislation concerning classification approval marketing labeling advertising manufacturing wholesale distribution integrity supply chain pharmacovigilance safety monitoring medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states particular eu regulators may approve products subject number postauthorization conditions examples typical postauthorization commitments include additional pharmacovigilance conduct clinical trials establishment patient registries physician patient education controlled distribution prescribing arrangements non compliance postauthorization conditions pharmacovigilance obligations lead regulatory action including variation suspension withdrawal marketing authorizations enforcement regulatory actions including imposition financial penalties companys policies procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs regulatory environment see research development discussion regulatory approval process access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes collaboration key stakeholders role play helping ensure science advances health care products accessible affordable company committed ensuring reliable safe global supply quality medicines vaccines developing testing implementing innovative solutions address barriers access affordability medicines vaccines companys approach designed enable serve greatest number patients today table contents meeting needs patients future companys efforts regard wideranging include set principles company strives embed operations business strategies guide companys worldwide approach expanding access health care addition innovative social investments including philanthropic programs impact investing merck also helping strengthen health systems build capacity particularly resourced communities merck patient assistance program provides medicines adult vaccines free people us prescription drug health insurance coverage without companys assistance afford merck medicines vaccines merck funded merck mothers longterm effort global health partners end preventable deaths complications pregnancy childbirth merck also provided funds merck foundation independent grantmaking organization partnered variety organizations dedicated improving global health privacy data protection company subject significant number privacy data protection laws regulations globally many place restrictions companys ability transfer access use personal data across business legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including eu general data protection regulation gdpr went effect may imposes penalties global revenue gdpr related implementing laws individual eu member states govern collection use personal health data personal data eu gdpr increased responsibility liability relation personal data company processes also imposes number strict obligations restrictions ability process includes collection analysis transfer personal data including health data clinical trials adverse event reporting gdpr also includes requirements relating consent individuals personal data relates information provided individuals prior processing personal data personal health data notification data processing obligations national data protection authorities security confidentiality personal data gdpr prohibits transfer personal data countries outside eu considered ec provide adequate level data protection including us except data controller meets specific requirements following schrems ii decision court justice eu july considerable uncertainty permissibility international data transfers gdpr light implications decision company may face difficulties regarding transfer personal data eu third countries failure comply requirements gdpr related national data protection laws eu member states may result significant monetary fines administrative penalties well civil liability claims individuals whose personal data processed data protection authorities different eu member states may still implement certain variations enforce gdpr national data protection laws differently introduce additional national regulations guidelines adds complexity processing personal data eu guidance developed eu level national level individual eu member states concerning implementation compliance practices often updated otherwise revised moreover growing trend towards required public disclosure clinical trial data eu adds complexity obligations relating processing health data clinical trials failing comply obligations could lead government enforcement actions significant penalties company harm reputation adversely impact business operating results uncertainty regarding interplay different regulatory frameworks adds complexity company faces regard data protection regulation august chinas th national peoples congress passed personal information protection law pipl aims standardize handling personal information china became effective november pipl currently applies processing personal information natural persons china processing personal information outside china purpose provide products services china analyze activities individuals china similar gdpr pipl contains unique requirements found gdpr table contents company developed implemented comprehensive plans ensure compliance pipl relating data localization crossborder transfers yet completed pending forthcoming guidance cyberspace administration china additional laws regulations enacted us california consumer privacy act europe asia latin america increased enforcement litigation activity us developed markets well increased regulatory cooperation among privacy authorities globally company adopted comprehensive global privacy program manage evolving requirements risks facilitate transfer personal information across international borders distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pbms institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices hospitals managed care organizations company sells animal health products veterinarians distributors animal producers patents trademarks licenses patent protection considered aggregate material importance companys marketing products us major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage food drug administration modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity us indications new currently marketed drugs certain agreed upon pediatric studies completed applicant current us patent law provides additional patent term periods patented product regulatory review fda eu also provides additional six months pediatric market exclusivity attached products supplementary protection certificate spc japan provides additional term pediatric studies attached market exclusivity unrelated patent term patent portfolios developed products introduced company normally provide market exclusivity company following key patent protection us eu japan china including potential patent term extensions pte spcs indicated following marketed products table contents product year expiration us year expiration eu year expiration japan year expiration china januvia janumet na janumet xr na na isentress simponi na na na lenvima spcs expired bridion expired bravecto pending pte patents spcs gardasil expired expired na gardasil patents spcs na keytruda lynparza pending pte patents spcs zerbaxa patents spcs pending pte na adempas na belsomra na na prevymis pending pte patents spcs na segluromet pending pte patents spcs na steglatro pending pte patents spcs na steglujan pending pte patents spcs na verquvo pending pte na na na vaxneuvance pending pte patent na na delstrigo pending pte patents spcs na pifeltro pending pte patents spcs recarbrio pending pte na na na welireg pending pte na na na note compound patent unless otherwise noted certain products listed may subject patent litigation see item financial statements supplementary data note contingencies environmental liabilities na currently marketing approval eu date represents expiration date following four countries france germany italy spain major eu markets spc applications filed granted major eu markets patent expiry date spc expiry date listed pte system japan allows patent extended provided later approval directed different indication previous approval may result multiple pte approvals given patent expiration date eligible months pediatric exclusivity expiry date reflects approved product includes granted pte mg tablet japan company marketing rights us japan china distribution agreement janssen pharmaceuticals inc expires october part global strategic oncology collaboration eisai co ltd part global strategic oncology collaboration astrazeneca commercialized worldwide collaboration bayer ag company marketing rights us commercialized promoted worldwide except japan collaboration pfizer inc company marketing rights japan company marketing rights eu japan china table contents company following key us patent protection drug candidates review us fda additional patent term may provided pipeline candidates based patent term restoration pediatric exclusivity currently anticipated review us year expiration us mk gefapixant company also following key us patent protection drug candidates phase development currently anticipated phase drug candidate year expiration us mk islatravir mk sotatercept mka doravirine islatravir pending pte doravirine mka quavonlimab pembrolizumab mka vibostolimab pembrolizumab mka favezelimab pembrolizumab mk clesrovimab mk molnupiravir received emergency use authorization fda treatment highrisk adults mild moderate covid unless otherwise noted patents charts compound patents patent may subject future patent term restoration five years six month pediatric market exclusivity either may available addition depending circumstances surrounding final regulatory approval compound may listed patents patent applications pending could relevance product finally approved relevance application would depend upon claims ultimately may granted nature final regulatory approval product also regulatory exclusivity tied protection clinical data complementary patent protection cases may provide effective longer lasting marketing exclusivity compounds patent estate us data protection generally runs five years first marketing approval new chemical entity extended seven years orphan drug indication years first marketing approval biological product expiration compound patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived laterexpiring patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv us certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought us countries relevant laws including laws increasing patent life benefits increases patent life partially offset increase number incentives use generic products additionally improvements intellectual property laws sought us countries reform patent relevant laws implementation international treaties information respect companys patents see item risk factors item financial statements supplementary data note contingencies environmental liabilities worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely table contents royalty income patent knowhow licenses rights amounted million merck also incurred royalty expenses amounting billion patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program december approximately people employed companys research activities company prioritizes research development efforts focuses candidates believes represent breakthrough science make difference patients payers company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources candidates company believes capable providing unambiguous promotable advantages patients payers delivering maximum value approved medicines vaccines new indications new formulations merck pursuing emerging product opportunities independent therapeutic area modality small molecule biologics vaccines building biologics capabilities company committed ensuring externally sourced programs remain important component pipeline strategy focus supplementing internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well access new technologies companys clinical pipeline includes candidates multiple disease areas including cancer cardiovascular diseases metabolic diseases infectious diseases neurosciences respiratory diseases vaccines development human health products industry practice government regulations us foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed us recorded data preclinical clinical experience included new drug application nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound biologic believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology immunogenicity toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse effects could limit compounds usefulness situations clinical program incorporates adaptive design methodology use accumulating data decide modify aspects ongoing clinical study continues without undermining validity integrity trial one type adaptive clinical trial adaptive phase ab trial design twostage trial design consisting phase proofofconcept stage phase b doseoptimization finding stage data phase trials satisfactory company commences largescale phase trials confirm compounds efficacy safety another type adaptive clinical trial adaptive phase trial design study includes interim analysis adaptation changes trial features common phase study eg multiple dose groups design similar phase trial adaptive phase trial design reduces timelines eliminating activities would required start separate study upon completion phase trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed table contents vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase studies doseranging studies finally phase trials provide necessary data effectiveness safety successful company submits regulatory filings appropriate regulatory agencies us fda review process begins complete nda bla submitted received accepted review agency within days receipt fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review pursuant prescription drug user fee act v pdufa fda review period target ndas original blas either six months priority review ten months standard review time application deemed sufficiently complete review timelines determined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information three months extensions review period communicated company fda act application either issuing approval letter issuing complete response letter crl stating application approved present form describing deficiencies fda identified company wish pursue application receiving crl resubmit application information addresses questions issues identified fda order support approval resubmissions subject review period targets vary depending underlying submission type content resubmission fda four program designations fast track breakthrough therapy accelerated approval priority review facilitate expedite development review new drugs address unmet medical needs treatment serious lifethreatening conditions fast track designation provides pharmaceutical manufacturers opportunities frequent interactions fda reviewers products development ability manufacturer rolling submission ndabla rolling submission allows completed portions application submitted reviewed fda ongoing basis breakthrough therapy designation provides manufacturers features fast track designation well intensive guidance implementing efficient development program product commitment fda involve senior managers experienced staff review accelerated approval designation allows fda approve product based effect surrogate intermediate endpoint reasonably likely predict products clinical benefit generally requires manufacturer conduct required postapproval confirmatory trials verify clinical benefit priority review designation means fdas goal take action ndabla within six months compared ten months standard review one special designations granted given application ie product designated breakthrough therapy may also eligible priority review due covid public health crisis us secretary health human services exercised statutory authority determine public health emergency exists declared circumstances justify emergency use drugs biological products authorized fda effect declaration enables fda issue emergency use authorizations euas permitting distribution use specific medical products absent ndabla submission approval including products treat prevent diseases conditions caused sarscov virus subject terms euas fda must make certain findings grant eua including reasonable believe based totality evidence drug biologic may effective known potential benefits used terms eua outweigh known potential risks additionally fda must find adequate approved available alternative emergency use fda may revise revoke eua circumstances justifying issuance longer exist criteria issuance longer met circumstances make revision revocation appropriate protect public health safety primary method company uses obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure table contents must file complete set safety data efficacy data part marketing authorization application maa european medicines agency ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure eu member states outside us eu company submits marketing applications national regulatory authorities examples ministry health labour welfare japan national medical products administration china health canada agncia nacional de vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia country separate independent review process timeline many markets approval times longer regulatory authority requires approval major market us eu issuance certificate pharmaceutical product market initiating local review process research development update company currently several candidates regulatory review us internationally latestage clinical development mk molnupiravir investigational oral antiviral medicine treatment mild moderate covid adults risk progressing severe disease merck developing molnupiravir collaboration ridgeback biotherapeutics lp fda granted emergency use authorization eua molnupiravir december updated february authorize molnupiravir treatment mild moderate covid adults positive results direct sarscov viral testing high risk progression severe covid including hospitalization death alternative covid treatment options approved authorized fda accessible clinically appropriate authorization based phase moveout trial molnupiravir approved use us authorized duration declaration circumstances exist justifying authorization emergency use food drug cosmetic act unless authorization terminated revoked sooner molnupiravir also received conditional marketing authorization uk special approval emergency japan november ema issued positive scientific opinion molnupiravir intended support national decisionmaking possible use molnupiravir prior marketing authorization october ema initiated rolling review molnupiravir treatment covid adults merck plans work committee medicinal products human use ema complete rolling review process facilitate initiating formal review maa applications regulatory bodies worldwide underway molnupiravir also evaluated postexposure prophylaxis phase moveahead trial evaluating efficacy safety molnupiravir prevention covid adults reside person covid previously announced data movein clinical trial indicated molnupiravir unlikely demonstrate clinical benefit hospitalized patients generally longer duration symptoms prior study entry therefore decision made proceed phase mk gefapixant investigational orally administered selective px receptor antagonist treatment refractory chronic cough unexplained chronic cough adults review fda nda gefapixant based results cough cough clinical trials january fda issued complete response letter crl regarding mercks nda gefapixant crl fda requested additional information related measurement efficacy crl related safety gefapixant merck reviewing letter considering next steps gefapixant also review eu although review period extended pending receipt additional information company v investigational valent pneumococcal conjugate vaccine review japan use adults v approved us use adults marketed vaxneuvance vaxneuvance also priority review fda prevention invasive pneumococcal disease children weeks years age fda grants priority review medicines vaccines approved would provide significant improvement safety effectiveness treatment prevention serious condition fda set pdufa date april supplemental bla supported results phase phase clinical studies pediatric populations including infants children adolescents table contents mk keytruda antipd therapy approved treatment many cancers clinical development expanded indications approvals result broad clinical development program currently consists clinical trials including trials combine keytruda cancer treatments studies encompass cancer types including biliary estrogen receptor positive breast cancer cervical colorectal cutaneous squamous cell endometrial esophageal gastric glioblastoma head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma nonsmallcell lung smallcell lung melanoma mesothelioma ovarian prostate renal triplenegative breast urothelial many currently phase clinical development trials planned cancers keytruda review eu adjuvant treatment adult pediatric years older patients stage iib iic melanoma following complete resection based data phase keynote trial keytruda review japan adjuvant treatment patients rcc intermediatehigh high risk recurrence following nephrectomy surgical removal kidney based data phase keynote trial keytruda review fda treatment patients advanced endometrial cancer msih dmmr disease progression following prior systemic therapy setting candidates curative surgery radiation submission based data keynote trial fda set pdufa date march keytruda review eu treatment unresectable metastatic msih dmmr colorectal endometrial gastric small intestine biliary pancreatic cancer adults received prior therapy proposed indication based results keynote keynote trials keytruda combination chemotherapy review eu japan treatment patients highrisk earlystage tnbc neoadjuvant treatment single agent adjuvant treatment surgery based data keynote trial keytruda review japan treatment adult patients advanced recurrent tmbh solid tumors progressed chemotherapy limited use difficult treat standard care based keynote trial keytruda combination chemotherapy without bevacizumab also review eu japan firstline treatment patients persistent recurrent metastatic cervical cancer based keynote trial january merck european organisation research treatment cancer european thoracic oncology platform announced phase keynote trial investigating keytruda met one dual primary endpoints diseasefree survival dfs adjuvant treatment patients stage ibiiia nsclc following surgical resection regardless pdl expression based interim analysis review conducted independent data monitoring committee adjuvant treatment keytruda resulted statistically significant clinically meaningful improvement dfs compared placebo allcomer population patients stage ibiiia nsclc interim analysis also improvement dfs patients whose tumors express pdl tumor proportion score tps treated keytruda compared placebo however dual primary endpoint meet statistical significance per prespecified statistical plan trial continue analyze dfs patients whose tumors express high levels pdl tps evaluate overall survival key secondary endpoint results presented upcoming medical meeting submitted regulatory authorities mk lynparza oral parp inhibitor currently approved certain types advanced ovarian breast pancreatic prostate cancers co developed multiple cancer types part collaboration astrazeneca plc november fda accepted priority review supplemental nda lynparza adjuvant treatment patients brcamutated human epidermal growth factor receptor hernegative highrisk earlystage breast cancer already treated chemotherapy either surgery based results phase olympia trial fda set pdufa date first quarter table contents indication also review eu lynparza also review eu treatment certain patients metastatic castrationresistant prostate cancer based propel clinical trial mk lenvima oral receptor tyrosine kinase inhibitor developed part collaboration eisai co ltd eisai merck eisai studying keytruda plus lenvima combination leap lenvatinib pembrolizumab clinical program includes phase studies across different tumor types biliary cancer crc endometrial carcinoma esophageal cancer gastric cancer glioblastoma hcc hnscc melanoma pancreatic cancer prostate cancer nsclc sclc rcc july merck eisai announced fda issued crl regarding mercks eisais applications seeking accelerated approval first line treatment patients unresectable hcc based keynotestudy trial ahead pdufa action dates mercks eisais applications another combination therapy approved based randomized controlled trial demonstrated improvement overall survival versus standardofcare treatment consequently crl stated mercks eisais applications provide evidence keytruda combination lenvima represents meaningful advantage available therapies treatment unresectable metastatic hcc prior systemic therapy advanced disease since applications keynotestudy longer meet criteria accelerated approval companies plan work fda take appropriate next steps include conducting wellcontrolled clinical trial demonstrates substantial evidence effectiveness clinical benefit combination leap phase trial evaluating keytruda plus lenvima combination firstline treatment advanced hcc currently underway fully enrolled crl impact current approved indications keytruda lenvima merck eisai stopped leap phase study evaluating firstline treatment lenvima combination keytruda participants metastatic squamous nonsquamous nsclc whose tumors pdl positive egfr alk genomic tumor aberrations trial discontinued following recommendation external data monitoring committee edmc met scheduled assess safety futility edmc determined study met criteria declaring futility benefitrisk profile combination support continuing trial merck eisai closed leap enrollment leap phase study evaluating lenvima combination keytruda first line treatments patients platinumineligible urothelial carcinoma enrollment closed following recommendation edmc met scheduled assess safety futility edmc determined benefitrisk profile combination support continuing trial improvements outcomes favor combination unlikely high initially hypothesized company also several programs phase clinical development mka coformulation quavonlimab mercks novel investigational antictla antibody pembrolizumab evaluated treatment rcc subcutaneous mk pembrolizumab evaluated comparability intravenous formulation nsclc mka coformulation favezelimab mercks novel investigational antilag therapy pembrolizumab evaluated treatment crc mk welireg belzutifan hypoxiainducible factor hif inhibitor evaluated supplemental indication treatment patients rcc mk tukysa small molecule tyrosine kinase inhibitor treatment herpositive cancers development treatment breast cancer september seagen granted merck exclusive license entered codevelopment agreement merck accelerate global reach tukysa mka coformulation vibostolimab antitigit therapy pembrolizumab evaluated treatment nsclc december merck announced fda placed clinical holds investigational new drug applications oral implant formulations islatravir mk hiv preexposure prophylaxis table contents prep injectable formulation islatravir hiv treatment prophylaxis oral doravirineislatravir mka hiv oncedaily treatment regimen fdas clinical hold based observations decreases total lymphocyte cd tcell counts participants receiving islatravir clinical studies merck previously announced stopped dosing phase imaginedr clinical trial islatravir combination mk mk paused enrollment oncemonthly phase prep studies mk mk fdas clinical hold new studies may initiated additionally merck gilead made decision stop dosing participants phase clinical study evaluating oralweekly combination treatment regimen islatravir gileads investigational lenacapavir people living hiv virologically suppressed antiretroviral therapy decision follows joint announcement november temporary hold enrollment screening study commenced october two companies assess whether different dosing islatravir combination lenacapavir may provide onceweekly oral therapy option people living hiv merck gilead remain committed collaboration aims develop longacting new treatment options address unmet needs people living hiv mk sotatercept potentially firstinclass therapy treatment pulmonary arterial hypertension pah sotatercept clinical trials addon current standard care treatment pah sotatercept obtained connection mercks acquisition acceleron pharma inc mk clesrovimab respiratory syncytial virus rsv monoclonal antibody evaluated prevention rsv medically attended lower respiratory tract infection infants certain children years age april merck announced discontinuation development mk evaluated treatment hospitalized patients covid merck obtained mk december acquisition oncoimmune privately held clinicalstage biopharmaceutical company merck received feedback fda additional data would needed support potential eua application therefore company expect mk would become available first half given timeline technical clinical regulatory uncertainties availability number medicines patients hospitalized covid need concentrate mercks resources accelerating development manufacture viable therapeutics vaccines merck decided discontinue development mk treatment covid september fda approved updated labeling steglatro steglujan segluromet medicines adults type diabetes include primary efficacy safety results vertis cv trial assessed effect steglatro compared placebo cardiovascular outcomes adult patients type diabetes established atherosclerotic cardiovascular disease fda issued crl concerning companys application new indication based additional results vertis cv trial reduce risk hospitalization heart failure company determined pursue indication chart reflects companys research pipeline february candidates shown phase include specific products date candidate entered phase development candidates shown phase include advanced compound specific mechanism listed compounds mechanism currently intended commercialization given therapeutic area small molecules biologics given mknumber designations vaccine candidates given vnumber designations except otherwise noted candidates phase additional indications therapeutic area respect cancer additional claims line extensions formulations inline products shown table contents phase phase phase entry date review cancer antiviral covid new molecular entitiesvaccines mk k n n n el mlc tae bl rl u l tiu nn ibg cam nck er molnupiravir may us ant miv kir l c v mi od l n u piravir eu hematological malignancies mka quavonlimabpembrolizumab cough mk k n n mq u qla l uv c ao ven l oll ni lm lu ia mnb ag b pembrolizumab mkr e n l c kel el ta rup dr ail pnem umk c c ca lg vef aap ccix inan e du u ls eu advanced solid tumors biliary september v jpn colorectal cutaneous squamous cell august eu h ep laa nto oc mel alular gastric may eu smallcelllung hepatocellular may eu certain supplemental filings mk b h n r e oe na st mz li al lo g lv cce er lt l lm laa ulb ng gv ne ad ct ii en prve os r tit aah tn ee l mo em ac ya e b e ry c ake dr j u v n tk te ry et ar tu md ea nt stage iib iic melanoma mk k h em v ok c f le ae od vy gt er iz cu e ad lii md ab lu igm ar ns cies mks nm oa nl l c e p al lel l l cbu ern llg l l zm uu nma gy b u u b g c u u st ta n e u adju vk kee n ety rn neo n oat tle ec e l l c ne jc pu e nr nonsmallcell lung mka favezelimabpembrolizumab msih dmmr endometrial cancer mk r en aa l cc e ef lla v le uz nel gimabpembrolizumab mkc l r ec wtal e l reo gv e mber ms ik oy rn mt r x uu ms r basket mk renal cell february keynote eu n r smo enn aa l ls l cm c ea e l l lc ue nll g lung mk b ou ck ty os ba e r high er uis k e jpa nrly stage triplenegative breast cancer keynote mk mk lynparza tumor mutational burdenhigh keynote jpn nonsmallcell lung colorectal august cervical cancer keynote eu jpn mks l l c le al dl il rau tun zg umab vedotin nonsmallcell lung june breast smallcell lung december esophageal mka vibostolimabpembrolizumab gastric nonsmallcell lung april mk lynparza h ne oea l nd n sa mn md aa l ln cec ek lung mk c lo r e cl tae ln v aim pa ri l brca em uu tated hernegative adjuvant breast cancer olympia us prostate esophageal july firstline metastatic prostate cancer mks l l c ell l il reu gn g gastric december propel eu biliary head neck february colorectal melanoma march mkh p r v ae np r n eca rt c heo aa tic nt p ue cc pl kel eu r ys sa l ar n dau diseaseassociated tumors eu h h mv v k n po n rn f ee v c et nm toa il n odl n oc rae vll rl inu en g sm lata rr ac vh r f eb ruary f k r k l ei yn l e n e ev tti eam c h uep sa c ellular carcinoma b b cd l el rv vaa r ce ac r led solid tumors pulm mmk kon r ri sts oel r ta ait tr ea l rv h ci er p p e f r e jb e ar n nu ua ar ry n v kan ec yed n u tr ees e c ab l e jp r nen l cell carcinoma c eno dlo mec et ta rl ial respiratory syncytial virus gastric mk clesrovimab november nonsmallcell lung mk lynparza advanced solid tumors mk vibostolimab melanoma mka vibostolimabpembrolizumab footnotes b bi rl ei aa sry developed collaboration cervical endometrial developed combination keytruda esophageal head neck developed monotherapy andor combination keytruda hematological malignancies h pre op sa tt ao tecellular fda clinical hold mk b il ia ry lenvima available us emergency use authorization g pali cb rela tit coma january fda issued crl merck reviewing crl prostate considering next steps smallcell lung v july fda issued crl mercks eisais applications b cr ue ta nt eous squamous cell merck eisai intend submit additional data available head neck fda melanoma solid tumors approved february cardiovascular mk chikungunya virus vaccine v hiv infection mkb islatravirmk mkd islatravirlenacapavir nonalcoholic steatohepatitis nash mk mk overgrowth syndrome mk miransertib pneumococcal vaccine adult v pulmonary arterial hypertension mk schizophrenia mk treatment resistant depression mk table contents human capital december company approximately employees worldwide approximately employed us including puerto rico additionally approximately thirdparty contractors globally approximately companys employees fulltime employees women individuals underrepresented ethnic groups comprise approximately workforce company defines workforce employees us respectively women comprise members board directors additionally companys executive team made women approximately companys employees represented various collective bargaining groups companys voluntary turnover rate approximately respectively company recognizes employees critical meet needs patients customers ability excel depends integrity skill diversity employees third party contractors include companys temporary workers independent contractors freelancers viewed fulltime equivalent employees exclude outsourced service providers talent acquisition company uses comprehensive approach ensure recruiting retention leadership development goals systematically executed throughout company hires talented leaders achieve improved gender parity representation across dimensions diversity company provides training managers external recruiting organizations strategies mitigate unconscious bias candidate selection hiring process addition company utilizes comprehensive communications strategy employee branding marketing outreach social media strategic alliance partnerships reach broad pool talent critical business areas company hired approximately employees across globe various channels including companys external career site direct passive candidate sourcing diversity partnerships employee referrals universities external sources global diversity inclusion diversity inclusion fundamental companys success core future innovation company fosters globally diverse inclusive workforce employees creating environment belonging engagement equity empowerment company proactive intentional diversity hiring development programs advance talent company creates competitive advantages leveraging diversity inclusion accelerate business performance includes fostering global supplier diversity integrating diversity inclusion companys commercialization strategies leveraging employee insights improve performance addition efforts company ten employee business resource groups provide opportunities employees take active part contributing companys inclusive culture work talent acquisition development business customer insights social community outreach companys diversity goals include increasing representation senior management roles women globally ii blackafrican americans us iii hispanicslatinos us december representation senior management roles company women globally ii blackafrican americans us iii hispanicslatinos us addition company seeks maintain exceed current inclusion index score current employee engagement index score senior management role defined individual holding either vice president senior vice president title inclusion index average favorability score employees responses three items employee pulse survey manager supports inclusion sense belonging leaders value perspective employee engagement index average favorability score employees responses items employee survey table contents gender ethnicity performance data women workforce women workforce us women board directors women executive roles women management roles members underrepresented ethnic groups board directors members underrepresented ethnic groups executive roles us members underrepresented ethnic groups workforce us members underrepresented ethnic groups management roles us new hires female new hires members underrepresented ethnic groups us selfidentified company prior period data restated adjust organon spinoff executive role defined individual holding executive vice president title management role defined managers direct reports executives defined note compensation benefits company provides valuable total rewards package reflecting commitment attract retain motivate talent support employees families every stage life company continuously monitors adjusts compensation benefit programs ensure competitive contemporary helpful engaging support strategic imperatives diversity inclusion equity flexibility quality security affordability example company added personal health care concierge service assist us employees participating company medical plan health care needs aligned business support cancer care strategy company also improved cancer screening benefits added resources provided immediate access leading cancer center excellence us employees globally company implemented minimum standard weeks paid parental leave inclusively applies parents us companys benefits rank top quartile fortune companies aon benefits index company included seramount previously working mother best companies ranking consecutive years named seramount top ten best company dads employee wellbeing company committed helping employees families improve health wellbeing companys culture wellbeing referred live includes programs support preventive health emotional financial wellbeing physical fitness nutrition designed inspire employees pursue enjoy share healthy lifestyles live launched us today available every country company employees addition many companys larger sites offer onsite health clinics provide array services help employees stay get well including vaccinations cancer biometric screenings travel medicine advice diagnosis treatment nonoccupational illnesses injuries health counseling referrals companys overall employee wellbeing program recognized excellence health wellbeing receiving recent highestlevel awards business group health american heart association covid response company recognizes unique responsibility help response covid pandemic committed supporting protecting employees families ensuring supply medicines vaccines reaches patients contributing scientific expertise development antiviral approaches supporting health care providers communities serve company continues provide employees easy regular access information including details regarding companys tracking process guidance around hygiene measures travel best practices working home examples pandemic support resources programs available companys employees include pay continuation workers sick exposed volunteer policy adjustment enable employees table contents medical backgrounds volunteer sarscovrelated activities resources prioritize physical mental wellness adjustments medical plans cover covidrelated diagnosis testing treatment backup childcare engaging employees company strives foster employee engagement promoting safe positive diverse inclusive work environment provides numerous opportunities twoway communication employees companys key programs initiatives include promoting global employee engagement surveys ongoing pulse checks organization interim feedback specific topics fostering professional networking collaboration identifying providing opportunities volunteering establishing positive cooperative business relations designated employee representatives talent management development company pursues goal becoming worlds premier researchbased biopharmaceutical company consistent focus importance continuously developing diverse talented people companys current talent management system supports companywide performance management leadership development talent reviews succession planning annual performance reviews help professional development companys employees ensure companys workforce aligned companys objectives company seeks continuously build skills capabilities workforce accelerate talent improve performance mitigate risk relevant continuous learning experiences includes limited building leadership management skills well providing technical functional training employees environmental matters environmental sustainability company strives strong environmental steward realizes strategy efforts need continuously improve company excel increasingly resourceconstrained world companys environmental sustainability strategy three areas focus driving efficiency operations designing new products minimize environmental impact reducing impacts companys upstream downstream value chain company recently adopted set new climate goals address rising expectations customers investors external stakeholders employees regarding environmental impact operations supply chain goals include achieving carbon neutrality greenhouse gas emissions across operations scopes reducing scope greenhouse gas emissions baseline reducing value chain scope greenhouse gas emissions baseline sourcing renewable energy purchased electricity companys absolute greenhouse gas reduction targets verified science based target initiative environmental sustainability initiatives company include global water use stewardship companys global water strategy aims achieve sustainable water management within operations supply chain well address waterrelated risk access clean water critical human health water key input companys manufacturing operations companys sites employ variety technologies techniques closedloop cooling systems reused reverse osmosis reject water reduce companys water footprint improve operational performance waste management diversion company continuously strives reduce amount operational waste generates maximize use environmentally beneficial disposal methods recycling composting wastetoenergy product stewardship green sustainable science companys product stewardship program focuses identifying either preventing minimizing potential safety environmental hazards throughout products life cycle company also committed table contents understanding managing reducing environmental impacts products materials associated discovering producing companys green sustainable science program uses greenbydesign approach using efficient innovative processing methods technologies company reducing amount energy water raw materials company uses make companys products thereby reducing amount waste company generates lowering companys production costs animal conservation company leading worldwide supplier individual identification realtime data access advanced analytics animal conservation community enables company produce actionable insights inform recovery actions global scale species ranging wild fish penguins company also provides wild fish conservation monitoring equipment realtime video monitoring technology advance fish health welfare together technologies help promote biodiversity support global need reliable safe sources protein management believe expenditures related initiatives material adverse effect companys financial condition results operations liquidity capital resources year december company completed inaugural issuance billion sustainability bond part billion underwritten bond offering company intends use net proceeds sustainability bond offering support projects partnerships companys priority environmental social governance esg areas contribute advancement united nations sustainable development goals merck believes climate change could present risks business potential impacts climate change business include increased operating costs due additional regulatory requirements physical risks companys facilities water limitations disruptions supply chain potential risks integrated companys business planning including investment reducing energy usage water use greenhouse gas emissions environmental regulation remediation company believes compliance issues associated applicable environmental laws regulations would material adverse effect company company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million estimated million aggregate years amounts consider potential recoveries parties company taken active role identifying accruing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed approximately million aggregate management also believe expenditures material adverse effect companys financial condition results operations liquidity capital resources year geographic area information companys operations outside us conducted primarily subsidiaries sales worldwide subsidiaries outside us percentage total company sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions table contents merck operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time available information companys internet website address merckcom company make available free charge investors portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished us securities exchange commission sec address website secgov addition company provide without charge copy annual report including financial statements schedules upon written request shareholder office secretary merck co inc galloping hill road k kenilworth nj usa companys corporate governance guidelines charters board directors four standing committees available companys website merckcomcompanyoverviewleadership information available print shareholder requests company companys environmental social governance esg progress report provides enhanced esg disclosures available companys website merckcomcompanyoverviewresponsibility information companys esg progress report incorporated reference item risk factors summary risk factors company subject number risks realized could materially adversely affect business results operations cash flow financial condition prospects following summary principal risk factors facing company company dependent patent rights patent rights invalidated circumvented business could materially adversely affected companys products lose market exclusivity company generally experiences significant rapid loss sales products key products generate significant amount companys profits cash flows events adversely affect markets leading products could material adverse effect companys results operations financial condition companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lose patent protection companys success dependent successful development marketing new products subject substantial risks company faces continued pricing pressure respect products unfavorable uncertain economic conditions together costreduction measures taken certain governments could negatively affect companys operating results company faces intense competition lower cost generic products company faces intense competition competitors products covidrelated disruptions adverse impact companys business operations financial performance company unable predict full extent table contents covid pandemic future pandemic epidemic similar public health threat adversely impact business operations financial performance results operations financial condition company significant global operations expose additional risks adverse event could material adverse effect companys results operations financial condition climate change legal regulatory market measures address climate change may negatively affect companys business results operations cash flows prospects environmental social governance esg matters may impact companys business reputation failure attract retain highly qualified personnel could affect companys ability successfully develop commercialize products company may experience difficulties delays manufacturing certain products including vaccines company may able realize expected benefits investments emerging markets company exposed market risk fluctuations currency exchange rates interest rates pharmaceutical products develop unexpected safety efficacy concerns reliance thirdparty relationships outsourcing arrangements could materially adversely affect companys business negative events animal health industry could material adverse effect future results operations financial condition biologics vaccines carry unique risks uncertainties could material adverse effect companys future results operations financial condition health care industry us continue subject increasing regulation political action companys products including products development marketed unless company obtains maintains regulatory approval developments following regulatory approval may adversely affect sales companys products company subject variety us international laws regulations company subject evolving complex tax laws may result additional liabilities may affect results operations financial condition adverse outcomes current future legal matters could negatively affect mercks business product liability insurance products may limited cost prohibitive unavailable company increasingly dependent sophisticated software applications computing infrastructure company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations company could target future cyberattacks social media mobile messaging platforms present risks challenges list exhaustive company faces additional challenges risks investors carefully consider information set forth including following risk factors deciding invest companys securities table contents risk factors risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations cash flow prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results risks related companys business company dependent patent rights patent rights invalidated circumvented business could materially adversely affected patent protection considered aggregate material importance companys marketing human health animal health products us major foreign markets patents covering products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business successfully assert defend patent rights provide market exclusivity products company often involved patent disputes relating challenges patents claims third parties infringement company company asserts defends patents within outside us including filing claims infringement parties see item financial statements supplementary data note contingencies environmental liabilities particular manufacturers generic pharmaceutical products time time file abbreviated ndas fda seeking market generic forms companys products prior expiration relevant patents owned licensed company company normally responds asserting patent lawsuit alleging patent infringement patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases thirdparty patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies circumstances could diminish eliminate sales profits regions negatively affect companys results operations court decisions relating companies patents potential legislation us certain foreign markets relating patents well regulatory initiatives may result general weakening intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available companys results operations may adversely affected lost sales unless company launched commercially successful products replace lost sales addition products measured fair value capitalized connection acquisitions experience difficulties market negatively affect product cash flows company may recognize material noncash impairment charges respect value products chart listing patent protection certain companys marketed products us patent protection candidates phase clinical development set forth item business patents trademarks licenses companys products lose market exclusivity company generally experiences significant rapid loss sales products company depends upon patents provide exclusive marketing rights products period time loss patent protection one companys products typically leads significant table contents rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss market exclusivity material adverse effect companys business cash flow results operations financial condition prospects januvia janumet lose market exclusivity us january januvia janumet lose market exclusivity eu september china july company anticipates sales januvia janumet markets decline substantially loss exclusivity key products generate significant amount companys profits cash flows events adversely affect markets leading products could material adverse effect companys results operations financial condition companys ability generate profits operating cash flow depends largely upon continued profitability companys key products keytruda gardasilgardasil lynparza bravecto bridion particular companys oncology portfolio led keytruda represented substantial portion companys revenue growth result companys dependence key products event adversely affects products markets products could significant adverse impact results operations financial condition events could include loss patent protection increased costs associated manufacturing generic overthecounter availability companys product competitive product discovery previously unknown side effects results postapproval trials increased competition introduction new effective treatments discontinuation removal market product reason events could material adverse effect sales products companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lose patent protection order remain competitive company like major pharmaceutical companies must continue launch new products expected declines sales products loss market exclusivity mean companys future success dependent pipeline new products including new products may develop collaborations joint ventures products able obtain license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research development process new drugs vaccines result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested description research development process see item business research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals therefore company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results competing products manufacturers may reach market first clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved regulators intended use may possible obtain patent new drug payers may refuse cover reimburse new product sales new product may disappointing company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications existing products sufficient cover substantial research development costs replace sales lost profitable products lose market exclusivity displaced competing products therapies failure short table contents term long term would material adverse effect companys business results operations cash flow financial condition prospects companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market fail succeed numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications anticipated labeling uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals failure certain markets obtain reimbursement commensurate level innovation clinical benefit presented product lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others future certain pipeline programs cancelled company believes commercial prospects reduced company may recognize material noncash impairment charges programs measured fair value capitalized connection acquisitions certain collaborations failure successfully develop market new products short term long term would material adverse effect companys business results operations cash flow financial condition prospects company faces continued pricing pressure respect products company faces continued pricing pressure globally particularly mature markets managed care organizations government agencies programs could negatively affect companys sales profit margins us include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act aca iii state activities aimed increasing price transparency including new laws noted item competition health care environment changes health care system enacted part health care reform us well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition us larger customers received higher rebates drugs certain highly competitive categories company must also compete placed formularies managed care organizations exclusion product formulary lead reduced usage managed care organization order provide information companys pricing practices company annually posts website pricing transparency report us report provides companys average annual list price net price increases across companys us portfolio dating back companys gross us sales reduced result rebates discounts returns outside us numerous major markets including eu japan china pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government decision making budgetary actions respect products japan pharmaceutical industry subject governmentmandated annual price reductions pharmaceutical products certain vaccines furthermore government order repricing specific products determines use product exceed certain thresholds defined applicable repricing rules table contents company expects pricing pressures continue future unfavorable uncertain economic conditions together costreduction measures taken certain governments could negatively affect companys operating results companys business may adversely affected local global economic conditions including respect inflation interest rates costs raw materials packaging uncertainty global economic geopolitical conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales result material adverse effect companys business cash flow results operations financial condition prospects discussed competition health care environment global efforts toward health care cost containment continue exert pressure product pricing market access worldwide changes us health care system part health care reform well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries contributed pricing pressure several international markets government mandated pricing actions reduced prices generic patented drugs addition companys revenue performance negatively affected costreduction measures taken governments third parties lower health care costs company anticipates actions additional actions future continue negatively affect revenue performance credit economic conditions worsen resulting economic currency impacts affected markets globally could material adverse effect companys results addition covid pandemic caused disruption volatility companys global supply chain network company may experience disruptions availability delays shipments raw materials packaging well related cost inflation disruptions delays costs may result companys inability meet demand companys products company faces intense competition lower cost generic products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent protection significantly weaker us eu us eu political pressure reduce spending prescription drugs led legislation measures encourage use generic biosimilar products although companys policy actively protect patent rights generic challenges companys products arise time companys patents may prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time us countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial condition prospects company faces intense competition competitors products companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective convenient use better insurance coverage reimbursement levels effectively marketed sold companys products alternatively case generic competition including generic availability competitors branded products may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial condition prospects addition products measured fair value capitalized table contents connection acquisitions experience difficulties market negatively impact product cash flows company may recognize material noncash impairment charges respect value products covidrelated disruptions adverse impact companys business operations financial performance company unable predict full extent covid pandemic future pandemic epidemic similar public health threat adversely impact business operations financial performance results operations financial condition companys business financial results negatively impacted covidrelated disruptions continued duration severity covid pandemic uncertain rapidly changing difficult predict degree covidrelated disruptions impact companys results depend future developments beyond companys knowledge control including limited duration pandemic severity success actions taken contain prevent virus treat impact quickly extent normal economic operating conditions resume covid pandemic impacted companys business numerous ways expected within companys human health business comprised largely physicianadministered products revenue negatively impacted social distancing measures fewer well visits negatively affected vaccine oncology sales particular estimated negative impact covidrelated disruptions mercks revenue full year approximately billion attributable pharmaceutical segment merck believes global health systems patients largely adapted impacts covid however roughly mercks pharmaceutical segment revenue comprised physicianadministered products could adversely affected pandemic effects worsen despite companys efforts manage impacts covid pandemic ultimate effect also depend factors beyond companys knowledge control including duration covid pandemic well governmental thirdparty actions taken contain prevent spread treatment virus mitigate public health economic effects addition future pandemic epidemic similar public health threat could present similar risks companys business cash flow results operations financial condition prospects company significant global operations expose additional risks adverse event could material adverse effect companys results operations financial condition extent companys operations outside us significant risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements including imposition trade sanctions similar restrictions us governments foreign exchange fluctuations diminished protection intellectual property countries possible nationalization expropriation addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease particular february armed conflict escalated russia ukraine possible predict broader consequences conflict could include sanctions embargoes regional instability geopolitical shifts adverse effects macroeconomic conditions currency exchange rates financial markets table contents climate change legal regulatory market measures address climate change may negatively affect companys business results operations cash flows prospects company believes climate change potential negatively affect business results operations cash flows prospects company exposed physical risks extreme weather conditions rising sea levels risks transitioning lowcarbon economy additional legal regulatory requirements changes technology market risk reputational risk social human effects population dislocations harm health wellbeing associated climate change risks either acute shortterm chronic longterm adverse impacts climate change include increased frequency severity natural disasters extreme weather events hurricanes tornados wildfires exacerbated drought flooding extreme heat extreme weather sealevel rise pose physical risks companys facilities well suppliers risks include losses incurred result physical damage facilities loss spoilage inventory business interruption caused natural disasters extreme weather events potential physical impacts due climate change include reduced access highquality water certain regions loss biodiversity could impact future product development risks could disrupt companys operations supply chain may result increased costs new legal regulatory requirements may enacted prevent mitigate adapt implications changing climate effects environment regulations may differ across jurisdictions could result company subject new expanded carbon pricing taxes increased compliance costs restrictions greenhouse gas emissions investment new technologies increased carbon disclosure transparency upgrade facilities meet new building codes redesign utility systems could increase companys operating costs including cost electricity energy used company companys supply chain would likely subject transitional risks would likely pass along increased costs company environmental social governance esg matters may impact companys business reputation governmental authorities nongovernmental organizations customers investors external stakeholders employees increasingly sensitive esg concerns diversity inclusion climate change water use recyclability recoverability packaging plastic waste focus esg concerns may lead new requirements could result increased costs associated developing manufacturing distributing companys products companys ability compete could also affected changing customer preferences requirements growing demand environmentally friendly products packaging supplier practices failure meet customer expectations demand company strives improve esg performance company risks negative stockholder reaction including proxy advisory services well damage brand reputation company act responsibly company perceived acting responsibly key esg areas including equitable access medicines vaccines product quality safety diversity inclusion environmental stewardship support local communities corporate governance transparency addressing human capital factors companys operations company meet esg expectations investors customers stakeholders company could experience reduced demand products loss customers negative impacts companys business results operations failure attract retain highly qualified personnel could affect companys ability successfully develop commercialize products companys success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry us internationally intense company sure able attract retain quality personnel costs materially increase table contents company may experience difficulties delays manufacturing certain products including vaccines merck past experienced difficulties manufacturing certain products including vaccines example company issued product recall zerbaxa following identification product sterility issues company may future experience difficulties delays manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including supply chain delays shortages raw materials changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply addition company could experience difficulties delays manufacturing products caused natural disasters hurricanes manufacturing difficulties result product shortages leading lost sales reputational harm company company may able realize expected benefits investments emerging markets company taking steps increase sales emerging markets however guarantee companys efforts expand sales markets succeed countries within emerging markets may especially vulnerable periods global financial instability may limited resources spend health care order company successfully implement emerging markets strategy must attract retain qualified personnel company may also required increase reliance thirdparty agents within less developed markets may affect ability realize continued growth may also increase companys risk exposure addition many countries currencies fluctuate substantially currencies devalue company offset devaluations companys financial performance within countries could adversely affected companys business china grown rapidly past years importance china companys overall pharmaceutical vaccines business outside us increased accordingly continued growth companys business china dependent upon ongoing development favorable environment innovative pharmaceutical products vaccines sustained access companys currently marketed products absence trade impediments adverse pricing controls noted competition health care environment pricing pressure china increased chinese government taking steps reduce costs including implementing health care reform led acceleration generic substitution available mechanism drugs added nrdl evolves inclusion may require price negotiation could impact outlook market selected brands drugs added nrdl average price reductions pricing pressure always existed china health care reform increased pressure part due acceleration generic substitution governments vbp program government implemented vbp program tendering process mature products generic substitutes generic quality consistency evaluation approval mature products entered last five rounds vbp average price reduction company expects vbp semiannual process significant impact mature products moving forward addition company anticipates reported inquiries made various governmental authorities involving multinational pharmaceutical companies china may continue reasons sales within emerging markets carry significant risks however time macroeconomic growth selected emerging markets expected outpace europe even us leading significant increased health care spending countries access innovative medicines patients failure maintain companys presence emerging markets could therefore material adverse effect companys business cash flow results operations financial condition prospects table contents company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter business development transactions borrowings financial transactions may give rise currency interest rate exposure since company certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates inflation could negatively affect companys business cash flow results operations financial condition prospects order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options forwards interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful certain companys interest rate derivatives investments based london interbank offered rate libor portion mercks indebtedness bears interest variable interest rates primarily based libor libor subject recent national international regulatory guidance proposals reform cause libor cease exist entirely future company begun implement alternative reference rates alternatives libor company predict consequences timing additional unexpected developments could include increase interest expense also require amendment contracts reference libor pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims including potential civil criminal governmental actions reliance thirdparty relationships outsourcing arrangements could materially adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies thirdparty service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business negative events animal health industry could material adverse effect future results operations financial condition future sales key animal health products could adversely affected number risk factors including certain risks specific animal health business example outbreak disease carried animals african swine fever could lead widespread death precautionary destruction well reduced consumption demand animals could adversely affect companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt manufacture animal health products sites force company incur substantial expenses procuring raw materials products elsewhere risks specific animal health include epidemics pandemics government procurement pricing practices weather global agribusiness economic events addition sales bravecto represent significant portion companys animal health segment sales negative event respect bravecto could material adverse effect companys animal health sales animal health segment companys business becomes significant impact events future results operations would also become significant table contents biologics vaccines carry unique risks uncertainties could material adverse effect companys future results operations financial condition successful development testing manufacturing commercialization biologics vaccines particularly human animal health vaccines long complex expensive uncertain process unique risks uncertainties related biologics vaccines including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions us eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics vaccines subject regulation fda ema regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example us bla including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval generally required release manufactured commercial human vaccine lot manufacturing biologics vaccines especially large quantities often complex may require use innovative technologies handle living microorganisms lot approved biologic vaccine must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics vaccines frequently costly manufacture production ingredients derived living animal plant material biologics vaccines made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead variability manufacturing process could lead allegations harm including infections allergic reactions allegations would reviewed standard investigation process could lead closure product facilities due possible contamination events could result substantial costs risks relating government regulation legal proceedings health care industry us continue subject increasing regulation political action discussed competition health care environment company believes health care industry continue subject increasing regulation well political legal action future proposals reform health care system considered executive branch congress state legislatures centers medicare medicaid services cms issued medicaid rebate final rule implemented provisions aca effective april rule provides comprehensive guidance calculation average manufacturer price best price two metrics utilized determine rebates drug manufacturers required pay state medicaid programs december cms issued final rule making significant changes requirements effective january final rule also changes way manufacturers must calculate best price relation certain patient support programs including coupons phrma pharmaceutical industry trade group company member filed complaint challenging rule invalid asserting conflicts plain language medicaid drug rebate statute legal table contents challenge fail impact provisions final rule could adversely impact companys business cash flow results operations financial condition prospects congress passed american rescue plan act included provision eliminates statutory cap rebates drug manufacturers pay medicaid beginning january rebates act discount list price eliminating cap means manufacturer discounts paid medicaid increase prior change manufacturers required pay average manufacturer price amp rebates state medicaid programs medicaidcovered drugs result provision beginning possible manufacturers may pay state medicaid programs rebates received sales particular products change could present risk merck future drugs high medicaid utilization rebate exposure amp us biden administration congress continue discuss legislation designed control health care costs including cost drugs company predict additional future changes health care industry general pharmaceutical industry particular occur however changes could material adverse effect companys business cash flow results operations financial condition prospects companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities us including fda foreign regulatory authorities including eu japan china us fda administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals cases fda requirements increased amount time resources necessary develop new products bring market us regulation outside us also primarily focused drug safety effectiveness many cases reduction cost drugs fda foreign regulatory authorities including eu japan china substantial discretion require additional testing delay withhold registration marketing approval otherwise preclude distribution sale product even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling products jurisdiction company would able realize revenues new products jurisdiction approval developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval may decrease demand companys products including following results postapproval phase trials studies rereview products already marketed recall loss marketing approval products already marketed changing government standards public expectations regarding safety efficacy quality labeling changes scrutiny advertising promotion withdrawal indications granted pursuant accelerated approvals past clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised concerns led recalls withdrawals adverse labeling table contents marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda ema japans pmda chinas nmpa increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability consumer protection claims civil criminal governmental actions related products research andor marketing activities addition dissemination promotional materials evolving digital channels serves increase visibility scrutiny marketplace company subject variety us international laws regulations company currently subject number government laws regulations future could become subject new government laws regulations costs compliance laws regulations negative results noncompliance could adversely affect business cash flow results operations financial condition prospects company laws regulations include additional health care reform initiatives us countries including additional mandatory discounts fees ii us foreign corrupt practices act antibribery corruption laws iii new laws regulations judicial governmental decisions affecting pricing drug reimbursement access marketing within across jurisdictions iv changes intellectual property laws v changes accounting standards vi new increasing data privacy regulations enforcement particularly eu us china vii legislative mandates preferences local manufacturing pharmaceutical vaccine products viii emerging new global regulatory requirements reporting payments value transfers health care professionals ix environmental regulations x potential impact importation restrictions embargoes trade sanctions legislative andor regulatory changes company subject evolving complex tax laws may result additional liabilities may affect results operations financial condition company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns routinely examined various tax authorities connection organization economic cooperation development oecd base erosion profit shifting project companies required disclose information tax authorities operations around world may lead greater audit scrutiny profits earned countries company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued addition company may negatively affected changes tax laws new tax laws affecting example tax rates andor revised tax law interpretations domestic foreign jurisdictions including among others potential changes existing us tax law current us presidential administration congress well changes tax law resulting implementation oecds twopillar solution reform international tax landscape company taken position based opinions tax counsel distribution organon common stock connection spinoff organon qualifies transaction taxfree us federal income tax purposes facts assumptions representations undertakings company organon regarding past future conduct respective businesses matters table contents incorrect otherwise satisfied spinoff may qualify taxfree treatment could result significant us federal income tax liabilities company shareholders adverse outcomes current future legal matters could negatively affect mercks business current future litigation claims proceedings government investigations could preclude delay commercialization mercks products could adversely affect mercks business results operations cash flow prospects financial condition legal matters may include limited intellectual property disputes ii adverse decisions litigation including product safety liability consumer protection commercial cases iii antibribery regulations us foreign corrupt practices act including compliance ongoing reporting obligations government resulting settlements iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v product pricing promotional matters vi lawsuits claims administrative proceedings asserting investigations violations securities antitrust federal state pricing consumer protection data privacy laws regulations vii environmental health safety sustainability matters including regulatory actions response climate change viii tax liabilities resulting assessments tax authorities see item financial statements supplementary data note contingencies environmental liabilities information companys legal matters merck informed us department health human services health resources services administration hhs merck implementing update section b program integrity initiative pursuant merck required hospital covered entities provide b claims data claims originating contract pharmacies entities declined submit claims data mercks new initiative provided would longer voluntarily honor b discounts chargebacks contract pharmacy transactions except single contract pharmacy hospital covered entitys choice also hhs sent letters numerous drug manufacturers stating determined manufacturers actions restricting contract pharmacy transactions violation b statute stating manufacturers cease restrictions hhs might seek repayment overcharges well civil monetary penalties manufacturers litigation us government seeking confirm legality restrictions merck receive similar letter hhs however hhs could seek implement administrative proceedings recover overcharges andor impose civil monetary penalties merck proceedings implemented merck negative outcome could material adverse effect mercks business results operations cash flow prospects financial condition product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost insurance increased significantly company subject substantial number product liability claims see item financial statements supplementary data note contingencies environmental liabilities information companys current product liability litigation respect product liability company selfinsures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise risks related technology company increasingly dependent sophisticated software applications computing infrastructure company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations company could target future cyberattacks company increasingly dependent sophisticated software applications complex information technology systems computing infrastructure cloud service providers collectively systems conduct table contents critical operations certain systems managed hosted provided used third parties assist conducting companys business disruption degradation manipulation systems intentional accidental means companys employees third parties authorized access unauthorized third parties could adversely affect key business processes cyberattacks companys systems thirdparty providers systems cloudbased systems could result exposure confidential information modification critical data andor failure critical operations misuse systems could result disclosure sensitive personal information theft trade secrets intellectual property confidential business information company continues leverage new innovative technologies across enterprise improve efficacy efficiency business processes including data acquisition use create new risks company experienced network cyberattack led disruption worldwide operations including manufacturing research sales operations resulting losses company implemented variety measures enhance modernize systems guard similar attacks future also pursuing enterprisewide effort enhance company 's resiliency future cyberattacks including incidents similar attack objective efforts protect future cyberattacks also improve speed companys recovery attacks enable continued business operations greatest extent possible recovery period although aggregate impact cyberattacks network disruptions including cyberattack companys operations financial condition material date company continues target events nature expects continue company monitors data information technology personnel usage company systems reduce risks continues ongoing basis current potential threats assurance companys efforts protect data systems efforts thirdparty providers protect systems successful preventing disruptions companys operations including manufacturing research sales operations disruptions past could future result loss revenue loss critical sensitive information companys companys thirdparty providers databases systems past could future also result financial legal business reputational harm company substantial remediation costs social media mobile messaging platforms present risks challenges inappropriate andor unauthorized use certain social media mobile messaging channels could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information addition negative inaccurate posts comments company products social networking platforms could damage companys reputation brand image goodwill disclosure nonpublic companysensitive information companys workforce others external media channels could lead information loss although internal company social media mobile messaging policies guide employees appropriate personal professional use platforms communication company processes place may completely secure protect information identifying new points entry new communication tools expand also presents new challenges cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product approvals product potential development programs environmental sustainability initiatives include table contents statements related expected impact covid pandemic one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic andor biosimilar products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures us abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general impact global covid pandemic future pandemic epidemic similar public health threat companys business operations financial performance changes government laws regulations including laws governing intellectual property enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant changes customer relationships changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products cyberattacks companys thirdparty providers information technology systems could disrupt companys operations lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including us eu china legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority states us requiring security breach notification changes tax laws including changes related taxation foreign earnings changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company table contents economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item properties companys corporate headquarters currently located kenilworth new jersey company previously announced intends consolidate new jersey campuses single corporate headquarters location rahway new jersey end company also maintains operational divisional headquarters kenilworth new jersey madison new jersey upper gwynedd pennsylvania principal us research facilities located rahway kenilworth new jersey west point pennsylvania boston cambridge massachusetts south san francisco california elkhorn nebraska animal health principal research facilities outside us located united kingdom switzerland china mercks manufacturing operations currently headquartered whitehouse station new jersey company also production facilities human health products seven locations us puerto rico outside us subsidiaries company owns interest manufacturing plants properties japan singapore south africa countries western europe central south america asia number properties transferred organon spinoff capital expenditures billion billion billion us amounted billion billion billion abroad expenditures amounted billion billion billion company subsidiaries principal facilities manufacturing plants titles consider satisfactory company believes properties good operating condition machinery equipment well maintained company believes plants manufacture products suitable intended purposes capacities projected capacities including previously disclosed capital expansion projects adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings information called item incorporated herein reference item financial statements supplementary data note contingencies environmental liabilities item mine safety disclosures applicable table contents executive officers registrant ages february officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer persons name age offices business experience robert davis chief executive officer president since july executive vice president global services chief financial officer since april sanat chattopadhyay executive vice president president merck manufacturing division since march richard r deluca jr executive vice president president merck animal health since september cristal downing executive vice president chief communications public affairs officer since august vice president medical devices global communications public affairs johnson johnson december august vice president financial communication johnson johnson january december prior senior director communications johnson johnson kenneth c frazier executive chairman since july prior chairman president chief executive officer julie l gerberding executive vice president chief patient officer population health sustainability since july rita karachun senior vice president finance global controller since march michael klobuchar executive vice president chief strategy officer since july senior vice president cfo merck rd head global portfolio alliance management january june senior vice president corporate strategy planning president emerging businesses december january prior vice president global business financial planning lisa lecointecephas senior vice president chief ethics compliance officer since april executive director head global investigations february april prior senior counsel litigation government investigations bristolmyers squibb company dean li president merck research laboratories since january senior vice president discovery sciences translational medicine merck research laboratories november january vice president translational medicine march november prior chief scientific officer associate vice president university utah health sciences caroline litchfield executive vice president chief financial officer since april senior vice president corporate treasurer january march prior senior vice president global human health steven c mizell executive vice president chief human resources officer since december david williams executive vice president chief information digital officer since august acting chief information digital officer december august vice president chief information officer merck animal health may december prior associate vice president chief information officer merck animal health jennifer zachary executive vice president general counsel corporate secretary since january executive vice president general counsel april january prior partner covington burling llp table contents february company announced ms arpa garay lead human health global marketing mr jannie oosthuizen lead us human health ms garay mr oosthuizen become executive officers company effective february name age offices business experience arpa garay president global oncology digital since january president global pharmaceuticals commercial analytics digital marketing march january senior vice president us vaccines business unit june march prior managing director msd norway jannie oosthuizen senior vice president president merck us human health since january senior vice president head global oncology commercial january december senior vice president president msd kk july december table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk january approximately shareholders record companys common stock issuer purchases equity securities three months ended december follows issuer purchases equity securities millions total number shares purchased total number average price part publicly approximate dollar value shares shares paid per announced plans may yet purchased period purchased share programs plans programs october october november november december december total shares purchased period made part plan approved board directors october purchase billion merck shares treasury table contents performance graph following graph assumes investment december reinvestment dividends companys common stock sp index composite peer group major us europeanbased pharmaceutical companies abbvie inc amgen inc astrazeneca plc bristolmyers squibb company johnson johnson eli lilly company glaxosmithkline plc novartis ag pfizer inc roche holding ag sanofi sa comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer group sp merck peer group sp compound annual growth rate peer group average calculated market cap weighted basis december performance graph deemed incorporated reference filing securities act securities exchange act except extent company specifically incorporates reference addition performance graph deemed soliciting material filed sec subject regulation c provided regulation sk liabilities section securities exchange act except extent company specifically requests information treated soliciting material specifically incorporates reference filing securities act exchange act table contents item managements discussion analysis financial condition results operations description mercks business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include two operating segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines company sells human health vaccines primarily physicians wholesalers physician distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers company previously healthcare services segment provided services solutions focused engagement health analytics clinical services improve value care delivered patients company divested remaining businesses segment first quarter spinoff organon co june merck completed spinoff products womens health biosimilars established brands businesses new independent publicly traded company named organon co organon distribution organons publicly traded stock company shareholders distribution expected qualify treated taxfree company shareholders us federal income tax purposes established brands included transaction consisted dermatology nonopioid pain management respiratory select cardiovascular products well rest mercks diversified brands franchise mercks existing research pipeline programs continue owned developed within merck planned historical results businesses contributed organon spinoff reflected discontinued operations companys consolidated financial statements date spinoff see note consolidated financial statements table contents overview financial highlights change change excluding foreign excluding foreign millions change exchange change exchange sales net income continuing operations attributable merck co inc gaap nongaap earnings per common share assuming dilution continuing operations attributable merck co inc common shareholders gaap nongaap calculation meaningful nongaap net income nongaap earnings per share eps exclude acquisition divestiturerelated costs restructuring costs certain items discussion reconciliation gaap nongaap net income eps see nongaap income nongaap eps executive summary merck delivered strategic priorities executing commercially drive strong revenue earnings growth year completing key business development transactions accelerating broad pipeline achieving notable regulatory milestones also june merck completed spinoff organon historical results businesses contributed organon spinoff reflected discontinued operations companys consolidated financial statements date spinoff worldwide sales billion increase compared excluding favorable effect foreign exchange sales increase driven primarily growth oncology vaccines hospital acute care animal health additionally revenue reflects benefit sales molnupiravir investigational oral antiviral covid treatment discussed covidrelated disruptions negatively affected sales lesser extent benefited yearoveryear sales growth merck continues execute scientifically compelling business development opportunities augment pipeline november merck acquired acceleron pharma inc acceleron publicly traded biopharmaceutical company evaluating transforming growth factor tgfbeta superfamily proteins development pulmonary hematologic therapies april merck acquired pandion therapeutics inc pandion clinicalstage biotechnology company developing novel therapeutics designed address unmet needs patients living autoimmune diseases additionally merck entered collaboration gilead sciences inc gilead jointly develop commercialize longacting treatments hiv merck received approvals filed new drug applications ndas supplemental biologics license applications blas across us eu japan china company received numerous regulatory approvals within oncology keytruda received approval additional indications us andor internationally monotherapy therapeutic areas breast colorectal cutaneous squamous cell esophageal melanoma renal cell cancers well combination chemotherapy therapeutic areas breast cervical gastric gastroesophageal junction cancers keytruda also approved combination lenvima treatment certain adult patients endometrial cancer treatment renal cell cancer lenvima developed collaboration eisai co ltd eisai lynparza developed collaboration astrazeneca plc astrazeneca received approval china monotherapy treatment certain adult patients metastatic castration resistant prostate cancer additionally us food drug administration fda approved welireg belzutifan oral hypoxiainducible factor alpha hif inhibitor treatment adult patients von hippellindau vhl table contents disease require therapy associated renal cell carcinoma rcc central nervous system hemangioblastomas pancreatic neuroendocrine tumors requiring immediate surgery also updated february fda granted emergency use authorization eua molnupiravir investigational oral antiviral covid treatment developed collaboration ridgeback biotherapuetics lp ridgeback molnupiravir also received conditional marketing authorization united kingdom uk special approval emergency japan also fda european commission ec approved vaxneuvance pneumococcal valent conjugate vaccine pneumococcal conjugate vaccine use adults additionally verquvo medicine reduce risk cardiovascular death heart failure hospitalization following hospitalization heart failure need outpatient intravenous diuretics adults approved us eu japan verquvo jointly developed bayer ag bayer january japan ministry health labor welfare mhlw approved lyfnua gefapixant adults refractory unexplained chronic cough addition recent regulatory approvals discussed company advanced latestage pipeline several regulatory submissions keytruda review us andor internationally supplemental indications treatment certain patients triple negative breast cervical endometrial melanoma renal cell tumor mutation burdenhigh tmbh cancers lynparza review supplemental indications treatment certain patients breast prostate cancers lenvima review combination keytruda supplemental indication treatment certain patients hepatocellular carcinoma hcc mk molnupiravir rolling review european medicines agency ema mk gefapixant selective nonnarcotic orallyadministered investigational pxreceptor antagonist developed treatment refractory chronic cough review us eu vaxneuvance v valent pneumococcal conjugate vaccine priority review fda prevention invasive pneumococcal disease pediatric patients v also review japan use adults companys phase oncology programs include keytruda therapeutic areas biliary cutaneous squamous cell gastric hepatocellular mesothelioma ovarian prostate smallcell lung cancers lynparza monotherapy colorectal cancer combination keytruda nonsmallcell lung smallcell lung cancers lenvima combination keytruda colorectal esophageal gastric head neck melanoma nonsmallcell lung cancers welireg rcc mka coformulation quavonlimab mercks novel investigational antictla antibody pembrolizumab rcc mk pembrolizumab subcutaneous nonsmallcell lung cancer nsclc mk tukysa tucatinib developed collaboration seagen inc seagen breast cancer mka coformulation favezelimab mercks novel investigational antilag therapy pembrolizumab colorectal cancer mka coformulation vibostolimab antitigit therapy pembrolizumab nsclc additionally company candidates phase clinical development several therapeutic areas including mk sotatercept treatment pulmonary arterial hypertension pah obtained acceleron acquisition mk clesrovimab prevention respiratory syncytial virus mk islatravir investigational nucleoside reverse transcriptase translocation inhibitor nrtti prevention hiv infection clinical hold table contents mka islatravir combination doravirine treatment hiv infection clinical hold mk molnupiravir reflected phase development us remains investigational following eua company allocating resources support commercial opportunities near term investing heavily research support future innovations longterm growth research development expenses reflect higher clinical development spending increased investment discovery research early drug development november mercks board directors approved increase companys quarterly dividend raising per share per share companys outstanding common stock company returned billion shareholders dividends share repurchases december company completed inaugural issuance billion sustainability bond part billion underwritten bond offering company intends use net proceeds sustainability bond offering support projects partnerships companys priority environmental social governance esg areas contribute advancement united nations sustainable development goals covid update covid pandemic merck remained focused protecting safety employees ensuring supply medicines vaccines reaches patients contributing scientific expertise development antiviral therapy supporting efforts expand manufacturing capacity supply sarscovcovid medicines vaccines see supporting health care providers mercks communities although covidrelated disruptions negatively affected results merck continues experience strong global underlying demand across business mercks sales unfavorably affected covidrelated disruptions resulted estimated negative impact mercks pharmaceutical segment sales approximately billion roughly mercks pharmaceutical segment revenue comprised physicianadministered products despite strong underlying demand affected social distancing measures fewer well visits mercks sales favorably affected authorization molnupiravir several markets discussed resulted sales million estimated negative impact covidrelated disruptions mercks sales approximately billion approximately billion attributable pharmaceutical segment approximately million attributable animal health segment april merck announced discontinuing development mk formerly known cdfc treatment hospitalized patients covid obtained part mercks acquisition oncoimmune see note consolidated financial statements decision resulted charges million cost sales january company announced discontinuation development programs covid vaccine candidates v v following mercks review findings phase clinical studies vaccines studies v v generally well tolerated immune responses inferior seen following natural infection reported sarscovcovid vaccines due discontinuation company recorded charge million million reflected cost sales remaining million costs reflected research development expenses operating expenses reflect minor positive effect investments covidrelated research largely offset favorable impact lower spending areas due covid pandemic operating expenses positively affected approximately million primarily due lower promotional selling costs well lower research development expenses net investments covidrelated antiviral vaccine research programs addition covid pandemic caused disruption volatility companys global supply chain network company may future experience disruptions availability delays shipments raw materials packaging well related cost inflation december fda granted eua molnupiravir based positive results phase moveout clinical trial additionally december japans mhlw granted special approval table contents emergency molnupiravir november uk medicines healthcare products regulatory agency granted conditional marketing authorization molnupiravir addition october ema initiated rolling review molnupiravir merck plans work committee medicinal products human use ema complete rolling review process facilitate initiating formal review marketing authorization application merck developing molnupiravir collaboration ridgeback companies actively working regulatory agencies worldwide submit applications emergency use marketing authorization merck entered advance purchase supply agreements molnupiravir markets see note consolidated financial statements additional information related collaboration ridgeback march merck announced entered multiple agreements support efforts expand manufacturing capacity supply sarscov covid medicines vaccines biomedical advanced research development authority barda division office assistant secretary preparedness response within us department health human services providing merck funding adapt make available number existing manufacturing facilities production sarscovcovid vaccines medicines merck also entered agreements support manufacturing supply johnson johnsons sarscovcovid vaccine merck using certain facilities us produce drug substance formulate fill vials johnson johnsons vaccine pricing global efforts toward health care cost containment continue exert pressure product pricing market access worldwide changes us health care system part health care reform enacted prior years well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries contributed pricing pressure several international markets governmentmandated pricing actions reduced prices generic patented drugs addition companys revenue performance negatively affected costreduction measures taken governments third parties lower health care costs us biden administration congress continue discuss legislation designed control health care costs including cost drugs company anticipates actions additional actions future continue negatively affect revenue performance operating results sales change change excluding foreign excluding foreign millions change exchange change exchange united states international total worldwide sales grew primarily due higher sales oncology franchise largely driven strong growth keytruda increased alliance revenue lynparza lenvima well higher sales vaccines franchise primarily attributable growth gardasilgardasil varivax proquad also contributing revenue growth higher sales virology franchise attributable molnupiravir higher sales hospital acute care franchise reflecting growth bridion prevymis well higher sales animal health products additionally sales benefited higher third party manufacturing sales achievement milestones outlicensed product triggered contingent payments merck discussed covidrelated disruptions unfavorably affected sales lesser extent benefited yearoveryear sales growth sales growth partially offset lower sales pneumovax suspension sales hospital acute care product zerbaxa lower sales virology products isentressisentress hd sales us grew primarily driven higher sales keytruda sales molnupiravir higher sales bridion gardasil varivax proquad increased alliance revenue lynparza lenvima table contents well higher sales animal health products lower sales pneumovax januviajanumet zerbaxa partially offset revenue growth us international sales increased primarily due growth gardasilgardasil keytruda sales molnupiravir increased alliance revenue lynparza lenvima well higher sales januviajanumet bridion prevymis animal health products international sales growth partially offset lower sales noxafil zerbaxa isentressisentress hd international sales represented total sales respectively worldwide sales increased primarily due higher sales oncology franchise well growth certain hospital acute care products animal health growth areas largely offset negative effects covid pandemic discussed competitive pressure virology franchise pricing pressure diabetes franchise see note consolidated financial statements details sales companys products discussion performance select products franchises follows pharmaceutical segment oncology change excluding change foreign excluding foreign millions change exchange change exchange keytruda alliance revenue lynparza alliance revenue lenvima emend alliance revenue represents mercks share profits product sales net cost sales commercialization costs see note consolidated financial statements keytruda antipd programmed death receptor therapy approved monotherapy treatment certain patients cervical cancer classical hodgkin lymphoma chl cutaneous squamous cell carcinoma cscc esophageal gastroesophageal junction gej carcinoma head neck squamous cell carcinoma hnscc hcc nsclc melanoma merkel cell carcinoma microsatellite instabilityhigh msih mismatch repair deficient dmmr cancer solid tumors including msihdmmr colorectal cancer primary mediastinal large bcell lymphoma tmbh cancer solid tumors urothelial carcinoma including nonmuscle invasive bladder cancer additionally keytruda approved monotherapy adjuvant treatment certain patients rcc keytruda also approved treatment certain patients combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy without bevacizumab cervical cancer combination chemotherapy esophageal cancer combination chemotherapy gastric cancer combination chemotherapy hnscc combination chemotherapy triplenegativebreast cancer tnbc combination axitinib advanced rcc combination lenvima endometrial carcinoma rcc keytruda clinical development program includes studies across broad range cancer types global sales keytruda grew driven higher demand company continues launch keytruda multiple new indications globally although covid pandemic dampening effect growing demand negatively affecting number new patients starting treatment sales us continue build across multiple approved indications particular treatment advanced nsclc monotherapy combination chemotherapy nonsquamous squamous metastatic nsclc along continued uptake tnbc rcc hnscc msih cancer esophageal cancer indications keytruda sales growth international markets reflects continued uptake predominately nsclc hnscc rcc indications particularly europe sales growth partially offset lower pricing europe china japan global sales keytruda grew driven higher demand globally particularly us europe although covid pandemic unfavorable effect growing demand sales growth partially offset lower pricing japan europe table contents keytruda received numerous regulatory approvals summarized date approval january ec approval firstline treatment adult patients msih dmmr colorectal cancer based keynote study ec approval expanded label monotherapy treatment adult pediatric patients aged years older relapsed march refractory chl failed autologous stem cell transplant asct following least two prior therapies asct treatment option based keynote keynote trials fda approval combination platinum fluoropyrimidinebased chemotherapy treatment certain patients locally advanced march metastatic esophageal gej carcinoma amenable surgical resection definitive chemoradiation based keynote trial fda approval combination trastuzumab fluoropyrimidine platinumcontaining chemotherapy firstline treatment patients may locally advanced unresectable metastatic human epidermal growth factor receptor herpositive gastric gej adenocarcinoma based keynote trial may ec approval mg every six weeks qw dosing regimen indications keytruda administered combination anticancer agents chinas national medical products administration nmpa approval firstline treatment adult patients msih dmmr colorectal june cancer kras nras braf wildtype based keynote study ec approval combination chemotherapy firstline treatment patients locally advanced unresectable metastatic carcinoma june esophagus hernegative gej adenocarcinoma adults whose tumors express pdl based keynote trial fda approval monotherapy treatment patients locally advanced cscc curable surgery radiation based july keynote trial fda approval keytruda plus lenvima treatment patients advanced endometrial carcinoma msih dmmr july disease progression following prior systemic therapy setting candidates curative surgery radiation based keynotestudy trial fda approval keytruda treatment patients highrisk earlystage tnbc combination chemotherapy neoadjuvant treatment july continued single agent adjuvant treatment surgery based keynote trial fda approval keytruda plus lenvima firstline treatment adult patients advanced rcc based keynote trialstudy august trial japans pharmaceuticals medical devices agency pmda approval treatment patients unresectable advanced recurrent august msih colorectal cancer based keynote trial japans pmda approval treatment patients pdlpositive hormone receptornegative hernegative inoperable recurrent august breast cancer based keynote trial chinas nmpa approval combination chemotherapy firstline treatment patients locally advanced unresectable september metastatic carcinoma esophagus gej based keynote trial fda approval combination chemotherapy without bevacizumab treatment patients persistent recurrent october metastatic cervical cancer based keynote trial ec approval combination chemotherapy firstline treatment locally recurrent unresectable metastatic tnbc adults whose october tumors express pdl received prior chemotherapy metastatic disease based keynote trial fda approval adjuvant treatment patients rcc intermediatehigh high risk recurrence following nephrectomy following november nephrectomy resection metastatic lesions based keynote trial table contents ec approval keytruda plus lenvima firstline treatment adult patients advanced rcc based clear study november keynote trial ec approval keytruda plus lenvima treatment advanced recurrent endometrial carcinoma adults disease progression november following prior treatment platinumcontaining therapy setting candidates curative surgery radiation based keynotestudy trial japans pmda approval combination chemotherapy fluorouracil plus cisplatin firstline treatment patients radically november unresectable advanced recurrent esophageal carcinoma combination chemotherapy based keynote trial fda approval adjuvant treatment adult pediatric years older patients stage iib iic melanoma following complete december resection based keynote trial fda expanded indication adjuvant treatment stage iii melanoma following complete resection include pediatric patients years older japans mhlw approval keytruda combination lenvima treatment patients unresectable advanced recurrent december endometrial carcinoma progressed cancer chemotherapy based keynotestudy trial march merck announced voluntarily withdrawing us indication keytruda treatment patients metastatic smallcell lung cancer disease progression platinumbased chemotherapy least one prior line therapy withdrawal indication done consultation fda affect indications keytruda announced january keynote confirmatory phase trial indication met one dual primary endpoints progressionfree survival reach statistical significance primary endpoint overall survival merck initiated withdrawal us accelerated approval indication keytruda treatment patients recurrent locally advanced metastatic gastric gej adenocarcinoma whose tumors express pdl disease progression two prior lines therapy decision made consultation fda following oncologic drugs advisory committee evaluation thirdline gastric cancer indication keytruda monotherapy failed meet postmarketing requirement demonstrating overall survival benefit phase study withdrawal indication affect indications keytruda company party certain thirdparty license agreements pursuant company pays royalties sales keytruda terms significant agreements merck pays royalty worldwide sales keytruda one third party royalty decline terminate thereafter company pays additional royalty worldwide sales keytruda another third party termination date varies country royalty expire us major european markets royalties included cost sales lynparza oral poly adpribose polymerase parp inhibitor developed part collaboration astrazeneca see note consolidated financial statements lynparza approved treatment certain types advanced ovarian breast pancreatic prostate cancers alliance revenue related lynparza grew due continued uptake across multiple approved indications us europe japan china june lynparza granted conditional approval china monotherapy treatment certain previously treated adult patients germline somatic brcamutated metastatic castrationresistant prostate cancer based results profound trial lenvima oral receptor tyrosine kinase inhibitor developed part collaboration eisai see note consolidated financial statements lenvima approved treatment certain types thyroid cancer hcc combination everolimus certain patients rcc combination keytruda treatment certain patients endometrial carcinoma treatment certain patients rcc alliance revenue related lenvima grew primarily due higher demand us china global sales emend aprepitant prevention certain chemotherapyinduced nausea vomiting declined reflecting lower volumes europe china worldwide sales emend table contents decreased primarily due lower demand pricing us due generic competition emend injection following us patent expiry september also contributing emend sales decline lower demand europe japan result generic competition oral formulation emend following loss market exclusivity may december respectively june koselugo selumetinib granted conditional approval eu treatment pediatric patients three years age older neurofibromatosis type symptomatic inoperable plexiform neurofibromas based positive results national cancer institute cancer therapy evaluation programsponsored sprint stratum trial koselugo approved fda april koselugo part collaboration astrazeneca referenced includes lynparza august fda approved welireg oral hif inhibitor treatment adult patients vhl disease require therapy associated rcc central nervous system hemangioblastomas pancreatic neuroendocrine tumors requiring immediate surgery approval based results openlabel study trial welireg obtained part mercks acquisition peloton therapeutics inc peloton see note consolidated financial statements vaccines change excluding change foreign excluding foreign millions change exchange change exchange gardasilgardasil proquad mmr ii varivax pneumovax worldwide sales gardasilgardasil vaccines help prevent certain cancers diseases caused certain types human papillomavirus hpv grew driven primarily strong global demand particularly china well increased supply higher pricing china us also contributed sales growth sales growth unfavorably affected replenishment doses borrowed us centers disease control prevention cdc pediatric vaccine stockpile favorably affected sales million timing public sector purchases us also partially offset sales growth global sales gardasilgardasil grew primarily due higher volumes china replenishment doses borrowed cdc pediatric vaccine stockpile replenishment resulted recognition sales million combined reduction sales million due borrowing resulted favorable impact sales million compared lower demand us hong kong sar prc attributable covid pandemic partially offset increase sales gardasilgardasil company party certain thirdparty license agreements pursuant company pays royalties sales gardasilgardasil terms significant agreements merck pays royalty worldwide sales gardasilgardasil one third party royalty obligations agreement expire december additional royalty sales gardasilgardasil us another third party royalty obligations expire december royalties included cost sales global sales proquad pediatric combination vaccine help protect measles mumps rubella varicella grew due higher sales us reflecting higher demand driven ongoing covid pandemic recovery well higher pricing worldwide sales proquad declined driven primarily lower demand us resulting fewer measles outbreaks compared coupled unfavorable impact covid pandemic partially offset higher pricing worldwide sales mmr ii vaccine help protect measles mumps rubella grew primarily due higher sales us reflecting ongoing covid pandemic recovery inclusive higher public sector mix business lower demand europe partially offset mmr ii sales growth global sales mmr ii declined driven primarily lower demand us resulting fewer table contents measles outbreaks compared coupled unfavorable impact covid pandemic lower demand brazil also contributed mm r ii sales decline global sales varivax vaccine help prevent chickenpox varicella grew primarily reflecting ongoing covid pandemic recovery higher pricing us higher government tenders brazil also contributed varivax sales growth worldwide sales varivax declined driven primarily lower demand us resulting covid pandemic partially offset higher pricing varivax sales decline also attributable lower government tenders brazil worldwide sales pneumovax vaccine help prevent pneumococcal disease declined primarily due lower sales us attributable lower demand reflecting prioritization covid vaccination partially offset higher pricing global sales pneumovax grew primarily due higher volumes europe us attributable part heightened awareness pneumococcal vaccination higher pricing us also contributed pneumovax sales growth july fda approved vaxneuvance active immunization prevention invasive disease caused streptococcus pneumoniae serotypes adults years age older december vaxneuvance approved ec approvals based data seven clinical studies assessing safety tolerability immunogenicity adults october cdcs advisory committee immunization practices acip voted recommend vaccination either sequential regimen vaxneuvance followed pneumovax single dose valent pneumococcal conjugate vaccine adults years older adults ages certain underlying medical conditions recommendations subsequently adopted director cdc us department health human services published cdcs morbidity mortality weekly report september merck announced settlement license agreement pfizer inc pfizer resolving worldwide patent infringement litigation related use mercks investigational licensed pneumococcal conjugate vaccine pcv products including vaxneuvance terms agreement merck make certain regulatory milestone payments pfizer well royalty payments worldwide sales pcv products company pay royalties net sales merck pcv products net sales merck pcv products vaxelis diphtheria tetanus toxoids acellular pertussis inactivated poliovirus haemophilus b conjugate hepatitis b vaccine developed part usbased partnership merck sanofi pasteur available us active immunization children six weeks four years age help prevent diphtheria tetanus pertussis poliomyelitis hepatitis b invasive disease due haemophilus influenzae type b february cdcs acip included vaxelis combination vaccine option cdcs recommended child adolescent immunization schedule sales vaxelis us made usbased mercksanofi pasteur partnership results reflected equity income affiliates included income expense net supply sales partnership recorded within sales vaxelis also approved eu marketed directly merck sanofi pasteur hospital acute care change change excluding foreign excluding foreign millions change exchange change exchange bridion prevymis noxafil zerbaxa calculation meaningful global sales bridion reversal two types neuromuscular blocking agents used surgery grew due higher demand globally particularly us europe attributable covid pandemic recovery well increased usage neuromuscular blockade reversal agents bridions growing share within class bridion also approved fda june pediatric patients aged years older undergoing surgery worldwide sales bridion grew due higher demand globally table contents particularly us however fewer elective surgeries result covid pandemic unfavorably affected demand worldwide sales prevymis medicine prophylaxis prevention cytomegalovirus cmv infection disease adult cmvseropositive recipients allogenic hematopoietic stem cell transplant grew increased due continued uptake since launch several markets particularly europe us worldwide sales noxafil antifungal agent prevention certain invasive fungal infections declined primarily due generic competition europe partially offset higher demand china patent provided market exclusivity noxafil number major european markets expired december result company experiencing lower demand noxafil markets due generic competition expects decline continue global sales noxafil declined due generic competition us europe patent provided us market exclusivity certain forms noxafil representing majority us noxafil sales expired july december company temporarily suspended sales zerbaxa combination antibacterial betalactamase inhibitor treatment certain bacterial infections subsequently issued product recall following identification product sterility issues result company recorded intangible asset impairment charge related zerbaxa see note consolidated financial statements phased resupply zerbaxa initiated fourth quarter company expects continue immunology change change excluding foreign excluding foreign millions change exchange change exchange simponi remicade sales simponi oncemonthly subcutaneous treatment certain inflammatory diseases marketed company europe russia turkey declined nearly flat sales simponi unfavorably affected biosimilar competition competing products company expects competition continue unfavorably affect sales simponi sales remicade treatment inflammatory diseases marketed company europe russia turkey declined decreased driven ongoing biosimilar competition companys marketing territories europe company lost market exclusivity remicade major european markets longer market exclusivity marketing territories company experiencing pricing volume declines markets result biosimilar competition expects declines continue companys marketing rights respect products revert janssen pharmaceuticals inc october virology change excluding change foreign excluding foreign millions change exchange change exchange molnupiravir isentressisentress hd zepatier molnupiravir investigational oral antiviral covid medicine developed collaboration ridgeback see note consolidated financial statements fda granted eua molnupiravir december updated february authorize molnupiravir treatment mild moderate covid highrisk adults alternative fdaapproved authorized treatment options table contents accessible clinically appropriate also december japans mhlw granted special approval emergency molnupiravir treat infectious disease caused sarscov november uks mhra granted conditional marketing authorization molnupiravir treat mild moderate covid adults risk developing severe illness merck entered advance purchase supply agreements molnupiravir markets merck began shipping molnupiravir fourth quarter countries approved authorized sales molnupiravir million primarily consisting sales us uk japan worldwide sales isentressisentress hd hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection declined decreased primarily due competitive pressure particularly europe us company expects competitive pressure isentressisentress hd continue global sales zepatier treatment adult patients chronic hepatitis c virus genotype gt gt infection declined primarily due lower demand competitive pressure us europe worldwide sales zepatier declined driven lower demand globally due competition declining patient volumes coupled impact covid pandemic cardiovascular change excluding change foreign excluding foreign millions change exchange change exchange alliance revenue adempasverquvo adempas alliance revenue represents mercks share profits sales bayers marketing territories product sales net cost sales commercialization costs see note consolidated financial statements adempas verquvo part worldwide collaboration bayer market develop soluble guanylate cyclase sgc modulators see note consolidated financial statements adempas approved treatment certain types pah verquvo approved us january reduce risk cardiovascular death heart failure hospitalization following hospitalization heart failure need outpatient intravenous diuretics adults symptomatic chronic heart failure reduced ejection fraction verquvo also approved japan june eu july approvals based results victoria trial alliance revenue collaboration grew rose revenue collaboration also includes sales adempas verquvo mercks marketing territories sales adempas mercks marketing territories grew primarily reflecting higher demand europe diabetes change change excluding foreign excluding foreign millions change exchange change exchange januviajanumet worldwide combined sales januvia janumet medicines help lower blood sugar levels adults type diabetes nearly flat declined sales performance periods reflects continued pricing pressure lower demand us largely offset higher demand certain international markets particularly china company expects us pricing pressure continue januvia janumet lose market exclusivity us january eu september china july company anticipates sales januvia janumet markets decline substantially loss exclusivity combined sales januvia janumet us europe china represented respectively total combined januvia janumet sales table contents animal health segment change change excluding foreign excluding foreign millions change exchange change exchange livestock companion animal sales livestock products grew primarily due higher demand ruminant products including animal health intelligence solutions animal identification monitoring traceability well higher demand poultry swine products sales livestock products increased predominantly due additional five months sales related april acquisition antelliq leader digital animal identification traceability monitoring solutions see note consolidated financial statements sales companion animal products grew rose primarily due higher demand parasiticides including bravecto line products well higher demand companion animal vaccines costs expenses millions change change cost sales selling general administrative research development restructuring costs income expense net calculation meaningful cost sales cost sales billion billion cost sales includes amortization intangible assets recorded connection acquisitions collaborations licensing arrangements totaled billion billion billion costs also include charges million million respectively related discontinuation covid development programs see note consolidated financial statements additionally costs include intangible asset impairment charges billion million related marketed products intangibles see note consolidated financial statements company may recognize additional impairment charges future related intangible assets measured fair value capitalized connection business combinations charges could material costs also include inventory writeoffs million related recall zerbaxa see note consolidated financial statements also included cost sales expenses associated restructuring activities amounted million million million primarily reflecting accelerated depreciation asset writeoffs related planned sale closure manufacturing facilities separation costs associated manufacturingrelated headcount reductions incurred reflected restructuring costs discussed gross margin compared gross margin improvement reflects lower impairments amortization intangible assets noted well favorable effects product mix lower inventory writeoffs partially offsetting gross margin improvement higher manufacturing costs impact molnupiravir lower gross margin due profit sharing ridgeback discussed note consolidated financial statements higher compensation benefit costs gross margin compared gross margin decline reflects unfavorable effects higher impairments amortization intangible assets pricing pressure charge related discontinuation covid vaccine development programs higher inventory writeoffs related recall zerbaxa noted partially offset favorable effects product mix lower restructuring costs table contents selling general administrative selling general administrative sga expenses billion increase compared increase primarily due higher administrative costs including compensation benefits higher promotional expenses support companys key growth pillars higher acquisitionrelated costs including costs related acquisition acceleron covid pandemic drove lower spending contributed increase sga expenses increases partially offset favorable effects foreign exchange contribution merck foundation sga expenses billion decline compared decline driven primarily lower administrative selling promotional costs including lower travel meeting expenses due part covid pandemic favorable effect foreign exchange partially offset contribution merck foundation research development research development rd expenses billion decline compared primarily due lower upfront payments related acquisitions collaborations decline partially offset higher clinical development spending increased investment discovery research early drug development net reimbursement portion molnupiravir development costs partnership ridgeback higher compensation benefit costs higher inprocess research development iprd impairment charges well costs related acquisition acceleron also partially offset decline rd expenses rd expenses billion increase compared increase driven largely higher upfront payments related acquisitions collaborations higher clinical development spending increased investment discovery research early drug development higher restructuring costs also contributed increase rd expenses increase rd expenses partially offset lower iprd impairment charges lower costs resulting covid pandemic net spending covidrelated vaccine antiviral research programs rd expenses comprised costs directly incurred merck research laboratories mrl companys research development division focuses human healthrelated activities billion billion billion also included rd expenses animal health research costs licensing costs costs incurred divisions support rd activities including depreciation production general administrative aggregate billion billion billion additionally rd expenses include billion charge acquisition pandion rd expenses include billion charge acquisition velosbio inc million charge acquisition oncoimmune charges million related transactions seagen rd expenses include million charge acquisition peloton see note consolidated financial statements information transactions rd expenses also include iprd impairment charges million million million respectively see note consolidated financial statements company may recognize additional impairment charges future related cancellation delay pipeline programs measured fair value capitalized connection business combinations charges could material addition rd expenses include million million respectively costs associated restructuring activities primarily relating accelerated depreciation rd expenses also include expense income related changes estimated fair value measurement liabilities contingent consideration recorded connection business combinations company recorded million expenses compared net reduction expenses million million respectively related changes estimates restructuring costs merck approved global restructuring program restructuring program part worldwide initiative focused optimizing companys manufacturing supply network well reducing global real estate footprint program continuation companys plant rationalization builds prior restructuring programs actions currently contemplated restructuring program expected substantially completed end cumulative pretax costs incurred company implement program estimated approximately billion company expects record charges table contents approximately million related restructuring program company anticipates actions restructuring program result annual net cost savings approximately million end restructuring costs primarily representing separation related costs associated restructuring activities million million million separation costs incurred associated actual headcount reductions well estimated expenses existing severance programs headcount reductions probable could reasonably estimated also included restructuring costs asset abandonment facility shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation plan costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included cost sales selling general administrative expenses research development costs company recorded aggregate pretax costs million million million related restructuring program activities see note consolidated financial statements income expense net income expense net billion income compared million income primarily due higher income investments equity securities net largely related higher realized unrealized gains certain investments including disposition companys ownership interest preventice solutions inc preventice result acquisition preventice boston scientific partially offset higher foreign exchange losses pension settlement costs income expense net million income compared million expense primarily due higher income investments equity securities net largely related moderna inc details components income expense net see note consolidated financial statements segment profits millions pharmaceutical segment profits animal health segment profits nonreportable segment profits income continuing operations taxes pharmaceutical segment profits comprised segment sales less standard costs well sga expenses directly incurred segment animal health segment profits comprised segment sales less cost sales well sga rd expenses directly incurred segment internal management reporting presented chief operating decision maker merck allocate remaining cost sales included segment profits described rd expenses incurred mrl general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits costs related restructuring activities acquisition divestiturerelated costs including amortization intangible assets amortization purchase accounting adjustments intangible asset impairment charges expense income related changes estimated fair value measurement liabilities contingent consideration additionally segment profits reflect expenses corporate manufacturing cost centers miscellaneous income expense unallocated items reflected table also included miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing sales beginning amortization intangible assets previously included part calculation table contents segment profits included unallocated nonsegment corporate expenses prior period pharmaceutical animal health segment profits recast reflect change comparable basis pharmaceutical segment profits grew primarily due higher sales favorable effect foreign exchange partially offset higher administrative promotional costs pharmaceutical segment profits increased driven primarily higher sales well lower selling promotional costs animal health segment profits grew reflecting higher sales partially offset higher promotional selling administrative costs animal health segment profits increased driven primarily higher sales lower promotional selling costs partially offset higher rd costs unfavorable effect foreign exchange taxes income effective income tax rates continuing operations full year effective income tax rate reflects favorable mix income expense well higher foreign tax credits ordinary business operations company able credit effective income tax rate continuing operations also reflects beneficial impact settlement foreign tax matter well net tax benefit million related settlement certain federal income tax matters see note consolidated financial statements effective income tax rate continuing operations also reflects unfavorable effect charge acquisition pandion tax benefit recognized effective income tax rate reflects unfavorable impact charge acquisition velosbio tax benefit recognized effective income tax rate reflects favorable impact million net tax benefit related settlement certain federal income tax matters see note consolidated financial statements reversal tax reserves established connection divestiture mercks consumer care mcc business due lapse statute limitations addition effective income tax rate reflects unfavorable impact charge acquisition peloton tax benefit recognized charges million related finalization treasury regulations transition tax associated enactment us tax legislation known tax cuts jobs act tcja see note consolidated financial statements net income loss attributable noncontrolling interests net income loss attributable noncontrolling interests million million million loss driven primarily portion goodwill impairment charges related certain businesses healthcare services segment attributable noncontrolling interests nongaap income nongaap eps continuing operations nongaap income nongaap eps alternative views companys performance merck providing management believes information enhances investors understanding companys results permits investors understand management assesses performance nongaap income nongaap eps exclude certain items nature items impact analysis underlying business performance trends excluded items considered nonrecurring consist acquisition divestiturerelated costs restructuring costs income losses investments equity securities certain items excluded items significant components understanding assessing financial performance nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap eps management uses measures internally planning forecasting purposes measure performance company along metrics addition senior managements annual compensation derived part using nongaap pretax income since nongaap income nongaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation similar measures companies information nongaap income nongaap eps considered addition substitute superior net income eps prepared accordance generally accepted accounting principles us gaap table contents reconciliation gaap financial measures nongaap financial measures continuing operations follows millions except per share amounts income continuing operations taxes reported gaap increase decrease excluded items acquisition divestiturerelated costs restructuring costs income investments equity securities net items charge acquisition pandion charges discontinuation covid development programs charge acquisition velosbio charges formation collaborations charge acquisition oncoimmune charge acquisition peloton nongaap income continuing operations taxes taxes income reported gaap estimated tax benefit excluded items net tax benefit settlement certain federal income tax matters adjustment tax benefits recorded conjunction cubist pharmaceuticals inc acquisition tax benefit reversal tax reserves related divestiture mcc net tax charge related finalization treasury regulations related enactment tcja nongaap taxes income continuing operations nongaap net income continuing operations less net income loss attributable noncontrolling interests reported gaap acquisition divestiturerelated costs attributable noncontrolling interests nongaap net income continuing operations attributable noncontrolling interests nongaap net income attributable merck co inc eps assuming dilution continuing operations reported gaap eps difference nongaap eps assuming dilution continuing operations amount includes billion intangible asset impairment charge related zerbaxa amount includes million intangible asset impairment charge related sivextro see note consolidated financial statements includes million related transactions seagen see note consolidated financial statements estimated tax impact excluded items determined applying statutory rate originating territory nongaap adjustments acquisition divestiturerelated costs nongaap income nongaap eps exclude impact certain amounts recorded connection acquisitions divestitures amounts include amortization intangible assets amortization purchase accounting adjustments inventories well intangible asset impairment charges expense income related changes estimated fair value measurement liabilities contingent consideration also excluded integration transaction certain costs associated acquisitions divestitures nongaap income nongaap eps also exclude amortization intangible assets related collaborations licensing arrangements table contents restructuring costs nongaap income nongaap eps exclude costs related restructuring actions see note consolidated financial statements amounts include employee separation costs accelerated depreciation associated facilities closed divested accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions restructuring costs also include asset abandonment facility shutdown related costs well employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation costs income losses investments equity securities nongaap income nongaap eps exclude realized unrealized gains losses investments equity securities either owned directly ownership interests investment funds certain items nongaap income nongaap eps exclude certain items items adjusted evaluating individual basis considering quantitative qualitative aspects typically consist items unusual nature significant results particular period indicative future operating results excluded nongaap income nongaap eps charges acquisitions pandion velosbio oncoimmune peloton well charges related collaborations including transactions seagen see note consolidated financial statements also excluded nongaap income nongaap eps charges related discontinuation covid development programs see note consolidated financial statements additionally excluded nongaap income nongaap eps certain tax items including net tax benefits related settlement certain federal income tax matters adjustment tax benefits recorded conjunction acquisition cubist pharmaceuticals inc tax benefit related reversal tax reserves established connection divestiture mcc net tax charge related finalization us treasury regulations related tcja see note consolidated financial statements research development research pipeline company currently several candidates regulatory review us internationally well latestage clinical development chart reflecting companys current research pipeline february related discussion set forth item business research development acquisitions research collaborations license agreements merck continues remain focused pursuing opportunities potential drive near longterm growth certain recent transactions summarized additional details included note consolidated financial statements merck actively monitors landscape growth opportunities meet companys strategic criteria march merck gilead entered agreement jointly develop commercialize longacting treatments hiv combine mercks investigational nrtti islatravir gileads investigational capsid inhibitor lenacapavir collaboration initially focus longacting oral formulations longacting injectable formulations combination products formulations potentially added collaboration mutually agreed upfront payment made either party upon entering agreement april merck acquired pandion clinicalstage biotechnology company developing novel therapeutics designed address unmet needs patients living autoimmune diseases total consideration billion pandion advancing pipeline precision immune modulators targeting critical immune control nodes november merck acquired acceleron publicly traded biopharmaceutical company total consideration billion acceleron evaluating tgfbeta superfamily proteins known play central role regulation cell growth differentiation repair accelerons lead therapeutic candidate table contents sotatercept mk novel mechanism action potential improve shortterm andor longterm clinical outcomes patients pah sotatercept phase trials addon current standard care treatment pah addition sotatercept accelerons portfolio includes reblozyl luspatercept firstinclass erythroid maturation recombinant fusion protein approved us europe canada australia treatment anemia certain rare blood disorders evaluated clinical trials additional indications hematology therapies reblozyl developed commercialized global collaboration bristol myers squibb acquired inprocess research development connection business combinations company recorded fair value inprocess research projects time acquisition yet reached technological feasibility december balance iprd billion see note consolidated financial statements iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval would delay prevent company realizing revenues products additionally iprd programs require additional clinical trial data previously anticipated programs fail abandoned development company realize future cash flows estimated recorded iprd acquisition date circumstances occur companys future operating results could adversely affected company may recognize impairment charges could material company recorded iprd impairment charges within research development expenses million million million respectively see note consolidated financial statements additional research development required remaining programs reach technological feasibility costs complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval capital expenditures capital expenditures billion billion billion expenditures us billion billion billion company plans invest approximately billion capital projects including expanding manufacturing capacity oncology vaccine animal health products depreciation expense billion billion billion billion billion billion related locations us total depreciation expense included accelerated depreciation million million million respectively associated restructuring activities see note consolidated financial statements analysis liquidity capital resources mercks strong financial profile enables fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders selected data millions working capital total debt total liabilities equity cash provided operating activities continuing operations total debt table contents increase working capital compared primarily related decreased shortterm debt cash provided operating activities continuing operations billion compared billion billion higher cash provided operating activities continuing operations reflects stronger operating performance cash provided operating activities continuing operations includes upfront milestone payments related collaborations million billion million cash provided operating activities continuing operations continues companys source funds finance operating needs excess cash serving primary source funds finance capital expenditures treasury stock purchases dividends paid shareholders cash used investing activities continuing operations billion compared billion higher use cash investing activities continuing operations primarily due higher cash used acquisitions including acquisition acceleron lower proceeds sales securities investments partially offset purchase seagen common stock cash used investing activities continuing operations billion compared billion increase driven primarily lower proceeds sales securities investments higher use cash acquisitions higher capital expenditures purchase seagen common stock partially offset lower purchases securities investments cash provided financing activities continuing operations billion compared use cash financing activities continuing operations billion change primarily driven cash distribution received organon connection spinoff see note consolidated financial statements higher proceeds issuance debt see lower purchases treasury stock partially offset net decrease shortterm borrowings compared net increase shortterm borrowings higher payments debt see higher dividends paid shareholders cash used financing activities continuing operations billion compared billion lower use cash financing activities continuing operations driven primarily net increase shortterm borrowings compared net decrease shortterm borrowing well lower purchases treasury stock partially offset higher payments debt see lower proceeds issuance debt see higher dividends paid shareholders lower proceeds exercise stock options december company issued billion principal amount senior unsecured notes consisting billion notes due billion notes due billion notes due billion notes due billion notes due merck used net proceeds offering notes notes notes notes general corporate purposes including repayment outstanding commercial paper borrowings including commercial paper borrowings connection mercks acquisition acceleron indebtedness merck allocated amount equal net proceeds offering notes due finance refinance whole part projects partnerships companys priority esg areas june company issued billion principal amount senior unsecured notes consisting billion notes due billion notes due billion notes due billion notes due merck used net proceeds offering general corporate purposes including repayment outstanding commercial paper borrowings indebtedness march company issued billion principal amount senior unsecured notes consisting million notes due billion notes due billion notes due billion notes due company used net proceeds offering general corporate purposes including repayment outstanding commercial paper borrowings february companys billion notes matured accordance terms repaid companys billion notes companys billion notes matured accordance terms repaid companys billion notes million floatingrate notes matured accordance terms repaid table contents company billion credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility company expects foreseeable liquidity capital resource requirements met existing cash cash equivalents anticipated cash flows operations well commercial paper borrowings longterm borrowings needed merck believes sources financing adequate meet future requirements companys material cash requirements arising normal course business primarily include debt obligations interest payments see note consolidated financial statements detail companys debt obligations timing expected future principal interest payments tax liabilities connection enactment tcja company required pay onetime transition tax company elected pay period eight years permitted tcja additionally company liabilities unrecognized tax benefits including interest penalties see note consolidated financial statements information pertaining transition tax liabilities unrecognized tax benefits operating leases see note consolidated financial statements details companys lease obligations timing expected future lease payments contingent milestone payments company accrued liabilities contingent salesbased milestone payments related collaborations astrazeneca eisai bayer payment deemed probable remains subject achievement related sales milestone see note consolidated financial statements additional information related salesbased milestones purchase obligations purchase obligations enforceable legally binding obligations purchases goods services including minimum inventory contracts research development advertising purchase obligations also include future inventory purchases company committed connection certain divestitures december company total purchase obligations billion billion estimated payable march company filed securities registration statement us securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date company believes maintains conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations november mercks board directors increased quarterly dividend declaring quarterly dividend per share companys outstanding common stock paid january january board directors declared quarterly dividend per share companys common stock second quarter payable april october mercks board directors authorized purchases billion mercks common stock treasury treasury stock purchase authorization time limit made time openmarket transactions block transactions exchange privately negotiated transactions may merck restarted share repurchase program company temporarily suspended march company spent million purchase million shares common stock treasury program december companys remaining share repurchase table contents authorization billion company purchased billion billion common stock respectively authorized share repurchase programs financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused changes foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings comprehensive income loss oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges unrealized gains losses contracts recorded accumulated comprehensive loss aocl reclassified sales hedged anticipated revenue recognized derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes merck principally sells foreign currency revenue hedging program uniform weakening us dollar would yield largest overall potential loss market value hedge instruments market value mercks hedges would declined estimated million million december respectively uniform weakening us dollar market value determined using foreign exchange option pricing model holding factors except exchange rates constant although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen british pound canadian dollar swiss franc exposures developing country currencies including chinese renminbi company enter forward contracts offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost table contents hedging instrument cash flows contracts reported operating activities consolidated statement cash flows monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly weakened currency exposures company december income continuing operations taxes would declined approximately million million respectively company net short payable position relative major foreign currencies consideration forward contracts uniform weakening us dollar yield largest overall potential net loss earnings due exchange measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows company also uses forward exchange contracts hedge portion net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation unrealized gains losses contracts recorded foreign currency translation adjustment within oci remain aocl either sale complete substantially complete liquidation subsidiary company excludes certain portions change fair value derivative instruments assessment hedge effectiveness excluded components changes fair value excluded components recognized oci company recognizes earnings initial value excluded components straightline basis life derivative instrument rather using marktomarket approach cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party nine payfloating receivefixed interest rate swap contracts designated fair value hedges fixed rate notes notional amounts match amount hedged fixedrate notes detailed table millions number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due interest rate swaps matured february table contents interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense along offsetting fair value changes swap contracts see note consolidated financial statements discussion pending discontinuation libor part reference rate reform cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value mercks investments debt change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments billion billion respectively one percentage point decrease december would negatively affected net aggregate market value billion billion respectively fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models critical accounting estimates companys consolidated financial statements prepared conformity gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities accruals contingent salesbased milestone payments reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements acquisitions dispositions determine whether transactions accounted acquisitions disposals assets businesses company makes certain judgments include assessment inputs processes outputs associated acquired set activities company determines substantially fair value gross assets included transaction concentrated single asset group similar assets assets would represent business considered business assets transaction need include input substantive process together significantly contribute ability create outputs business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions fair values intangible assets determined utilizing information available near acquisition date based expectations assumptions deemed reasonable management given considerable judgment involved determining fair values company typically obtains assistance thirdparty valuation specialists significant items assets acquired liabilities assumed business combination arise contingencies generally recognized fair value fair value determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred table contents estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition judgments made determining estimated fair values assigned assets acquired liabilities assumed business combination well asset lives materially affect companys results operations fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows consider historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent related patent term extension net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd also determined using income approach fair value estimated based assets probabilityadjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate amounts allocated acquired iprd capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion iprd project merck make determination thenuseful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization certain companys business combinations involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows subsequent acquisition date reporting period contingency resolved contingent consideration liability remeasured current fair value changes either expense income recorded earnings changes inputs may result significantly different fair value adjustment company determines transaction accounted acquisition business transaction accounted asset acquisition rather business combination therefore goodwill recorded asset acquisition acquired iprd alternative future use charged expense contingent consideration recognized acquisition date instances product development milestones recognized upon achievement salesbased milestones recognized milestone deemed probable company achieved revenue recognition recognition revenue requires evidence contract probable collection sales proceeds completion substantially performance obligations merck acts principal substantially customer arrangements therefore records revenue gross basis majority companys contracts related pharmaceutical animal health segments single performance obligation promise transfer goods shipping considered immaterial context overall customer arrangement damages loss goods transit rare therefore shipping deemed separately recognized performance obligation vast majority revenues sales products recognized point time control goods transferred customer company determined title risks rewards table contents ownership transfer customer company entitled payment certain services animal health segment revenue recognized time generally ratably contract term services provided service revenues material nature companys business gives rise several types variable consideration including discounts returns estimated time sale generally using expected value method although likely amount method used prompt pay discounts us sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition collection accounts receivable expected excess one year sales recorded net time value money discounts material us provision aggregate customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases intermediary wholesaler contracted customer generally purchases product wholesaler contracted price plus markup wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers company uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision amounts accrued aggregate customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued company continually monitors provision aggregate customer discounts material adjustments estimates associated aggregate customer discount provision summarized information changes aggregate customer discount accrual related us sales follows millions balance january current provision adjustments prior years payments balance december accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million billion respectively december million billion respectively december outside us variable consideration form discounts rebates combination commerciallydriven discounts highly competitive product classes discounts required gain maintain reimbursement legislatively mandated rebates certain european countries legislatively mandated rebates calculated based estimate governments total unbudgeted spending companys specific payback obligation rebates may also required based specific product sales thresholds company applies estimated factor actual invoiced sales represent expected level future discount rebate obligations associated sale company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months table contents months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market generic competition changes formularies launch overthecounter products among others product returns provision us pharmaceutical sales percentage us net pharmaceutical sales outside us returns allowed certain countries limited basis mercks payment terms us pharmaceutical customers typically days receipt invoice us animal health customers typically days receipt invoice however certain products including keytruda longer payment terms days outside us payment terms typically days days although certain markets longer payment terms distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns wholesalers generally provide abovementioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin related product candidates phase clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december million million respectively contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including governmental environmental matters see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense table contents reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying accruing costs past merck performed worldwide survey assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation environmental liabilities million estimated million aggregate years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed approximately million aggregate management also believe expenditures result material adverse effect companys financial condition results operations liquidity year sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options total pretax sharebased compensation expense continuing operations million million million december million total pretax unrecognized compensation expense related nonvested stock option restricted stock unit performance share unit awards recognized weightedaverage period years segment reporting share based compensation costs unallocated expenses pensions postretirement benefit plans net periodic benefit cost pension plans totaled million million million net periodic benefit credit postretirement benefit plans million million million pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations table contents expected rate return plan assets changes net periodic benefit cost year year pension plans attributable settlement charges incurred certain plans well changes discount rate company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due discount rates companys us pension postretirement benefit plans ranged december compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data current market conditions actual returns companys plan assets using reference information company develops forwardlooking return expectations asset category weightedaverage expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans compared range company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests international pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact companys net periodic benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact mercks net periodic benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net loss amounts primarily reflect differences expected actual returns plan assets well effects changes actuarial assumptions recorded component aocl expected returns pension plans based calculated marketrelated value assets net loss amounts aocl excess certain thresholds amortized net periodic benefit cost average remaining service life employees restructuring costs restructuring costs recorded connection restructuring programs designed streamline companys cost structure result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place accruing termination costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets severance related costs reflected within restructuring costs assetrelated charges reflected within cost sales selling general administrative expenses research development expenses depending upon nature asset table contents impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance reporting unit whether sustained declines companys share price company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed carrying value reporting unit greater fair value goodwill impairment charge recorded difference carrying value goodwill acquired intangible assets excluding iprd initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows iprd company acquires conjunction acquisition business represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects company evaluates iprd impairment least annually frequently impairment indicators exist performing quantitative test compares fair value iprd intangible asset carrying value impairment testing purposes company may combine separately recorded iprd intangible assets one unit account based relevant facts circumstances generally company combine iprd intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized operating results judgments made evaluating impairment longlived intangibles materially affect companys results operations taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax table contents position tax positions likely sustained upon audit company recognizes amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements recently issued accounting standards discussion recently issued accounting standards see note consolidated financial statements cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning negative variations foregoing one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product approvals product potential development programs environmental sustainability initiatives include statements related expected impact covid pandemic one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income comprehensive income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses cost sales selling general administrative research development restructuring costs income expense net income continuing operations taxes taxes income continuing operations net income continuing operations less net income loss attributable noncontrolling interests net income continuing operations attributable merck co inc income discontinued operations net taxes amounts attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders income continuing operations income discontinued operations net income earnings per common share assuming dilution attributable merck co inc common shareholders income continuing operations income discontinued operations net income consolidated statement comprehensive income merck co inc subsidiaries years ended december millions net income attributable merck co inc comprehensive income loss net taxes net unrealized gain loss derivatives net reclassifications net unrealized loss gain investments net reclassifications benefit plan net gain loss prior service credit cost net amortization cumulative translation adjustment comprehensive income attributable merck co inc accompanying notes integral part consolidated financial statements table contents consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents accounts receivable net allowance doubtful accounts inventories excludes inventories classified assets see note current assets current assets discontinued operations total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less accumulated depreciation goodwill intangibles net assets noncurrent assets discontinued operations liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable current liabilities discontinued operations total current liabilities longterm debt deferred income taxes noncurrent liabilities noncurrent liabilities discontinued operations merck co inc stockholders equity common stock par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement table contents consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc comprehensive loss net taxes cash dividends declared common stock per share treasury stock shares purchased net loss attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive loss net taxes cash dividends declared common stock per share treasury stock shares purchased net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc comprehensive income net taxes cash dividends declared common stock per share treasury stock shares purchased spinoff organon co net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities continuing operations net income continuing operations adjustments reconcile net income continuing operations net cash provided operating activities continuing operations amortization depreciation intangible asset impairment charges income investments equity securities net charge acquisition pandion therapeutics inc charge acquisition velosbio inc charge acquisition peloton therapeutics inc deferred income taxes sharebased compensation net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities continuing operations cash flows investing activities continuing operations capital expenditures purchase seagen inc common stock purchases securities investments proceeds sales securities investments acquisition acceleron pharma inc net cash acquired acquisition pandion therapeutics inc net cash acquired acquisition velosbio inc net cash acquired acquisition arqule inc net cash acquired acquisition antelliq corporation net cash acquired acquisition peloton therapeutics inc net cash acquired acquisitions net cash acquired net cash used investing activities continuing operations cash flows financing activities continuing operations net change shortterm borrowings payments debt proceeds issuance debt distribution organon co purchases treasury stock dividends paid stockholders proceeds exercise stock options net cash provided used financing activities continuing operations discontinued operations net cash provided operating activities net cash used investing activities net cash used financing activities net cash flows provided discontinued operations effect exchange rate changes cash cash equivalents restricted cash net increase decrease cash cash equivalents restricted cash cash cash equivalents restricted cash beginning year includes restricted cash january included assets see note less cash cash equivalents related discontinued operations cash cash equivalents restricted cash end year includes restricted cash december included assets see note accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health products companys operations principally managed products basis include two operating segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines company sells human health vaccines primarily physicians wholesalers physician distributors government entities animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers company previously healthcare services segment provided services solutions focused engagement health analytics clinical services improve value care delivered patients company divested remaining businesses segment first quarter spinoff organon co june merck completed spinoff products womens health biosimilars established brands businesses new independent publicly traded company named organon co organon distribution organons publicly traded stock company shareholders distribution expected qualify treated taxfree company shareholders us federal income tax purposes established brands included transaction consisted dermatology nonopioid pain management respiratory select cardiovascular products well rest mercks diversified brands franchise mercks existing research pipeline programs continue owned developed within merck planned historical results businesses contributed organon spinoff reflected discontinued operations companys consolidated financial statements date spinoff see note summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies generally recognized fair value fair value determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value table contents defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded asset acquisition acquired inprocess research development iprd alternative future use charged expense contingent consideration recognized acquisition date foreign currency translation net assets international subsidiaries local currencies determined functional currencies translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included accumulated comprehensive loss aocl reflected separate component equity subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost net realizable value cost substantial majority us pharmaceutical vaccine inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products well certain inventories produced preparation product launches considered high probability regulatory approval evaluating recoverability inventories produced preparation product launches company considers likelihood revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt securities classified availableforsale reported fair value fair values companys investments marketable debt securities determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities changes fair value impairment related reported net taxes comprehensive income oci company considers available evidence evaluating potential impairments investments marketable debt securities including extent fair value less cost whether allowance credit loss required well adverse factors could affect value securities impairment occurred company expect recover entire amortized cost basis marketable debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion impairment related factors recognized oci realized gains losses debt securities included income expense net investments publicly traded equity securities reported fair value determined using quoted market prices active markets identical assets quoted prices similar assets inputs observable corroborated observable market data changes fair value included income expense net unrealized gains losses investments directly owned determined end reporting period gains losses ownership interests investment funds accounted equity method investments reported one quarter lag investments equity securities without readily determinable fair values recorded cost plus minus subsequent observable price changes orderly transactions identical table contents similar investments minus impairments adjustments recognized income expense net realized gains losses equity securities included income expense net revenue recognition recognition revenue requires evidence contract probable collection sales proceeds completion substantially performance obligations merck acts principal substantially customer arrangements therefore records revenue gross basis majority companys contracts related pharmaceutical animal health segments single performance obligation promise transfer goods shipping considered immaterial context overall customer arrangement damages loss goods transit rare therefore shipping deemed separately recognized performance obligation vast majority revenues sales products recognized point time control goods transferred customer company determined title risks rewards ownership transfer customer company entitled payment company recognizes revenue sales vaccines federal government placement vaccine stockpiles accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile interpretation allows companies recognize revenue sales vaccines us government stockpiles even though sales might meet criteria revenue recognition accounting guidance customers billand hold arrangements company revenue billandhold arrangements recognized control transfers customer even though customer yet physical possession goods control transfers billandhold arrangement requested customer product identified belonging customer ready physical transfer product directed use anyone customer certain circumstances customer inspected accepted product companys facility certain services animal health segment revenue recognized time generally ratably contract term services provided service revenues material nature companys business gives rise several types variable consideration including discounts returns estimated time sale generally using expected value method although likely amount method used prompt pay discounts us sales discounts issued customers pointofsale intermediary wholesaler known chargebacks form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition collection accounts receivable expected excess one year sales recorded net time value money discounts material us provision aggregate customer discounts covering chargebacks rebates billion billion billion chargebacks discounts occur contracted customer purchases intermediary wholesaler contracted customer generally purchases product wholesaler contracted price plus markup wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers company uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision amounts accrued aggregate customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued accrued balances relative provisions chargebacks rebates included accounts receivable accrued current liabilities table contents million billion respectively december million billion respectively december outside us variable consideration form discounts rebates combination commerciallydriven discounts highly competitive product classes discounts required gain maintain reimbursement legislatively mandated rebates certain european countries legislatively mandated rebates calculated based estimate governments total unbudgeted spending companys specific payback obligation rebates may also required based specific product sales thresholds company applies estimated factor actual invoiced sales represent expected level future discount rebate obligations associated sale company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market generic competition changes formularies launch overthecounter products among others outside us returns allowed certain countries limited basis mercks payment terms us pharmaceutical customers typically days receipt invoice us animal health customers typically days receipt invoice however certain products including keytruda longer payment terms days outside us payment terms typically days days although certain markets longer payment terms see note disaggregated revenue disclosures depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated tax methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings depreciation expense billion billion billion advertising promotion costs advertising promotion costs expensed incurred company recorded advertising promotion expenses billion billion billion software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development costs included property plant equipment addition company capitalizes certain costs incurred implement cloud computing arrangement considered service agreement included assets capitalized software costs amortized periods ranging years longer lives generally associated enterprisewide projects implemented multiple years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses acquired goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed carrying value reporting unit greater fair value goodwill impairment charge recorded difference carrying value goodwill acquired intangibles acquired intangibles include products product rights trade names patents licenses initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years company periodically evaluates whether current facts circumstances indicate carrying values acquired intangibles may recoverable circumstances determined exist estimate undiscounted table contents future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference carrying value intangible asset fair value determined based net present value estimated future cash flows acquired inprocess research development iprd company acquires conjunction acquisition business represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion iprd project merck make determination thenuseful life intangible asset generally determined period substantial majority cash flows expected generated begin amortization company evaluates iprd impairment least annually frequently impairment indicators exist performing quantitative test compares fair value iprd intangible asset carrying value fair value less carrying amount impairment loss recognized operating results contingent consideration certain companys acquisitions involve potential future payment consideration contingent upon achievement performance milestones including product development milestones royalty payments future product sales transaction accounted business combination fair value contingent consideration liabilities determined acquisition date using unobservable inputs inputs include estimated amount timing projected cash flows probability success achievement contingent event riskadjusted discount rate used present value probabilityweighted cash flows subsequent acquisition date reporting period contingency resolved contingent consideration liability remeasured current fair value changes either expense income recorded earnings significant events increase decrease probability achieving development regulatory milestones increase decrease projected cash flows result corresponding increases decreases fair values related contingent consideration obligations transaction accounted acquisition asset rather business contingent consideration recognized acquisition date instances product development milestones recognized upon achievement salesbased milestones recognized milestone deemed probable company achieved research development research development expensed incurred nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made research development expenses include restructuring costs iprd impairment charges addition research development expenses include expense income related changes estimated fair value measurement liabilities contingent consideration associated iprd assets research development expenses also include upfront milestone payments related asset acquisitions licensing transactions involving clinical development programs yet received regulatory approval collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners merck principal sales transactions third parties company recognizes sales cost sales selling general administrative expenses gross basis profit sharing amounts pays collaborative partners recorded within cost sales collaborative partner principal sales transactions third parties company records profit sharing amounts received collaborative partners alliance revenue within sales alliance revenue recorded net cost sales includes adjustment share commercialization costs partners accordance collaboration agreement adjustment determined comparing commercialization costs merck incurred directly reported within selling general administrative expenses costs collaborative partner incurred research development costs merck incurs related collaborations recorded within research development expenses cost reimbursements collaborative partner payments received collaborative partner share costs pursuant terms collaboration agreements recorded increases decreases research development expenses table contents addition terms collaboration agreements may require company make payments based upon achievement certain developmental regulatory approval commercial milestones upfront milestone payments payable merck collaborative partners prior regulatory approval expensed incurred included research development expenses payments due collaborative partners upon subsequent regulatory approval capitalized amortized estimated useful life corresponding intangible asset cost sales provided future cash flows support amounts capitalized salesbased milestones payable merck collaborative partners accrued capitalized subject cumulative amortization catchup probable achieved amortization catchup calculated either time first regulatory approval indications unapproved time collaboration formed time formation collaboration approved products related intangible asset recognized amortized cost sales remaining useful life subject impairment testing sharebased compensation company expenses sharebased payments employees requisite service period based grantdate fair value awards restructuring costs company records liabilities costs associated exit disposal activities period liability incurred accordance existing benefit arrangements employee termination costs accrued restructuring actions probable estimable accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest penalties associated uncertain tax positions component taxes income continuing operations company accounts tax effects tax global intangible lowtaxed income gilti certain foreign subsidiaries income tax provision period tax arises use estimates consolidated financial statements prepared conformity accounting principles generally accepted us gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets contingent consideration well subsequent fair value measurements additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities accruals contingent salesbased milestone payments reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation table contents recently adopted accounting standards december financial accounting standards board fasb issued amended guidance accounting reporting income taxes guidance intended simplify accounting income taxes removing exceptions related certain intraperiod tax allocations deferred tax liabilities clarifying guidance primarily related evaluating stepup tax basis goodwill business combination reflecting enacted changes tax laws rates annual effective tax rate company adopted new guidance effective january impact companys consolidated financial statements upon adoption january fasb issued new guidance intended clarify certain interactions accounting standards related equity securities equity method investments certain derivatives guidance addresses accounting transition equity method accounting measuring certain purchased options forward contracts acquire investments company adopted new guidance effective january impact companys consolidated financial statements upon adoption august fasb issued amended guidance accounting convertible instruments contracts entitys equity guidance removes separation model convertible debt instruments preferred stock amends requirements conversion options classified equity well amends diluted earnings per share eps calculations certain convertible debt instruments amended guidance effective interim annual periods application amendments new guidance applied either modified retrospective retrospective basis impact companys consolidated financial statements upon adoption january recently issued accounting standards yet adopted march fasb issued optional guidance ease potential burden accounting recognizing effects reference rate reform financial reporting subsequently issued clarifying amendments guidance provides optional expedients exceptions accounting contracts hedging relationships transactions reference london interbank offered rate libor another reference rate expected discontinued reference rate reform optional guidance effective upon issuance applied prospective basis time january december company currently evaluating impact adoption consolidated financial statements company progressing evaluation libor cessation exposures including review debtrelated contracts leases business development licensing arrangements royalty agreements company amended certain agreements continues review agreements potential impacts regard debtrelated exposures particular existing interest rate swaps linked libor mature company still evaluating impact liborbased debt based evaluation thus far company anticipate material impact consolidated financial statements result reference rate reform october fasb issued amended guidance requires acquiring entities recognize measure contract assets liabilities business combination accordance existing revenue recognition guidance amended guidance effective interim annual periods applied prospectively early adoption permitted retrospective basis beginning fiscal year adoption adoption guidance material impact companys consolidated financial statements prior acquisitions however impact future periods dependent upon contract assets contract liabilities acquired future business combinations november fasb issued new guidance increase transparency transactions government accounted applying grant contribution accounting model analogy guidance requires annual disclosures transactions include nature transactions significant terms conditions accounting treatment impact companys financial statements guidance effective annual periods beginning applied either prospective retrospective basis company currently evaluating impact adoption consolidated financial statements spinoff organon co june merck completed spinoff organon distribution organons publicly traded stock company shareholders connection spinoff merck shareholder received onetenth share organons common stock share merck common stock held shareholder table contents distribution expected qualify treated tax free merck shareholders us federal income tax purposes indebtedness billion principal amount consisting term loans senior notes issued connection spinoff assumed organon merck longer obligor organon debt financing arrangements cash proceeds billion distributed organon merck connection spinoff also connection spinoff merck organon entered separation distribution agreement also entered various agreements effect spinoff provide framework relationship merck organon spinoff including transition services agreement tsa manufacturing supply agreements msas trademark license agreements intellectual property license agreements employee matters agreement tax matters agreement certain commercial agreements tsa merck provide organon various services similarly organon provide merck various services provision services tsa generally terminate within months following spinoff merck organon also entered series interim operating agreements pursuant various jurisdictions merck held licenses permits rights connection marketing import andor distribution organon products prior separation merck continue market import distribute products time relevant licenses permits transferred organon interim operating agreements accordance separation distribution agreement merck continue operations affected markets behalf organon organon receiving economic benefits burdens activities additionally merck organon entered number msas pursuant merck manufacture supply certain active pharmaceutical ingredients organon b toll manufacture supply certain formulated pharmaceutical products organon c package label certain finished pharmaceutical products organon similarly organon merck entered number msas pursuant organon manufacture supply certain formulated pharmaceutical products merck b package label certain finished pharmaceutical products merck terms msas range initial duration four years ten years amounts included consolidated statement income msas include sales million related cost sales million amounts included consolidated statement income tsas immaterial amount due organon agreements million december reflected current assets amount due organon agreements million december included accrued current liabilities results womens health biosimilars established brands businesses previously included pharmaceutical segment contributed organon spinoff well interest expense related debt issuance reflected discontinued operations companys consolidated statement income income discontinued operations net taxes amounts attributable noncontrolling interests june date spinoff prior periods recast reflect presentation result spinoff organon merck incurred separation costs million million also included income discontinued operations net taxes amounts attributable noncontrolling interests costs primarily relate professional fees separation activities within finance tax legal information technology functions well investment banking fees december assets liabilities associated businesses classified assets liabilities discontinued operations consolidated balance sheet table contents details income discontinued operations net taxes amounts attributable noncontrolling interests follows years ended december sales costs expenses cost sales selling general administrative research development restructuring costs income expense net income discontinued operations taxes tax provision income discontinued operations net taxes less income discontinued operations attributable noncontrolling interests income discontinued operations net taxes amounts attributable noncontrolling interests reflects amounts june spinoff date details assets liabilities discontinued operations follows december cash cash equivalents accounts receivable less allowance doubtful accounts inventories current assets current assets discontinued operations property plant equipment net goodwill intangibles net assets noncurrent assets discontinued operations trade accounts payable accrued current liabilities income taxes payable total current liabilities discontinued operations deferred income taxes noncurrent liabilities noncurrent liabilities discontinued operations result spinoff organon merck distributed net liabilities billion june consisting debt billion described goodwill billion property plant equipment million cash million inventory million intangibles net million net liabilities million spinoff also resulted net decrease aocl million consisting million derecognition net losses foreign currency translation adjustments million associated employee benefit plans distribution net liabilities reduction aocl resulted net billion increase paidin capital table contents expenses curtailments settlements termination benefits provided certain employees incurred connection spinoff see note additionally outstanding merck stock options restricted stock units rsus performance share units psus whether vested unvested converted adjusted merck awards current former merck employees organon awards organon employees see note acquisitions research collaborations license agreements company continues pursue acquisitions establishment external alliances research collaborations licensing agreements complement internal research capabilities arrangements often include upfront payments well expense reimbursements payments third party milestone royalty profit share arrangements contingent upon occurrence certain future events linked success asset development company also reviews marketed products pipeline examine candidates may provide value outlicensing part portfolio assessment process may also divest certain assets pro forma financial information acquired businesses presented historical financial results acquired entity significant compared companys financial results transactions november merck acquired acceleron pharma inc acceleron publicly traded biopharmaceutical company total consideration billion acceleron evaluating transforming growth factor tgfbeta superfamily proteins known play central role regulation cell growth differentiation repair accelerons lead therapeutic candidate sotatercept mk novel mechanism action potential improve shortterm andor longterm clinical outcomes patients pulmonary arterial hypertension pah sotatercept phase trials addon current standard care treatment pah previous agreement assumed merck bristol myers squibb bms granted exclusive license develop commercialize sotatercept outside pulmonary hypertension ph field merck would eligible receive contingent milestones royalty payments however merck retains worldwide exclusive rights develop commercialize sotatercept ph field agreement provides merck pay royalties future sales sotatercept ph field bms addition sotatercept accelerons portfolio includes reblozyl luspatercept firstinclass erythroid maturation recombinant fusion protein approved us europe canada australia treatment anemia certain rare blood disorders also evaluated phase phase trials additional indications hematology therapies reblozyl developed commercialized global collaboration bms connection ongoing collaboration merck receives sales royalty bms could increase maximum based sales levels royalty reduced upon earlier patent expiry generic entry indicationbyindication basis market merck eligible receive future contingent milestone payments including million regulatory milestones million salesbased milestones transaction accounted business combination company incurred million costs directly related acquisition acceleron consisting primarily sharebased compensation payments settle nonvested equity awards attributable postcombination service severance well investment banking legal fees costs included selling general administrative expenses research development costs table contents estimated fair value assets acquired liabilities assumed acceleron follows november cash cash equivalents investments identifiable intangible assets iprd sotatercept products product rights reblozyl year useful life deferred income tax liabilities net assets liabilities net total identifiable net assets goodwill consideration transferred estimated fair value identifiable intangible assets related sotatercept reblozyl determined using income approach specifically multiperiod excess earnings method future probabilityweighted net cash flows discounted present value utilizing discount rate sotatercept reblozyl actual cash flows likely different assumed goodwill recognized largely attributable anticipated synergies expected arise acquisition allocated pharmaceutical segment goodwill deductible tax purposes april merck acquired pandion therapeutics inc pandion clinicalstage biotechnology company developing novel therapeutics designed address unmet needs patients living autoimmune diseases pandion advancing pipeline precision immune modulators targeting critical immune control nodes total consideration paid billion included million costs primarily comprised sharebased compensation payments settle equity awards transaction accounted acquisition asset merck recorded net assets million primarily cash research development expenses billion related transaction future contingent payments associated acquisition march merck gilead sciences inc gilead entered agreement jointly develop commercialize longacting treatments hiv combine mercks investigational nucleoside reverse transcriptase translocation inhibitor islatravir gileads investigational capsid inhibitor lenacapavir collaboration initially focus longacting oral formulations longacting injectable formulations combination products formulations potentially added collaboration mutually agreed upfront payment made either party upon entering agreement terms agreement merck gilead share operational responsibilities well development commercialization marketing costs future revenues global development commercialization costs shared gilead merck across oral injectable formulation programs longacting oral products gilead lead commercialization us merck lead commercialization eu rest world longacting injectable products merck lead commercialization us gilead lead commercialization eu rest world gilead merck copromote us certain major markets merck gilead share global product revenues equally product revenues surpass certain preagreed per formulation revenue tiers upon passing billion year net product sales oral combination revenue split adjust gilead merck revenues threshold upon passing billion year net product sales injectable combination revenue split adjust gilead merck revenues threshold beyond potential combinations investigational lenacapavir investigational islatravir gilead option license certain mercks investigational oral integrase inhibitors develop combination lenacapavir reciprocally merck option license certain gileads investigational oral integrase inhibitors develop combination islatravir company may exercise option investigational oral integrase inhibitor company following completion first phase clinical trial integrase inhibitor upon exercise option companies split development costs revenues unless nonexercising company decides optout december us food drug administration fda placed full partial clinical holds investigational new drug applications certain oral implant injectable formulations islatravir based table contents observations decreases total lymphocyte cd tcell counts participants receiving islatravir clinical studies result holds merck gilead made decision stop dosing participants phase clinical study evaluating islatravir lenacapavir people living hiv virologically suppressed antiretroviral therapy two companies assessing whether different dosing islatravir combination lenacapavir may provide onceweekly oral therapy option people living hiv merck gilead remain committed collaboration january merck entered exclusive license research collaboration agreement artiva biotherapeutics inc artiva discover develop manufacture carnk cells target certain solid tumors using artivas proprietary platform merck artiva agreed engage three different research programs covering collaboration target merck sole responsibility development commercialization activities including regulatory filing approval terms agreement merck made upfront payment million included research development expenses license rights first two collaboration targets agreed make another upfront payment million license rights third collaboration target selected merck accepted artiva addition artiva eligible receive future contingent milestone payments span three collaboration targets aggregating million developmental milestones million regulatory milestones billion salesbased milestones agreement also provides merck pay tiered royalties ranging future sales transactions december merck acquired oncoimmune privately held clinicalstage biopharmaceutical company upfront payment million oncoimmunes lead therapeutic candidate mk evaluated treatment patients hospitalized covid transaction accounted acquisition asset agreement prior completion acquisition oncoimmune spunout certain rights assets unrelated mk program new entity owned existing shareholders oncoimmune connection closing acquisition merck invested million ownership interest new entity valued million resulting million premium merck also recognized net liabilities million company recorded research development expenses million related transaction merck received feedback fda additional data would needed support potential emergency use authorization eua application therefore company expect mk would become available first half given timeline technical clinical regulatory uncertainties availability number medicines patients hospitalized covid need concentrate mercks resources accelerating development manufacture viable therapeutics vaccines merck decided discontinue development mk treatment covid due discontinuation company recorded charges million reflected cost sales relate fixed assets materials written well recognition liabilities purchase commitments also december merck acquired velosbio inc velosbio privately held clinicalstage biopharmaceutical company billion velosbios lead investigational candidate zilovertamab vedotin mk antibodydrug conjugate targeting receptor tyrosine kinaselike orphan receptor ror currently evaluated treatment patients hematologic malignancies solid tumors transaction accounted acquisition asset merck recorded net assets million primarily cash research development expenses billion related transaction company recorded adjustments amounts resulted reduction research development expenses million increase total consideration paid million increase net assets recorded million september merck seagen inc seagen announced oncology collaboration globally develop commercialize seagens ladiratuzumab vedotin mk investigational antibodydrug conjugate targeting liv currently phase clinical trials collaboration pursue broad joint development program evaluating ladiratuzumab vedotin monotherapy combination keytruda pembrolizumab triplenegative breast cancer hormone receptorpositive breast cancer livexpressing solid tumors companies equally share profits worldwide terms agreement table contents merck made upfront payment million billion equity investment million shares seagen common stock price per share merck recorded million research development expenses related transaction reflecting upfront payment well million premium relating equity shares based price seagen common stock closing date seagen also eligible receive future contingent milestone payments billion including million development milestones billion salesbased milestones concurrent transaction seagen granted merck exclusive license commercialize tukysa tucatinib small molecule tyrosine kinase inhibitor treatment human epidermal growth factor receptor herpositive cancers asia middle east latin america regions outside us canada europe merck responsible marketing applications seeking approval territories supported positive results herclimb clinical trial merck also cofund portion tukysa global development plan encompasses several ongoing planned trials across herpositive cancers including breast colorectal gastric cancers set forth global product development plan merck solely fund conduct countryspecific clinical trials necessary support anticipated regulatory applications territories terms agreement merck made upfront payments aggregating million recorded research development expenses seagen also eligible receive future contingent regulatory approval milestones million receive tiered royalties ranging based annual sales levels tukysa mercks territories additionally september merck acquired biologics manufacturing facility located dunboyne ireland takeda pharmaceutical company limited million million transaction accounted acquisition asset merck recorded property plant equipment million net assets million future contingent payments associated acquisition july merck acquired us rights sentinel flavor tabs sentinel spectrum chews virbac corporation million sentinel products provide protection common parasites dogs transaction accounted acquisition asset merck recognized intangible assets million related currently marketed products inventory million acquisition date estimated fair values identifiable intangible assets related currently marketed products determined using income approach actual cash flows likely different assumed intangible assets related currently marketed products amortized estimated useful lives years future contingent payments associated acquisition also july merck ridgeback biotherapeutics lp ridgeback closely held biotechnology company closed collaboration agreement develop molnupiravir mk orally available antiviral candidate clinical development treatment patients covid see note additional information related collaboration june merck acquired privately held themis bioscience gmbh themis company focused vaccines including covid vaccine candidate v immunemodulation therapies infectious diseases cancer million acquisition originally provided merck make additional contingent payments million transaction accounted business combination company determined fair value contingent consideration million acquisition date utilizing probabilityweighted estimated cash flow stream using appropriate discount rate dependent nature timing milestone payments merck recognized intangible assets iprd million cash million deferred tax assets million net liabilities million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair values identifiable intangible assets related iprd determined using income approach actual cash flows likely different assumed january company announced discontinuing development v discussed result company recorded iprd impairment charge million within research development expenses company also recorded reduction research development expenses resulting decrease related liability contingent consideration million since future contingent milestone payments reduced million aggregate including million development milestones million regulatory approval milestones million commercial milestones table contents may merck international aids vaccine initiative inc iavi nonprofit scientific research organization dedicated addressing urgent unmet global health challenges announced collaboration develop v investigational vaccine sarscov studied prevention covid agreement provided upfront payment merck million also provided future contingent payments based sales merck also signed agreement biomedical advanced research development authority barda part office assistant secretary preparedness response within agency us department health human services provide initial funding support merck effort january company announced discontinuing development v discussed january company announced discontinuation development programs covid vaccine candidates v v following mercks review findings phase clinical studies vaccines studies v v generally well tolerated immune responses inferior seen following natural infection reported sarscovcovid vaccines due discontinuation company recorded charge million million reflected cost sales related fixed assets materials written well recognition liabilities purchase commitments remaining million costs reflected research development expenses represent amounts related themis acquisition noted iprd impairment charge partially offset reduction related liability contingent consideration january merck acquired arqule inc arqule publicly traded biopharmaceutical company focused kinase inhibitor discovery development treatment patients cancer diseases total consideration paid billion included million sharebased compensation payments settle equity awards attributable precombination service cash paid transaction costs behalf arqule company incurred million costs directly related acquisition arqule consisting almost entirely sharebased compensation payments settle nonvested equity awards attributable postcombination service costs included selling general administrative expenses arqules lead investigational candidate nemtabrutinib mk novel oral brutons tyrosine kinase btk inhibitor currently evaluated treatment bcell malignancies transaction accounted business combination estimated fair value assets acquired liabilities assumed arqule follows january cash cash equivalents iprd nemtabrutinib licensing arrangement arq deferred income tax liabilities assets liabilities net total identifiable net assets goodwill consideration transferred estimated fair value nemtabrutinib determined using income approach future probabilityweighted net cash flows discounted present value utilizing discount rate actual cash flows likely different assumed goodwill allocated pharmaceutical segment deductible tax purposes merck recorded million intangible asset impairment charge related nemtabrutinib see note transactions july merck acquired peloton therapeutics inc peloton clinicalstage biopharmaceutical company focused development novel small molecule therapeutic candidates targeting hypoxiainducible factor hif treatment patients cancer nononcology diseases merck made upfront payment billion transaction accounted acquisition asset merck recorded cash million deferred tax liabilities million net liabilities million acquisition table contents date well research development expenses million related transaction former peloton shareholders received million milestone payment merck upon first commercial sale pelotons lead candidate welireg belzutifan approved monotherapy us august former peloton shareholders also eligible receive million upon us regulatory approval combination therapy well billion salesbased milestones april merck acquired antelliq corporation antelliq leader digital animal identification traceability monitoring solutions solutions help veterinarians farmers pet owners gather critical data improve management health wellbeing livestock pets merck paid billion acquire outstanding shares antelliq spent billion repay antelliqs debt transaction accounted business combination estimated fair value assets acquired liabilities assumed antelliq follows april cash cash equivalents accounts receivable inventories property plant equipment identifiable intangible assets useful lives ranging years deferred income tax liabilities assets liabilities net total identifiable net assets goodwill consideration transferred estimated fair values identifiable intangible assets relate primarily trade names determined using income approach future probabilityweighted net cash flows discounted present value utilizing discount rate actual cash flows likely different assumed goodwill recognized largely attributable anticipated synergies expected arise acquisition allocated animal health segment goodwill deductible tax purposes company incurred million transaction costs directly related acquisition antelliq consisting largely advisory fees reflected selling general administrative expenses also april merck acquired immune design latestage immunotherapy company employing nextgeneration vivo approaches enable bodys immune system fight disease million cash transaction accounted business combination merck recognized intangible assets million cash million net assets million excess consideration transferred fair value net assets acquired million recorded goodwill allocated pharmaceutical segment deductible tax purposes fair values identifiable intangible assets related iprd determined using income approach actual cash flows likely different assumed collaborative arrangements merck entered collaborative arrangements provide company varying rights develop produce market products together collaborative partners parties arrangements active participants exposed significant risks rewards dependent commercial success activities collaboration mercks significant collaborative arrangements discussed astrazeneca merck astrazeneca plc astrazeneca entered global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza olaparib multiple cancer types independently merck astrazeneca develop commercialize lynparza combinations respective pd pdl medicines keytruda imfinzi companies also jointly developing table contents commercializing astrazenecas koselugo selumetinib multiple indications terms agreement astrazeneca merck share development commercialization costs lynparza koselugo monotherapy nonpdlpd combination therapy opportunities profits lynparza koselugo product sales generated monotherapies combination therapies shared equally astrazeneca principal lynparza koselugo sales transactions merck records share lynparza koselugo product sales net cost sales commercialization costs alliance revenue share development costs associated collaboration part research development expenses reimbursements received astrazeneca research development expenses recognized reductions research development costs part agreement merck made upfront payment astrazeneca also made payments multiyear period certain license options addition agreement provides contingent payments merck astrazeneca related successful achievement salesbased regulatory milestones merck made salesbased milestone payments astrazeneca aggregating million million respectively december salesbased milestone payments accrued yet paid totaled million potential future salesbased milestone payments billion yet accrued deemed company probable time lynparza received regulatory approvals triggering capitalized milestone payments million million respectively aggregate merck astrazeneca potential future regulatory milestone payments billion remain agreement intangible asset balance related lynparza includes capitalized salesbased regulatory milestone payments billion december included intangibles net amount amortized estimated useful life supported projected future cash flows subject impairment testing summarized financial information related collaboration follows years ended december alliance revenue lynparza alliance revenue koselugo total alliance revenue cost sales selling general administrative research development december receivables astrazeneca included current assets payables astrazeneca included trade accounts payable accrued current liabilities represents amortization capitalized milestone payments includes accrued milestone payments eisai merck eisai co ltd eisai announced strategic collaboration worldwide codevelopment cocommercialization lenvima lenvatinib orally available tyrosine kinase inhibitor discovered eisai agreement merck eisai develop commercialize lenvima jointly monotherapy combination keytruda eisai records lenvima product sales globally eisai principal lenvima sales transactions merck eisai share applicable profits equally merck records share lenvima product sales net cost sales commercialization costs alliance revenue expenses incurred codevelopment shared two companies accordance collaboration agreement reflected research development expenses certain expenses incurred solely merck eisai table contents shareable collaboration agreement including costs incurred excess agreed upon caps costs related certain combination studies keytruda lenvima agreement merck made upfront payment eisai also made payments multiyear period certain option rights final million option payment made march addition agreement provides contingent payments merck eisai related successful achievement salesbased regulatory milestones merck made salesbased milestone payments eisai aggregating million million million respectively december salesbased milestone payments accrued yet paid totaled million potential future sales based milestone payments billion yet accrued deemed company probable time lenvima received regulatory approvals triggering capitalized milestone payments million million respectively merck eisai december regulatory approval milestone payment million accrued yet paid potential future regulatory milestone payments million remain agreement intangible asset balance related lenvima includes capitalized salesbased regulatory milestone payments billion december included intangibles net amount amortized estimated useful life supported projected future cash flows subject impairment testing summarized financial information related collaboration follows years ended december alliance revenue lenvima cost sales selling general administrative research development december receivables eisai included current assets payables eisai included accrued current liabilities payables eisai included noncurrent liabilities represents amortization capitalized milestone payments includes accrued milestone future option payments includes accrued milestone payments bayer ag company entered worldwide clinical development collaboration bayer ag bayer market develop soluble guanylate cyclase sgc modulators including bayers adempas riociguat two companies implemented joint development commercialization strategy collaboration also includes development bayers verquvo vericiguat approved us january japan june eu july agreement bayer commercializes adempas americas merck commercializes rest world verquvo merck commercializes us bayer commercializes rest world companies share development costs profits sales merck records sales adempas verquvo marketing territories well alliance revenue alliance revenue represents mercks share profits sales adempas verquvo bayers marketing territories product sales net cost sales commercialization costs cost sales includes bayers share profits sales mercks marketing territories addition agreement provided contingent payments merck bayer related successful achievement salesbased milestones merck made salesbased milestone payment bayer million following approval verquvo noted merck determined probable sales adempas verquvo future would trigger remaining million salesbased milestone table contents payment outstanding agreement accordingly merck recorded liability million corresponding increase intangible assets related collaboration merck also recognized million cumulative amortization catchup expense related recognition milestone january merck made final milestone payment bayer intangible asset balances related adempas includes acquired intangible asset balance well capitalized salesbased milestone payments attributed adempas verquvo reflects portion final salesbased milestone payment attributed verquvo million million respectively december included intangibles net assets amortized estimated useful lives adempas verquvo supported projected future cash flows subject impairment testing summarized financial information related collaboration follows years ended december alliance revenue adempasverquvo net sales adempas recorded merck net sales verquvo recorded merck total sales cost sales selling general administrative research development december receivables bayer included current assets payables bayer included accrued current liabilities includes amortization intangible assets amount includes million cumulative amortization catchup expense noted addition cost sales periods includes bayers share profits sales mercks marketing territories includes accrued milestone payment ridgeback biotherapeutics lp july merck ridgeback closely held biotechnology company entered collaboration agreement develop molnupiravir mk orally available antiviral candidate clinical development treatment patients covid merck gained exclusive worldwide rights develop commercialize molnupiravir related molecules terms agreement ridgeback received upfront payment eligible receive future contingent payments dependent upon achievement certain developmental regulatory approval milestones agreement also provides merck reimburse ridgeback portion certain thirdparty contingent milestone payments royalties net sales part profit share calculation merck principal sales transactions recognizing sales related costs profit sharing amounts recorded within cost sales profits collaboration split equally partners reimbursements ridgeback share research development costs deducted ridgebacks share profits reflected decreases research development expenses december fda granted eua molnupiravir previously announced procurement agreement us government merck agreed supply million courses molnupiravir us government upon eua approval fda approximately courses delivered procurement molnupiravir supported whole part federal funds additionally december japans ministry health labor welfare granted special approval emergency japan molnupiravir supply agreement japanese government purchase million courses molnupiravir approximately courses delivered also november medicines healthcare products regulatory agency united kingdom uk granted conditional marketing authorization molnupiravir uk government committed purchase total million courses molnupiravir approximately courses delivered merck entered advance purchase supply agreements molnupiravir markets table contents merck ridgeback committed providing timely access molnupiravir globally comprehensive supply access approach includes investing risk produce millions courses therapy tiered pricing based ability governments finance health care entering supply agreements governments noted allocating million courses therapy united nations childrens fund unicef use adults granting voluntary licenses generic manufacturers medicines patent pool mpp make generic molnupiravir available low middleincome countries following local regulatory authorizations approvals merck ridgeback emory university receive royalties sales molnupiravir mpp agreement molnupiravir invented emory university licensed ridgeback long covid remains classified public health emergency international concern world health organization summarized financial information related collaboration follows years ended december molnupiravir sales cost sales selling general administrative research development december payables ridgeback included accrued current liabilities includes royalty expense amortization capitalized milestone payments amount includes upfront payment includes accrued royalty milestone payments restructuring merck approved global restructuring program restructuring program part worldwide initiative focused optimizing companys manufacturing supply network well reducing global real estate footprint program continuation companys plant rationalization builds prior restructuring programs actions currently contemplated restructuring program expected substantially completed end cumulative pretax costs incurred company implement program estimated approximately billion company estimates approximately cumulative pretax costs result cash outlays primarily related employee separation expense facility shutdown costs approximately cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company recorded total pretax costs million million million related restructuring program activities since inception restructuring program december merck recorded total pretax accumulated costs approximately billion company expects record charges approximately million related restructuring program segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related restructuring program activities type cost separation accelerated costs depreciation total year ended december cost sales selling general administrative research development restructuring costs year ended december cost sales selling general administrative research development restructuring costs year ended december cost sales selling general administrative research development restructuring costs separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated accelerated depreciation costs primarily relate manufacturing research administrative facilities equipment sold closed part programs accelerated depreciation costs represent difference depreciation expense recognized revised useful life asset based upon anticipated date site closed divested equipment disposed depreciation expense determined utilizing useful life prior restructuring actions sites continue operate respective closure dates since future undiscounted cash flows sufficient recover respective book values merck recording accelerated depreciation revised useful life site assets anticipated site closure dates particularly related manufacturing locations may continue adjusted reflect changes resulting regulatory factors activity includes asset abandonment facility shutdown related costs well pretax gains losses resulting sales facilities related assets additionally activity includes certain employeerelated costs associated pension postretirement benefit plans see note sharebased compensation following table summarizes charges spending relating restructuring program activities separation accelerated costs depreciation total restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december remaining cash outlays expected substantially completed end table contents financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused changes foreign exchange rates objective revenue hedging program reduce variability caused changes foreign exchange rates would affect us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales forecasted sales expected occur planning cycle typically two years future company layer hedges time increasing portion forecasted sales hedged gets closer expected date forecasted sales portion forecasted sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments company manages anticipated transaction exposure principally purchased local currency put options forward contracts purchased collar options fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges unrealized gains losses contracts recorded aocl reclassified sales hedged anticipated revenue recognized derivatives designated cash flow hedges serve economic hedges forecasted sales unrealized gains losses recorded sales period cash flows designated nondesignated contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes company manages operating activities net asset positions local subsidiary order mitigate effects exchange monetary assets liabilities company also uses balance sheet risk management program mitigate exposure net monetary assets denominated currency subsidiarys functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen british pound canadian dollar swiss franc exposures developing country currencies including chinese renminbi company enter forward contracts offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument cash flows contracts reported operating activities consolidated statement cash flows monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year table contents company also uses forward exchange contracts hedge portion net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation unrealized gains losses contracts recorded foreign currency translation adjustment within oci remain aocl either sale complete substantially complete liquidation subsidiary company excludes certain portions change fair value derivative instruments assessment hedge effectiveness excluded components changes fair value excluded components recognized oci company recognizes earnings initial value excluded components straightline basis life derivative instrument rather using marktomarket approach cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci effects companys net investment hedges oci consolidated statement income shown amount pretax gain loss recognized amount pretax gain loss recognized income expense net amounts excluded comprehensive income effectiveness testing years ended december net investment hedging relationships foreign exchange contracts eurodenominated notes amounts reclassified aocl income related sale subsidiary interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk january five interest rate swaps total notional amount billion matured swaps effectively converted companys billion fixedrate notes due variable rate debt december company party nine payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes detailed table number interest rate total swap notional debt instrument par value debt swaps held amount notes due notes due interest rate swaps matured february interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark libor swap rate fair value changes notes attributable changes libor swap rate recorded interest expense along offsetting fair value changes swap contracts see note discussion pending discontinuation libor part reference rate reform cash flows contracts reported operating activities consolidated statement cash flows table contents table presents location amounts recorded consolidated balance sheet related cumulative basis adjustments fair value hedges december cumulative amount fair value hedging adjustment increase decrease included carrying amount hedged liabilities carrying amount balance sheet line item hedged item included loans payable current portion longterm debt longterm debt presented table fair value derivatives gross basis segregated derivatives designated hedging instruments designated hedging instruments december fair value fair value derivative us dollar derivative us dollar balance sheet caption asset liability notional asset liability notional derivatives designated hedging instruments interest rate swap contracts current assets interest rate swap contracts assets foreign exchange contracts current assets foreign exchange contracts assets foreign exchange contracts accrued current liabilities foreign exchange contracts noncurrent liabilities derivatives designated hedging instruments foreign exchange contracts current assets foreign exchange contracts accrued current liabilities noted company records derivatives gross basis consolidated balance sheet company master netting agreements several financial institution counterparties see concentrations credit risk following table provides information companys derivative positions subject master netting arrangements presented net basis allowing right offset counterparty cash collateral exchanged per master agreements related credit support annexes december asset liability asset liability gross amounts recognized consolidated balance sheet gross amounts subject offset master netting arrangements offset consolidated balance sheet cash collateral postedreceived net amounts table contents table provides information regarding location amount pretax gains losses derivatives designated fair value cash flow hedging relationships sales income expense net comprehensive income loss years ended december financial statement line items effects fair value cash flow hedges recorded gain loss fair value hedging relationships interest rate swap contracts hedged items derivatives designated hedging instruments impact cash flow hedging relationships foreign exchange contracts amount gain loss recognized oci derivatives decrease increase sales result aocl reclassifications interest rate contracts amount gain recognized income expense net derivatives amount loss recognized oci derivatives interest expense component income expense net table provides information regarding income statement effects derivatives designated hedging instruments amount derivative pretax gain loss recognized income years ended december derivatives designated hedging instruments income statement caption foreign exchange contracts income expense net foreign exchange contracts sales interest rate contracts income expense net forward contract related seagen common stock research development expenses derivative contracts primarily mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates amount includes loss forward exchange contracts entered conjunction spinoff organon derivatives serve economic hedges forecasted transactions derivatives serve economic hedges rising treasury rates december company estimates million pretax net unrealized gains derivatives maturing within next months hedge foreign currency denominated sales period reclassified aocl sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity table contents investments debt equity securities information investments debt equity securities december follows gross unrealized gross unrealized amortized fair amortized fair cost gains losses value cost gains losses value us government agency securities foreign government bonds corporate notes bonds total debt securities publicly traded equity securities total debt publicly traded equity securities unrealized net losses recorded income expense net equity securities still held december million unrealized net gains recorded income expense net equity securities still held december million december company also million million respectively equity investments without readily determinable fair values included assets company records unrealized gains equity investments based favorable observable price changes transactions involving similar investments investee records unrealized losses based unfavorable observable price changes included income expense net company recorded unrealized gains million unrealized losses million related certain equity investments still held december company recorded unrealized gains million unrealized losses million related certain investments still held december cumulative unrealized gains cumulative unrealized losses based observable price changes investments equity investments without readily determinable fair values still held december million million respectively december company also billion million respectively recorded assets equity securities held ownership interests investment funds gains losses recorded income expense net relating investment funds billion million million years ended december respectively fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date company uses fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets liabilities whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well assets liabilities determination fair value requires significant judgment estimation inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument table contents financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis december summarized fair value measurements using fair value measurements using level level level total level level level total assets investments foreign government bonds publicly traded equity securities assets us government agency securities corporate notes bonds publicly traded equity securities derivative assets forward exchange contracts purchased currency options interest rate swaps total assets liabilities liabilities contingent consideration derivative liabilities forward exchange contracts written currency options total liabilities investments included assets restricted use including payment benefits employee benefit plans fair value determination derivatives includes impact credit risk counterparties derivatives companys credit risk effects significant december cash cash equivalents include cash equivalents billion would considered level fair value hierarchy table contents contingent consideration summarized information changes fair value liabilities contingent consideration associated business combinations follows fair value january additions changes estimated fair value payments fair value december recorded cost sales research development expenses income expense net includes cumulative translation adjustments balance december includes million recorded current liability amounts expected paid within next months december million million respectively liabilities relate termination sanofi pasteur msd joint venture part termination merck recorded liability contingent future royalty payments net sales merck products previously sold joint venture december fair value liability determined utilizing estimated amount timing projected cash flows using riskadjusted discount rate present value cash flows additions contingent consideration relate acquisition themis see note payments contingent consideration years relate sanofi pasteur msd liabilities described fair value measurements companys financial instruments cash cash equivalents receivables payables reflected balance sheet carrying value approximates fair value due shortterm nature estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using recent observable market prices would considered level fair value hierarchy concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate government issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines majority companys accounts receivable arise product sales us europe china primarily due drug wholesalers retailers hospitals government agencies managed health care providers pharmacy benefit managers company monitors financial performance creditworthiness customers properly assess respond changes credit profile company also continues monitor global economic conditions including volatility associated international sovereign economies associated impacts financial markets business companys customers largest accounts receivable balances mckesson corporation amerisourcebergen corporation cardinal health inc represented approximately respectively total accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales company accounts receivable factoring agreements financial institutions certain countries sell accounts receivable company factored billion billion accounts receivable december respectively factoring arrangements reduced outstanding accounts receivable cash received financial institutions reported within operating activities consolidated statement cash flows certain factoring arrangements ease administration company collect customer payments related factored receivables remits financial institutions december company collected million million table contents respectively behalf financial institutions reflected restricted cash current assets related obligation remit cash within accrued current liabilities company remitted cash financial institutions january respectively net cash flows relating collections reported financing activities consolidated statement cash flows cost factoring accounts receivable de minimis derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty cash collateral received company various counterparties million december obligation return collateral recorded accrued current liabilities cash collateral advanced company counterparties million december inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost decrease lifo cost recognized inventories assets inventories valued lifo method comprised approximately billion billion december respectively amounts recognized assets comprised almost entirely raw materials work process inventories december amounts included billion billion respectively inventories expected sold within one year addition amounts included million million december respectively inventories produced preparation product launches goodwill intangibles following table summarizes goodwill activity segment pharmaceutical animal health total balance january acquisitions divestitures balance december acquisitions balance december includes cumulative translation adjustments goodwill balances accumulated goodwill impairment losses million december additions goodwill pharmaceutical segment primarily related acquisition acceleron additions goodwill pharmaceutical segment primarily related acquisitions arqule themis see note information acquisitions table contents acquired intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net products product rights iprd trade names licenses acquired intangibles include products product rights iprd trade names patents licenses initially recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives significant acquired intangibles net basis related human health marketed products included products product rights december include reblozyl billion zerbaxa million gardasilgardasil million bridion million dificid million sivextro million simponi million additionally company billion net acquired intangibles related animal health marketed products december billion relate primarily trade names obtained acquisition antelliq see note december iprd primarily relates mk sotatercept billion obtained acquisition acceleron see note mk nemtabrutinib billion obtained acquisition arqule see note mk gefapixant million obtained acquisition afferent pharmaceuticals significant net intangible assets included licenses december include lynparza billion related collaboration astrazeneca lenvima billion related collaboration eisai adempas million related collaboration bayer verquvo million also related collaboration bayer see note additional information related intangible assets associated collaborations company recorded impairment charge billion within cost sales related zerbaxa ceftolozane tazobactam injection combination antibacterial betalactamase inhibitor treatment certain bacterial infections december company temporarily suspended sales zerbaxa subsequently issued product recall following identification product sterility issues recall constituted triggering event requiring evaluation zerbaxa intangible asset impairment company revised cash flow forecasts zerbaxa utilizing certain assumptions around return market timeline anticipated uptake sales thereafter revised cash flow forecasts indicated zerbaxa intangible asset value fully recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair value intangible asset related zerbaxa compared related carrying value resulted impairment charge noted company also wroteoff inventory million cost sales related zerbaxa recall phased resupply zerbaxa initiated fourth quarter company recorded impairment charges related marketed products intangibles million amount million related sivextro tedizolid phosphate product treatment acute bacterial skin skin structure infections caused designated susceptible grampositive organisms part reorganization reprioritization internal sales force company made decision cease promotion sivextro us market end decision resulted reduced cash flow projections sivextro indicated sivextro intangible asset value fully recoverable undiscounted cash flows basis company utilized market participant assumptions determine best estimate fair value intangible asset related sivextro compared related carrying value resulted impairment charge noted iprd company acquires business combinations represents fair value assigned incomplete research projects time acquisition reached technological feasibility amounts capitalized iprd accounted indefinitelived intangible assets subject impairment testing table contents completion abandonment projects upon successful completion iprd project company make separate determination useful life asset begin amortization company recorded million iprd impairment charge within research development expenses related nemtabrutinib mk novel oral btk inhibitor currently evaluated treatment bcell malignancies obtained connection acquisition arqule see note part mercks annual impairment assessment iprd intangible assets company estimated current fair value nemtabrutinib utilizing projected future cash flows market participant assumptions used derive forecasted cash flows updated reflect current competitive landscape nemtabrutinib including increased expected development costs additional clinical trial data needed develop nemtabrutinib well delay anticipated launch date nemtabrutinib collectively reduced projected future cash flows estimated fair value additionally discount rate utilized determine current fair value asset reduced reflect current risk profile asset revised estimated fair value nemtabrutinib compared related carrying value resulted iprd impairment charge noted remaining iprd intangible asset related nemtabrutinib billion assumptions used estimate fair value nemtabrutinib prove incorrect development nemtabrutinib progress anticipated thereby adversely affecting projected future cash flows company may record additional impairment charge future charge could material company recorded million iprd impairment charge related decision discontinue development program covid vaccine candidate v following mercks review findings phase clinical study vaccine study v generally well tolerated immune responses inferior seen following natural infection reported sarscovcovid vaccines discontinuation development program also resulted reversal related liability contingent consideration million company recorded million iprd impairment charges amount million relates writeoff intangible asset balance programs obtained connection acquisition iomet pharma ltd following review clinical trial results conducted merck along external clinical trial results similar compounds discontinuation clinical development program also resulted reversal related liability contingent consideration million iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates company may recognize additional noncash impairment charges future related marketed products pipeline programs charges could material aggregate amortization expense primarily recorded within cost sales billion billion billion estimated aggregate amortization expense next five years follows billion billion billion billion billion loans payable longterm debt leases loans payable loans payable december included billion notes due million longdated notes subject repayment option holders loans payable december included billion notes due billion commercial paper borrowings million longdated notes subject repayment option holders weightedaverage interest rate commercial paper borrowings years ended december respectively table contents longterm debt longterm debt december consisted notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due eurodenominated notes due notes due notes due notes due notes due notes due notes due eurodenominated notes due eurodenominated notes due eurodenominated notes due notes due notes due notes due debentures due notes due debentures due debentures due notes due notes due presented table includes borrowings variable rates resulted effective interest rates zero respectively exception debentures due notes listed table redeemable whole part mercks option time varying redemption prices december company issued billion principal amount senior unsecured notes consisting billion notes due billion notes due billion notes due billion notes due billion notes due merck used net proceeds offering notes notes notes notes general corporate purposes including repayment outstanding commercial paper borrowings including commercial paper borrowings connection mercks acquisition acceleron indebtedness merck allocated amount equal net proceeds offering notes due finance refinance whole part projects partnerships companys priority environmental social governance esg areas table contents effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent date certain companys borrowings require merck comply covenants december company compliance covenants aggregate maturities longterm debt next five years follows billion billion billion billion billion interest payments related debt obligations follows million million million million million company billion credit facility matures june facility provides backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding facility leases company operating leases primarily manufacturing facilities research development facilities corporate offices employee housing vehicles certain equipment company determines arrangement lease inception evaluating contracts embedded leases company exercises judgment determine explicit implicit identified asset contract merck controls use asset embedded leases primarily associated contract manufacturing organizations immaterial lease term includes options extend terminate lease reasonably certain merck exercise option real estate leases facilities average remaining lease term seven years include options extend leases four years applicable vehicle leases generally effect four years company record shortterm leases leases initial term months less balance sheet however merck currently shortterm leases lease expense operating lease payments recognized straightline basis term lease operating lease assets liabilities recognized based present value lease payments lease term since companys leases readily determinable implicit discount rate company uses incremental borrowing rate calculate present value lease payments asset class quarterly basis updated incremental borrowing rate determined based average remaining lease term asset class companys pretax cost debt term updated rates asset class applied prospectively new leases company separate lease components eg payments rent real estate taxes insurance costs nonlease components eg commonarea maintenance costs event agreement contains merck includes lease nonlease components purposes calculating rightofuse asset related lease liability nonlease components fixed vehicle leases employee housing company applies portfolio approach account operating lease assets liabilities certain companys lease agreements contain variable lease payments adjusted periodically inflation actual operating expense true ups compared estimated amounts however amounts immaterial sublease income activity related sale leaseback transactions immaterial mercks lease agreements contain material residual value guarantees material restrictive covenants operating lease cost million million million cash paid amounts included measurement operating lease liabilities million million million operating lease assets obtained exchange lease obligations million million million table contents supplemental balance sheet information related operating leases follows december assets assets liabilities accrued current liabilities noncurrent liabilities weightedaverage remaining lease term years weightedaverage discount rate includes prepaid leases related lease liability maturities operating leases liabilities follows thereafter total lease payments less imputed interest december company entered additional real estate operating leases yet commenced obligations associated leases total million contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well certain additional matters including governmental environmental matters opinion company unlikely resolution matters material companys financial condition results operations cash flows given nature litigation discussed complexities involved matters company unable reasonably estimate possible loss range possible loss matters company knows among factors claims survive dispositive motion practice ii extent claims including size potential class particularly damages specified indeterminate iii discovery process affect litigation iv settlement posture parties litigation v factors may material effect litigation company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance product liabilities table contents product liability litigation fosamax previously disclosed merck defendant product liability lawsuits us involving fosamax fosamax litigation december approximately cases pending merck either federal multidistrict litigation femur fracture mdl state court plaintiffs vast majority cases generally allege sustained femur fractures andor bone injuries femur fractures association use fosamax march femur fracture mdl court dismissed prejudice approximately cases preemption grounds plaintiffs approximately cases appealed decision us court appeals third circuit third circuit march third circuit issued decision reversing femur fracture mdl courts preemption ruling remanding appealed cases back femur fracture mdl court may us supreme court decided third circuit incorrectly concluded issue preemption resolved jury accordingly vacated judgment third circuit remanded proceedings back third circuit address issue manner consistent supreme courts opinion november third circuit remanded cases back district court order allow court determine first instance whether plaintiffs state law claims preempted federal law standards described supreme court opinion briefing issue closed parties await decision district court discovery presently stayed femur fracture mdl part spinoff organon organon required indemnify merck liabilities relating arising resulting fosamax litigation januviajanumet previously disclosed merck defendant product liability lawsuits us involving januvia andor janumet december merck aware approximately product users alleging januvia andor janumet caused development pancreatic cancer injuries claims filed multidistrict litigation us district court southern district california mdl march mdl court issued omnibus order granting defendants summary judgment motions based preemption failure establish general causation well granting defendants motions exclude plaintiffs expert witnesses plaintiffs appealed order since time half claims dismissed prejudice merck october us court appeals ninth circuit dismissed appeal merck two codefendants outside mdl majority claims filed coordinated proceedings superior court california county los angeles california state court april court california issued omnibus order granting defendants summary judgment motions also granting defendants motions exclude plaintiffs expert witnesses december six product users claims pending merck state courts california including illinois june illinois trial court denied mercks motion summary judgment based federal preemption merck appealed illinois appellate court affirmed december merck filed petition leave appeal illinois supreme court february april illinois supreme court stayed consideration pending petition appeal us supreme court issued opinion merck sharp dohme corp v albrecht relating fosamax matter discussed merck filed opinion albrecht illinois supreme court june petition leave appeal decided september illinois supreme court directed intermediate appellate court reconsider earlier ruling illinois appellate court issued favorable decision concluding consistent albrecht preemption presents legal question resolved court may illinois appellate court issued mandate state trial court december scheduled case management conference otherwise taken action addition claims noted company agreed toll statute limitations approximately additional claims company intends continue defending remaining lawsuits table contents governmental proceedings previously disclosed fall company received records subpoena us attorneys office district vermont vt usao pursuant section health insurance portability accountability act hipaa relating investigation potential health care offenses subpoena sought information relating actual potential business relationship arrangement merck practice fusion inc pfi cloudbased electronic health records ehr company acquired allscripts january company cooperated government responded subpoena subsequently may merck received second records subpoena vt usao broadened governments information request seeking information relating mercks relationship ehr company shortly thereafter vt usao served civil investigation demand cid upon merck similarly seeking information companys relationships ehr vendors cid explains government conducting false claims act investigation concerning whether merck andor pfi submitted claims federal health care programs violate federal antikickback statute merck cooperating governments investigation previously disclosed april merck received set investigative interrogatories california attorney generals office pursuant investigation conduct agreements allegedly affected delayed competition lantus insulin market interrogatories seek information concerning mercks development insulin glargine product subsequent termination well mercks patent litigation sanofi sa concerning lantus resolution litigation merck cooperating california attorney generals investigation previously disclosed june merck received cid us department justice cid requests answers interrogatories well various documents regarding temperature excursions thirdparty storage facility containing certain merck products merck cooperating governments investigation intends produce information andor documents necessary response cid previously disclosed companys subsidiaries china received may continue receive inquiries regarding operations various chinese governmental agencies inquiries may related matters involving multinational pharmaceutical companies well chinese entities business companies companys policy cooperate authorities provide responses appropriate previously disclosed time time company receives inquiries subject preliminary investigation activities competition governmental authorities markets outside us authorities may include regulators administrative authorities law enforcement similar officials preliminary investigation activities may include site visits formal informal requests demands documents materials inquiries interviews similar matters certain preliminary inquiries activities may lead commencement formal proceedings proceedings determined adversely company monetary fines andor remedial undertakings may required commercial litigation zetia antitrust litigation previously disclosed merck msd schering corporation scheringplough corporation msp singapore company llc collectively merck defendants defendants putative class action optout lawsuits filed behalf direct indirect purchasers zetia alleging violations federal state antitrust laws well state statutory common law causes action cases consolidated pretrial purposes federal multidistrict litigation judge rebecca beach smith eastern district virginia december court denied merck defendants motions dismiss stay direct purchaser putative class actions pending bilateral arbitration august district court adopted full report recommendation magistrate judge respect merck defendants motions dismiss nonarbitration issues thereby granting part denying part merck defendants motions dismiss addition june representatives putative direct purchaser class filed amended complaint august retailer optout plaintiffs filed amended complaint december district court granted merck defendants motion dismiss extent motion sought dismissal claims overcharges paid entities table contents purchased generic ezetimibe par pharmaceutical inc par pharmaceutical dismissed claims overcharges november direct purchaser plaintiffs indirect purchaser plaintiffs filed motions class certification august district court granted part direct purchasers motion class certification certified class direct purchasers august fourth circuit vacated district courts class certification order remanded proceedings consistent courts ruling september direct purchaser plaintiffs filed renewed motion class certification january magistrate judge recommended district court deny motion class certification february direct purchaser plaintiffs filed objections recommendation briefing objections ongoing august merck defendants filed motion summary judgment motions plaintiffs filed motion partial summary judgment motions motions fully briefed court heard argument certain motions court may hold additional hearings motions trial matter adjourned also august magistrate judge recommended court grant motion class certification filed putative indirect purchaser class august district court granted certification class indirect purchasers september merck defendants petitioned appeal class certification decision fourth circuit fourth circuit denied petition september september united healthcare services inc filed lawsuit us district court district minnesota merck defendants others uhc action uhc action makes similar allegations made zetia class action well allegations vytorin september us judicial panel multidistrict litigation transferred case eastern district virginia proceed multidistrict zetia litigation already progress december humana inc filed lawsuit superior court state california county san francisco merck others alleging defendants violated state antitrust laws multiple states also december centene corporation others filed lawsuit superior court state california county san francisco defendants humana lawsuits allege similar anticompetitive acts alleged zetia class action july california court ruled defendants motion quash lack personal jurisdiction granting motion outofstate claims defendants ordering limited jurisdictional discovery regard california claims also july humana centene filed actions merck defendants new jersey bergen county superior court reasserting claims dismissed california action september parties reached agreement humana centene would file claims new jersey federal court seek transfer claims multidistrict zetia litigation already progress subsequently dismiss actions previously filed california new jersey state courts june kaiser foundation health plan inc similarly filed lawsuit superior court state california county san francisco defendants humana centene kaiser lawsuit alleges similar anticompetitive acts alleged zetia class action kaiser action removed us district court northern district california july september us judicial panel multidistrict litigation transferred case eastern district virginia proceed multidistrict zetia litigation already progress december insurer plaintiffs kaiser humana centene part multidistrict zetia litigation proceeding discovery action february united healthcare kaiser humana filed amended complaint rotavirus vaccines antitrust litigation previously disclosed msd defendant putative class action lawsuits filed behalf direct purchasers rotateq alleging violations federal antitrust laws cases consolidated eastern district pennsylvania january court denied msds motions compel arbitration dismiss consolidated complaint february msd appealed courts order arbitration third circuit october third circuit vacated district courts order remanded limited discovery issue table contents arbitrability july msd filed renewed motion compel arbitration plaintiffs filed cross motion summary judgment arbitrability november district court denied msds motion granted plaintiffs motion december msd filed notice appeal third circuit msds appeal fully briefed third circuit heard argument september bravecto litigation previously disclosed january company served complaint us district court district new jersey following motion practice plaintiffs filed second amended complaint july seeking certify nationwide class action purchasers users bravecto fluralaner products us territories may july plaintiffs contend bravecto causes neurological events dogs cats alleges violations new jersey consumer fraud act breach warranty product liability related theories company moved dismiss alternatively strike class allegations second amended complaint motion pending similar case filed quebec canada may superior court certified class dog owners quebec gave bravecto chew dogs february november whose dogs experienced one conditions postmarketing adverse reactions section labeling approved november company plaintiffs appealed class certification decision court appeal quebec heard appeal february took matter advisement qui tam litigation previously disclosed june us district court eastern district pennsylvania unsealed complaint filed company federal false claims act two former employees alleging among things company defrauded us government falsifying data connection clinical study conducted mumps component companys mmr ii vaccine complaint alleges fraud took place us government right participate take prosecution lawsuit notified court declined exercise right two former employees pursuing lawsuit without involvement us government addition previously disclosed two putative class action lawsuits behalf direct purchasers mmr ii vaccine charge company misrepresented efficacy mmr ii vaccine violation federal antitrust laws various state consumer protection laws pending eastern district pennsylvania september court denied mercks motion dismiss false claims act suit granted part denied part motion dismiss thenpending antitrust suit result false claims act suit antitrust suits proceeded discovery complete parties filed briefed cross motions summary judgment currently pending court merck kgaa litigation previously disclosed january protect longestablished brand rights us company filed lawsuit merck kgaa darmstadt germany kgaa historically operating emd group us alleging improperly uses name merck us kgaa filed suit company france uk germany switzerland mexico india australia singapore hong kong sar prc china alleging among things unfair competition trademark infringement andor corporate name infringement uk australia singapore hong kong sar prc india kgaa also alleges breach parties coexistence agreement litigation ongoing us trial date set also ongoing numerous jurisdictions outside us patent litigation time time generic manufacturers pharmaceutical products file abbreviated new drug applications ndas fda seeking market generic forms companys products prior expiration relevant patents owned company protect patent rights company may file patent infringement lawsuits generic companies similar lawsuits defending companys patent rights may exist countries company intends vigorously defend patents believes valid infringement companies attempting market products prior expiration patents litigation assurance outcomes adverse could result significantly shortened table contents periods exclusivity products respect products acquired acquisitions potentially significant intangible asset impairment charges bridion previously disclosed january november company received multiple paragraph iv certification letters hatchwaxman act notifying company generic drug companies filed applications fda seeking prepatent expiry approval sell generic versions bridion sugammadex injection march april december company filed patent infringement lawsuits us district courts district new jersey northern district west virginia generic companies actions district new jersey consolidated lawsuits assert one patents covering sugammadex methods using sugammadex automatically stay fda approval generic applications june adverse court decisions whichever may occur earlier mylan pharmaceuticals inc mylan api us llc mylan inc mylan filed motions dismiss district new jersey lack venue failure state claim certain defendants northern district west virginia failure state claim certain defendants new jersey motion yet decided west virginia action stayed pending resolution new jersey motion company settled four generic companies providing generic companies bring generic versions bridion market january may delayed applicable pediatric exclusivity earlier certain circumstances company agreed stay lawsuit filed one generic company exchange agreed bound judgment merits consolidated action district new jersey one generic companies consolidated action requested dismissal action company oppose request subsequently granted court company expect company bring generic version bridion market january later depending applicable pediatric exclusivity unless company receives adverse court decision januvia janumet janumet xr previously disclosed fda granted pediatric exclusivity respect januvia janumet janumet xr provides six months exclusivity us beyond expiration patents listed fdas orange book adding exclusivity term key patent protection extends exclusivity products january company currently anticipates sales januvia janumet us decline significantly date however januvia janumet janumet xr contain sitagliptin phosphate monohydrate company another patent covering certain phosphate salt polymorphic forms sitagliptin saltpolymorph patent determined valid would preclude generic manufacturers making sitagliptin phosphate salt polymorphic forms expiration patent plus pediatric exclusivity par pharmaceutical filed suit company us district court district new jersey seeking declaratory judgment invalidity saltpolymorph patent response company filed patent infringement lawsuit us district court district delaware par pharmaceutical additional companies also indicated intent market generic versions januvia janumet janumet xr following expiration key patent protection prior expiration saltpolymorph patent later granted patent owned company covering janumet formulation term plus pediatric exclusivity ends company also filed patent infringement lawsuit mylan northern district west virginia judicial panel multidistrict litigation entered order transferring companys lawsuit mylan us district court district delaware coordinated consolidated pretrial proceedings cases pending district prior beginning scheduled october trial us district court district delaware invalidity issues company settled defendants scheduled participate trial companys case mylan bench trial held december us district court northern district west virginia closing arguments scheduled april total company settled generic companies providing generic companies bring generic versions januvia janumet market may earlier certain circumstances generic versions janumet xr market july earlier certain circumstances table contents additionally mylan filed petition inter partes review ipr us patent trademark office uspto seeking invalidity claims saltpolymorph patent uspto instituted ipr proceedings may finding reasonable likelihood challenged claims valid trial held february final decision rendered may holding challenged claims invalid mylan appealed usptos decision us court appeals federal circuit march company filed patent infringement lawsuit us district court district delaware zydus worldwide dmcc zydus pharmaceuticals usa inc cadila healthcare ltd collectively zydus lawsuit company alleged infringement saltpolymorph patent based filing zyduss application seeking approval sitagliptin tablets us district court district delaware set threeday bench trial matter beginning october germany generic companies sought revocation supplementary protection certificate spc janumet generic companies successful janumet could lose market exclusivity germany time expiry januvia pediatric market exclusivity september hearing held june court decided spc janumet invalid decision company appealed challenges janumet spc also occurred following european countries austria czech republic finland france hungary italy portugal romania slovakia sweden litigation various pending legal proceedings involving company principally product liability intellectual property lawsuits feasible predict outcome proceedings opinion company either likelihood loss remote reasonably possible loss associated resolution proceedings expected material companys financial condition results operations cash flows either individually aggregate legal defense reserves legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate environmental matters company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability table contents would material adverse effect financial condition results operations liquidity company company taken active role identifying accruing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed approximately million aggregate management also believe expenditures result material adverse effect companys financial condition results operations liquidity year equity merck certificate incorporation authorizes shares common stock shares preferred stock capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january purchases treasury stock issuances balance december issuances primarily reflect activity sharebased compensation plans sharebased compensation plans company sharebased compensation plans company grants restricted stock units rsus performance share units psus certain management level employees addition employees nonemployee directors may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders december million shares collectively authorized future grants companys sharebased compensation plans awards settled treasury shares employee stock options granted purchase shares company stock fair market value time grant awards generally vest one third year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price rsus psus dividends declared vesting period payable employees upon vesting psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued rsu psu distributions shares company stock end vesting performance period subject terms applicable awards psu awards generally vest three years rsu awards generally vest onethird year threeyear period table contents total pretax sharebased compensation cost recorded million million million respectively including million million million respectively related continuing operations income tax benefits sharebased compensation expense recognized million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments riskfree interest rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents amount time options granted expected outstanding based historical forecasted exercise behavior weighted average exercise price options granted per option respectively weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term years value outstanding january granted exercised forfeited awards transferred organon spinoff adjustment merck awards related spinoff organon outstanding december vested expected vest december exercisable december activity prior organon spinoff restated connection spinoff organon outstanding merck stock options whether vested unvested converted adjusted merck awards current former merck employees organon awards organon employees adjusted awards preserved intrinsic value general terms conditions including vesting place immediately prior adjustments additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options table contents summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited awards transferred organon spinoff adjustment merck awards related spinoff organon nonvested december expected vest december activity prior organon spinoff restated connection spinoff organon outstanding merck rsus psus whether vested unvested converted adjusted merck awards current former merck employees organon awards organon employees adjusted awards preserved intrinsic value general terms conditions including vesting place immediately prior adjustments december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pension postretirement benefit plans company defined benefit pension plans covering eligible employees us certain international subsidiaries addition company provides medical benefits principally eligible us retirees dependents postretirement benefit plans company uses december yearend measurement date pension plans postretirement benefit plans net periodic benefit cost net periodic benefit cost credit pension postretirement benefit plans including certain costs reported part discontinued operations consisted following components pension benefits us international postretirement benefits years ended december service cost interest cost expected return plan assets amortization unrecognized prior service cost net loss gain amortization termination benefits curtailments settlements net periodic benefit cost credit net periodic benefit cost credit pension postretirement benefit plans includes expenses curtailments settlements termination benefits provided certain employees connection spinoff organon connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities curtailments settlements recorded table contents certain pension plans increase lump sum payments us pension plan participants also contributed settlements recorded components net periodic benefit cost credit service cost component included income expense net see note exception certain amounts termination benefits curtailments settlements recorded restructuring costs event giving rise termination benefits curtailment settlement related restructuring actions income discontinued operations net taxes amounts attributable noncontrolling interests related spinoff organon noted obligations funded status summarized information changes plan assets benefit obligations funded status amounts recorded december follows pension benefits postretirement us international benefits fair value plan assets january actual return plan assets company contributions effects exchange rate changes benefits paid settlements spinoff organon fair value plan assets december benefit obligation january service cost interest cost actuarial gains losses benefits paid effects exchange rate changes plan amendments curtailments termination benefits settlements spinoff organon benefit obligation december funded status december recognized assets accrued current liabilities noncurrent liabilities actuarial gains losses primarily reflect changes discount rates december accumulated benefit obligation billion billion respectively pension plans billion billion respectively related us pension plans table contents information related funded status selected pension plans december follows us international pension plans projected benefit obligation excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligation excess plan assets accumulated benefit obligation fair value plan assets plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation december million million respectively approximately companys pension investments categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument table contents fair values companys pension plan assets december asset category follows fair value measurements using fair value measurements using level level level nav total level level level nav total us pension plans cash cash equivalents investment funds developed markets equities emerging markets equities mortgage assetbacked securities equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments plan assets fair value international pension plans cash cash equivalents investment funds developed markets equities government agency obligations emerging markets equities corporate obligations fixed income obligations real estate equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments insurance contracts plan assets fair value certain investments measured net asset value nav per share equivalent classified fair value hierarchy nav amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques table contents table provides summary changes fair value including transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets insurance real insurance real contracts estate total contracts estate total us pension plans balance january actual return plan assets relating assets still held december relating assets sold year purchases sales net balance december international pension plans balance january actual return plan assets relating assets still held december purchases sales net transfers level balance december fair values companys postretirement benefit plan assets december asset category follows fair value measurements using fair value measurements using level level level nav total level level level nav total cash cash equivalents investment funds developed markets equities emerging markets equities government agency obligations mortgage assetbacked securities equity securities developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities plan assets fair value certain investments measured net asset value nav per share equivalent classified fair value hierarchy nav amounts presented table intended permit reconciliation fair value hierarchy fair value plan assets december company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests international pension plans table contents targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines expected contributions contributions expected approximately million us pension plans approximately million international pension plans approximately million postretirement benefit plans expected benefit payments expected benefit payments follows international pension postretirement us pension benefits benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service amounts recognized comprehensive income net loss amounts reflect differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net periodic benefit cost average remaining service life employees following amounts reflected components oci pension plans postretirement us international benefit plans years ended december net gain loss arising period prior service cost credit arising period net loss gain amortization included benefit cost prior service credit amortization included benefit cost table contents actuarial assumptions company reassesses benefit plan assumptions regular basis weighted average assumptions used determining us pension postretirement benefit plan international pension plan information follows us pension postretirement benefit plans international pension plans december net periodic benefit cost discount rate expected rate return plan assets salary growth rate interest crediting rate benefit obligation discount rate salary growth rate interest crediting rate pension postretirement benefit plans discount rate evaluated measurement dates modified reflect prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined plan basis expected rate return plan developed considering longterm historical returns data current market conditions actual returns plan assets using reference information longterm return expectations asset category weightedaverage expected return plans target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate expected rate return companys us pension postretirement benefit plans compared range health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate savings plans company also maintains defined contribution savings plans us company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively table contents income expense net income expense net consisted years ended december interest income interest expense exchange losses income investments equity securities net net periodic defined benefit plan credit cost service cost net includes net realized unrealized gains losses investments equity securities either owned directly ownership interests investment funds unrealized gains losses investments directly owned determined end reporting period gains losses ownership interests investment funds accounted one quarter lag company estimates losses approximately million recorded first quarter ownership interests investment funds net presented table includes million goodwill impairment charges related certain businesses healthcare services segment fully divested first quarter interest paid million million million taxes income reconciliation effective tax rate income continuing operations us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income continuing operations taxes differential arising foreign earnings gilti foreignderived intangible income deduction tax settlements rd tax credit acquisition velosbio acquisition pandion valuation allowances restructuring acquisitionrelated costs including amortization state taxes acquisition oncoimmune acquisition peloton tax cuts jobs act tax cuts jobs act tcja enacted december company reflected impact tcja financial statements however since application certain provisions tcja table contents remained subject interpretation certain instances company made reasonable estimates effects tcja since finalized resulted additional income tax expense companys remaining transition tax liability tcja reduced payments utilization foreign tax credits billion december million included income taxes payable remainder billion included noncurrent liabilities result transition tax tcja company longer indefinitely reinvested respect undistributed earnings foreign subsidiaries provided deferred tax liability foreign withholding taxes would apply company remains indefinitely reinvested respect financial statement basis excess tax basis foreign subsidiaries determination deferred tax liability respect basis difference practicable foreign earnings tax rate differentials tax rate reconciliation primarily reflect impacts operations jurisdictions different tax rates us particularly ireland switzerland well singapore puerto rico operate tax incentive grants begin expire thereby yielding favorable impact effective tax rate compared us statutory rate beginning company additional tax incentive form tax holiday switzerland newly active legal entity effective income continuing operations taxes consisted years ended december domestic foreign taxes income continuing operations consisted years ended december current provision federal foreign state deferred provision federal foreign state table contents deferred income taxes december consisted assets liabilities assets liabilities product intangibles licenses inventory related accelerated depreciation equity investments pensions postretirement benefits compensation related unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized assets deferred income taxes company net operating loss nol carryforwards several jurisdictions december million deferred tax assets nol carryforwards relate foreign jurisdictions valuation allowances million established foreign nol carryforwards foreign deferred tax assets addition company million deferred tax assets relating various us tax credit carryforwards nol carryforwards valuation allowances million established us tax credit carryforwards nol carryforwards income taxes paid including amounts attributable discontinued operations billion billion billion respectively tax benefits relating stock option exercises million million million reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions reductions tax positions prior years settlements lapse statute limitations spinoff organon balance december amounts reflect settlements irs discussed amount includes million related divestiture mercks consumer care business company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion company examination numerous tax authorities various jurisdictions globally company believes reasonably possible total amount unrecognized tax benefits december could decrease approximately million next months result various audit closures settlements expiration statute limitations ultimate finalization companys table contents examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures interest penalties associated uncertain tax positions amounted benefit expense million million million amounts reflect beneficial impacts various tax settlements including settlements discussed liabilities accrued interest penalties million million december respectively internal revenue service irs concluded examinations mercks us federal income tax returns result company required make payment million million related continuing operations million related discontinued operations companys reserves unrecognized tax benefits years examination exceeded adjustments relating examination period therefore company recorded million net tax benefit million related continuing operations million related discontinued operations net benefit reflects reductions reserves unrecognized tax benefits related liabilities tax positions relating years examination irs concluded examinations mercks us federal income tax returns result company required make payment million million related discontinued operations offsetting credit million related continuing operations companys reserves unrecognized tax benefits years examination exceeded adjustments relating examination period therefore company recorded million net tax benefit million related continuing operations million related discontinued operations net benefit reflects reductions reserves unrecognized tax benefits tax positions relating years examination partially offset additional reserves tax positions previously reserved irs currently conducting examinations companys tax returns years addition various state foreign tax examinations progress jurisdictions companys income tax returns open examination period earnings per share calculations earnings per share shares millions follows years ended december net income continuing operations attributable merck co inc income discontinued operations net taxes amounts attributable noncontrolling interests net income attributable merck co inc average common shares outstanding common shares issuable average common shares outstanding assuming dilution basic earnings per common share attributable merck co inc common shareholders income continuing operations income discontinued operations net income earnings per common share assuming dilution attributable merck co inc common shareholders income continuing operations income discontinued operations net income issuable primarily sharebased compensation plans table contents million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive comprehensive income loss changes component comprehensive income loss follows foreign employee currency accumulated benefit translation comprehensive derivatives investments plans adjustment income loss balance january net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes balance december net taxes comprehensive income loss reclassification adjustments pretax tax comprehensive income loss reclassification adjustments net taxes reclassification adjustments pretax tax reclassification adjustments net taxes comprehensive income loss net taxes spinoff organon see note balance december net taxes primarily relates foreign currency cash flow hedges reclassified aocl sales represents net realized gains sales availableforsale debt securities reclassified aocl income expense net includes net amortization prior service cost actuarial gains losses included net periodic benefit cost see note includes pension plan net loss billion billion december respectively postretirement benefit plan net gain million million december respectively well pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table contents segment reporting companys operations principally managed products basis include two operating segments pharmaceutical animal health segments reportable segments pharmaceutical segment includes human health pharmaceutical vaccine products human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccine products consist preventive pediatric adolescent adult vaccines company sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccine sales made us centers disease control prevention vaccines children program funded us government additionally company sells vaccines federal government placement vaccine stockpiles animal health segment discovers develops manufactures markets wide range veterinary pharmaceutical vaccine products well health management solutions services prevention treatment control disease major livestock companion animal species company also offers extensive suite digitally connected identification traceability monitoring products company sells products veterinarians distributors animal producers beginning amortization intangible assets previously included part calculation segment profits included unallocated nonsegment corporate expenses prior period pharmaceutical animal health segment profits recast reflect change comparable basis company previously healthcare services segment provided services solutions focused engagement health analytics clinical services improve value care delivered patients company divested remaining businesses segment first quarter table contents sales companys products follows years ended december us intl total us intl total us intl total pharmaceutical oncology keytruda alliance revenue lynparza alliance revenue lenvima vaccines gardasilgardasil proquadmmr iivarivax pneumovax rotateq vaqta hospital acute care bridion prevymis primaxin noxafil cancidas invanz zerbaxa immunology simponi remicade neuroscience belsomra virology molnupiravir isentressisentress hd cardiovascular alliance revenue adempasverquvo adempas diabetes januvia janumet pharmaceutical total pharmaceutical segment sales animal health livestock companion animals total animal health segment sales segment sales total segment sales us plus international may equal total due rounding alliance revenue represents mercks share profits product sales net cost sales commercialization costs see note alliance revenue represents mercks share profits sales bayers marketing territories product sales net cost sales commercialization costs see note pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately represents sales healthcare services segment businesses healthcare services segment fully divested first quarter primarily comprised miscellaneous corporate revenues including revenue hedging activities well thirdparty manufacturing sales including sales organon also includes million related achievement milestones outlicensed product triggered contingent payments merck table contents consolidated sales geographic area derived follows years ended december united states europe middle east africa china japan asia pacific china japan latin america reconciliation segment profits income continuing operations taxes follows years ended december segment profits pharmaceutical segment animal health segment segments total segment profits profits unallocated interest income interest expense amortization depreciation research development restructuring costs unallocated net pharmaceutical segment profits comprised segment sales less standard costs well selling general administrative expenses directly incurred segment animal health segment profits comprised segment sales less cost sales well selling general administrative expenses research development costs directly incurred segment internal management reporting presented chief operating decision maker merck allocate remaining cost sales included segment profits described research development expenses incurred merck research laboratories companys research development division focuses human healthrelated activities general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits addition costs related restructuring activities well amortization intangible assets purchase accounting adjustments allocated segments profits primarily comprised miscellaneous corporate profits well operating profits related thirdparty manufacturing sales unallocated net includes expenses corporate manufacturing cost centers goodwill intangible asset impairment charges gains losses sales businesses expense income related changes estimated fair value measurement liabilities contingent consideration miscellaneous income expense items table contents equity loss affiliates depreciation included segment profits follows pharmaceutical animal health total year ended december included segment profits equity loss affiliates depreciation year ended december included segment profits equity loss affiliates depreciation year ended december included segment profits equity loss affiliates depreciation property plant equipment net geographic area located follows december united states europe middle east africa asia pacific china japan china latin america japan company disaggregate assets products services basis internal management reporting therefore information presented table contents report independent registered public accounting firm board directors stockholders merck co inc opinions financial statements internal control financial reporting audited accompanying consolidated balance sheet merck co inc subsidiaries company december related consolidated statements income comprehensive income equity cash flows three years period ended december including related notes collectively referred consolidated financial statements also audited companys internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion consolidated financial statements referred present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso basis opinions companys management responsible consolidated financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included managements report internal control financial reporting appearing item responsibility express opinions companys consolidated financial statements companys internal control financial reporting based audits public accounting firm registered public company accounting oversight board united states pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audits obtain reasonable assurance whether consolidated financial statements free material misstatement whether due error fraud whether effective internal control financial reporting maintained material respects audits consolidated financial statements included performing procedures assess risks material misstatement consolidated financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures consolidated financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation consolidated financial statements audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements table contents inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate critical audit matters critical audit matter communicated matter arising current period audit consolidated financial statements communicated required communicated audit committee relates accounts disclosures material consolidated financial statements ii involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matter providing separate opinion critical audit matter accounts disclosures relates us rebate accruals medicaid managed care medicare part described note consolidated financial statements company records certain variable consideration including discounts estimated time sale generally using expected value method amounts accrued aggregate customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers federal state agencies customers amounts accrued certain discounts representing portion accrual take form rebates amounts owed based upon definitive contractual agreements legal requirements private sector managed care public sector medicaid medicare part benefit providers final dispensing product benefit plan participant provision rebates based expected patient usage well inventory levels distribution channel determine contractual obligation benefit providers management uses historical customer segment utilization mix sales forecasts changes product mix price inventory levels distribution channel government pricing calculations prior payment history order estimate expected provision accrued balance relative provision rebates included accrued current liabilities billion december majority relates us rebate accruals medicaid managed care medicare part principal considerations determination performing procedures relating us rebate accruals medicaid managed care medicare part critical audit matter significant judgment management due significant measurement uncertainty involved developing rebate accruals accruals based assumptions developed using pricing information historical customer segment utilization mix high degree auditor judgment subjectivity effort performing procedures evaluating evidence related assumptions addressing matter involved performing procedures evaluating audit evidence connection forming overall opinion consolidated financial statements procedures included testing effectiveness controls relating us rebate accruals medicaid managed care medicare part including managements controls assumptions used estimate corresponding rebate accruals procedures also included among others developing independent estimate rebate accruals utilizing third party data historical customer segment utilization mix us pricing information terms specific rebate programs historical trend actual rebate claims paid ii comparing independent estimate rebate accruals recorded management iii testing rebate claims paid including evaluating claims consistency contractual terms companys rebate agreements pricewaterhousecoopers llp florham park new jersey february served companys auditor since table contents b supplementary data selected quarterly financial data unaudited millions except per share amounts th q rd q nd q st q sales gross profit net income continuing operations attributable merck co inc loss income discontinued operations net taxes amounts attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders income continuing operations loss income discontinued operations net income earnings per common share assuming dilution attributable merck co inc common shareholders income continuing operations loss income discontinued operations net income sales gross profit net loss income continuing operations attributable merck co inc income discontinued operations net taxes amounts attributable noncontrolling interests net loss income attributable merck co inc basic loss earnings per common share attributable merck co inc common shareholders loss income continuing operations income discontinued operations net loss income loss earnings per common share assuming dilution attributable merck co inc common shareholders loss income continuing operations income discontinued operations net loss income amounts fourth quarter include charges related acquisitions velosbio inc oncoimmune see note intangible asset impairment charge related zerbaxa see note amounts third quarter include charges related transactions seagen inc see note amounts second quarter include charge related acquisition pandion therapeutics inc see note reflects results businesses spunoff organon june discontinued operations periods presented see note table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective fourth quarter changes internal control financial reporting materially affected reasonably likely materially affect companys internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices annually employees company required complete code conduct training training reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated table contents framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein robert davis caroline litchfield chief executive officer president executive vice president chief financial officer item b information none item c disclosure regarding foreign jurisdictions prevent inspections applicable table contents part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion proposal election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document required information compliance section securities exchange act applicable incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may company code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer controller code conduct available companys website merckcomcompanyoverviewculture andvaluescodeofconductvaluesandstandards company intends disclose future amendments certain provisions code conduct waivers code conduct granted executive officers directors website within four business days following date amendment waiver every merck employee responsible adhering business practices accordance law ethical principles reflect highest standards corporate individual behavior required information identification audit committee audit committee financial expert incorporated reference discussion heading board meetings committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards table option exercises stock vested table pension benefits table nonqualified deferred compensation table potential payments upon termination change control including discussion subheadings separation change control well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related schedule director fees table director compensation table companys proxy statement annual meeting shareholders held may required information headings compensation management development committee interlocks insider participation compensation management development committee report incorporated reference companys proxy statement annual meeting shareholders held may table contents item security ownership certain beneficial owners management related stockholder matters information respect security ownership certain beneficial owners management incorporated reference discussion heading stock ownership information companys proxy statement annual meeting shareholders held may equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity compensation plans close business december table include information tax qualified plans merck us savings plan number number securities remaining securities available future issued upon weightedaverage issuance equity exercise exercise price compensation plans outstanding outstanding excluding options warrants options warrants securities rights rights reflected column plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck co inc incentive stock plans merck co inc nonemployee directors stock option plan excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans also excludes shares phantom stock deferred msd employee deferral program shares phantom stock deferred merck co inc plan deferred payment directors compensation item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion proposal ratification appointment independent registered public accounting firm beginning caption preapproval policy services independent registered public accounting firm fees services provided independent registered public accounting firm companys proxy statement annual meeting shareholders held may table contents part iv item